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ABSTRACT OF DISSERTATION 
 
 
 
MICROELECTRODE ARRAY STUDIES OF NORMAL AND DISEASE-ALTERED 
L-GLUTAMATE REGULATION IN THE MAMMALIAN CENTRAL NERVOUS 
SYSTEM 
 
 
 L-glutamate (Glu) is the major excitatory neurotransmitter in the 
mammalian central nervous system. Monitoring extracellular Glu is critical to 
understanding Glu regulation to discriminate physiological and pathological roles. 
To overcome the limitations of previous in vivo extracellular Glu studies, we 
developed Glu selective microelectrode arrays with better spatial and temporal 
resolutions than commonly used techniques like microdialysis. We used these 
microelectrode arrays to characterize basal and potassium-evoked Glu 
neurotransmission in the normal rat brain. We then investigated disease-related 
Glu alterations in a rat model of Parkinson’s disease and normal Glu regulation in 
young and aged rhesus monkeys. In the normal anesthetized rat striatum and 
frontal cortex, basal Glu was regulated by active release and uptake 
mechanisms, fully TTX-dependent, and measured at ~2 micromolar levels. 
Potassium-evoked Glu kinetics were fast, concentration-dependent, and rapidly 
reproducible at 15-20 seconds intervals. In the unilateral 6-hydroxydopamine-
lesioned rat, there were significant bilateral increases in potassium-evoked Glu 
release in the striatum and frontal cortex compared to hemisphere-matched non-
lesioned rats. Ipsilateral striatal effects may have been related to DA loss, while 
contralateral striatal effects and the bilateral frontal cortical
 
effects may have resulted from parkinsonian neurotransmitter changes or 
bilateral neuranatomical connectivity, especially in the cortex. There were also 
alterations in Glu kinetics in the nucleus accumbens in both non-lesioned and 
lesioned rats.  With appropriate technological and methodological modifications, 
we successfully recorded normal Glu signaling in anesthetized nonhuman 
primates in the operating room. Fast potassium-evoked Glu signals were 
recorded in the motor cortex of all monkeys, and Glu ejections showed robust 
Glu uptake in the motor and frontal cortices of all monkeys. These findings are 
comparable to initial rat studies. Slow evoked Glu kinetics and high basal Glu 
levels with oscillatory behavior were recorded in the frontal cortex. The primary 
age-related differences between monkeys were the nearly ten-fold increases in 
the volumes of Glu ejected needed in the aged monkey to achieve amplitude-
matched signals in the motor and frontal cortices and a decreased uptake rate in 
the motor cortex. Preliminary work with excised human tissue and future plans 
for patient-oriented research and clinical applications are discussed. 
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 Chapter One: Introduction 
 
A Brief Introduction to Intracranial Electrode Applications 
 
 This dissertation documents continuing work towards the long-term goal of 
clinically using implanted microelectrode arrays that detect specific 
neurochemicals to positively impact the management of human neurological 
diseases. Although the concept of putting electrodes into the human brain may 
sound like science fiction or at least an extreme medical approach, in fact, 
neurosurgeons routinely use a wide variety of intracranial electrodes to care for 
patients in the modern era. Both recording and stimulating electrode protocols 
have become standards of care or good alternative approaches for patients 
suffering from brain disorders such as Parkinson’s disease (PD) and epilepsy 
(Starr, Vitek, and Bakay, 1998, Wyler and Abson-Kraemer, 1994). Ultimately, we 
hope that microelectrodes coupled with electrochemical detection will provide 
similar benefit and take their place alongside other intracranial electrodes used to 
monitor, diagnose, and treat human nervous system disorders. 
 Both recording and stimulating electrodes are used in the surgical 
treatment of PD, a progressive neurodegenerative disease which primarily 
affects movement. When the symptoms are no longer well-controlled by standard 
medications, advanced PD patients may elect to ablate or stimulate different 
subcortical areas of their brains. These approaches attempt to alter signals 
emerging from the basal ganglia or thalamus to alleviate some parkinsonian 
symptoms. Targeting deep brain nuclei usually begins with an imaging study 
(computed tomography (CT) and/or magnetic resonance imaging (MRI)) but is 
routinely accompanied by intraoperative electrophysiological brain recordings 
that use implanted electrodes. Because the patterns of spontaneous neuronal 
firing predictably differ between discrete brain nuclei, electrodes can be used to 
precisely locate brain areas of interest. Typically tungsten or platinum-iridium 
microelectrodes are used to record single-unit, extracellular action potentials for 
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 this type of mapping. In addition or as an alternative, stimulation protocols can be 
followed which use these microelectrodes (microstimulation) and/or 
macroelectrodes (macrostimulation) and rely on reported or observed changes in 
visual, motor, or sensory responses to localize electrode placement. In the case 
of ablation, alternating current can be passed in a monopolar fashion from the 
electrode to a dispersive grounding pad on the patient’s skin to lesion the 
targeted area, a technique known as radiofrequency thermocoagulation. In fact, 
pallidotomies and thalamotomies (ablative surgeries which target the globus 
pallidus internal segment (GPi) and motor thalamus, respectively) most often use 
this technique (Krauss and Jankovic, 1996, Starr, Vitek, and Bakay, 1998, Krack 
et al., 2000). 
 PD patients who decide with their physicians that permanent lesioning is 
not the best option may elect to have a chronic indwelling stimulating electrode, 
called a deep brain stimulator (DBS), implanted in one or both brain hemispheres 
(Starr, Vitek, and Bakay, 1998). Again, confirming placement of the DBS 
electrode may involve initial microelectrode mapping or microstimulation, and the 
DBS electrode itself can be used for localizing macrostimulation prior to final 
placement. Although some clinical researchers have questioned the benefit of 
extensive microelectrode mapping, it is highly accepted that some form of 
recording or stimulation is absolutely critical for electrode placement (Eskandar et 
al., 2000, Guridi et al., 2000, Pollak et al., 2002). An extension wire is tunneled 
under the patient’s skin and connected to a battery-powered pulse generator 
implanted in the patient’s upper chest. A physician programs the stimulation 
parameters of the pulse generator using a wireless controller, and the patient can 
turn the stimulator on or off as needed. Early applications of DBS electrodes 
targeted the thalamus; however, the GPi and subthalamic nucleus (STN) are 
becoming increasingly popular targets (Olanow, Brin, and Obeso, 2000). Exactly 
how deep brain stimulation works to alleviate PD symptoms is unknown; 
functional lesioning and altering basal ganglia signaling are leading theories 
(Starr, Vitek, and Bakay, 1998, Benazzouz and Hallett, 2000). 
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  A wide variety of electrodes are also used in the surgical management of 
patients with intractable epilepsy, a brain disorder characterized by multiple 
seizures caused by abnormal cerebral electrical activity. The goal is to identify 
and remove epileptogenic foci, which are local networks of hyperactive neurons 
that burst-fire continuously, often at levels sufficient to initiate an epileptic 
seizure. Strip, grid, and depth electrodes are all useful intra- and post-operative 
tools that aid in the search for epileptogenic foci (Wyler and Abson-Kraemer, 
1994). Strip and grid electrodes are both implanted in the epidural or subdural 
spaces in close contact with the cortical surface and differ primarily in their 
geometry. Strip electrodes have 2-16 circular contacts arranged in a linear 
fashion on a flexible, flat plastic strip. Grid electrodes are two-dimensional arrays 
that have 40-64 circular contacts and are basically parallel rows of strip 
electrodes. Depth electrodes have 6 cylindrical contacts fabricated along flexible 
tubing similar to a catheter that can be implanted into deep brain structures using 
a rigid guide cannula (McCarthy, Spencer, and Riker, 1991). All three types of 
electrodes are used to make electroencephalographic (EEG) recordings of brain 
activity, and epileptogenic foci can be localized in relation to EEG findings from 
the multiple recording sites (Olivier and Boling, Jr., 1994). Sometimes it is 
necessary to determine the relationship of an epileptogenic focus to functional 
cortex using a technique known as cortical mapping. This requires using an 
implanted grid electrode with bipolar stimulation to determine the functional 
significance of cortical regions near the area targeted for resection. In this way, 
cortex that, if removed, would severely impair the patient is identified (Wyler and 
Abson-Kraemer, 1994). Epileptogenic foci tend to be surgically removed not 
ablated as previously discussed (Kim and Spencer, 1994). 
 Clearly, intracranial electrode applications such as electrophysiological 
recordings and the ability to stimulate brain regions are common, valuable tools 
used to monitor and manipulate the intracranial environment to benefit patient 
care; however, physicians and scientists alike have been interested in 
complementing these techniques with the ability to monitor specific 
neurochemicals in the intact brain. Neurochemicals, such as neurotransmitters, 
3 
 are key components of the nervous system because the major communication 
system between neurons is chemical signaling (Cooper, Bloom, and Roth, 1996). 
Advancing the techniques employed to investigate neurochemicals will deepen 
our insight and understanding of the biology, pathology, and pharmacology of the 
nervous system. Currently the most widely used technique to study 
neurochemicals is intracerebral microdialysis (Timmerman and Westerink, 1997). 
However, the limitations of this technique (discussed later) have motivated some 
scientists to develop new technologies to monitor molecules in the intracranial 
environment. In the last decade, our group has developed enzyme-coated 
ceramic-based microelectrode arrays capable of recording specific 
neurochemicals and created exciting new tools for basic scientific research. 
Already these high-quality devices are routinely used in animal models and may 
soon record Glu from an intact human brain. This dissertation documents how we 
have pushed this technology from the lab bench to the veterinary operating room 
and beyond on a course to advance and diversify the ways that we study the 
brain and possibly manage patients in the 21st century.  
 
The Evolution of Enzyme-Coated Ceramic-Based Microelectrode Arrays 
 
 The idea of coupling enzyme reactions with electrodes to measure 
biologically active molecules extends at least as far back as 1966 when Kajihara 
and Hagihara reported measuring serum glucose levels using an oxygen 
electrode coupled with glucose oxidase. Other groups were also working with the 
concept; Updike and Hicks (1967) reviewed “The enzyme electrode” in Nature 
the following year. By 1970, Guilbault and Hrabankova had expanded the list of 
measurable chemicals to include the amino acids, but it was not until 1987 that 
Korenbrot, Perry, and Copenhagen reported an enzyme electrode specifically for 
the measurement of L-glutamate. Work continued, but the new technologies 
suffered from slow response times, poor selectivities, inadequate sensitivities, 
and limited in vivo applications. In the early 1990’s, the first reports of Glu 
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 recordings in the intact brain emerged (Tamiya and Karube, 1992, Hu et al., 
1994). Although it would take many more years to improve the quality and 
reproducibility of electrode fabrication and performance, the technology was 
beginning to move beyond the development stages and enter the exciting era of 
in vivo applications. 
 The electrode design and performance of Hu et al. (1994), in particular, 
surpassed the rest and served as one of the predecessors to our group’s 
enzyme-coated ceramic-based microelectrode arrays. Their electrode consisted 
of a Teflon-coated platinum-iridium wire stripped at the end and epoxyed at the 
tip to create a ~700 micron long sensing cavity. Nafion™ and cellulose acetate 
coatings, applied first, provided electrostatic repulsion of anionic interferents, 
while subsequent application of L-glutamate oxidase and L-ascorbate oxidase in 
a bovine serum albumin/glutaraldehyde protein matrix provided sensitivity to Glu 
and further selectivity against ascorbic acid. Sealed in glass, starting 8-12 mm 
behind the sensing cavity, the electrode was rigid enough for stereotactic 
implantation into the brain of anesthetized rats. Beyond what we now recognize 
as several time-tested design elements, the electrode performed exceptionally 
well, using high-speed amperometry to record Glu signals not just in vitro but in 
vivo. In the rat hippocampus, they investigated Glu uptake with exogenous 
challenges as well as both potassium-evoked and electrically stimulated Glu 
release. With average sensitivity, selectivity, limit of detection, and response 
speed on par with even today’s standards, their enzyme-based electrode truly set 
the bar. 
 However, there was room for improvement. Demonstrating reproducibility 
of evoked Glu signals required a 20 minute rest interval presumed by the authors 
to be necessary for neurotransmitter replenishment. This was despite the fact 
that the recorded Glu signals lasted only ~1 minute, and intracellular Glu levels 
were known to be sufficiently high to make a lengthy rest period for 
replenishment unlikely. Furthermore, the electrode lost on average over 50% 
sensitivity following brain exposure. It was a hand-made electrode that could not 
easily be mass-produced for distribution or readily fabricated by other 
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 investigators. Despite its reported in vitro selectivity, the singular nature of the 
electrode left the identity of its signal as Glu open to criticism without difficult 
placement of a second, Glu-insensitive but otherwise identical, electrode within 
microns of the first. 
 While enzyme-based techniques were advancing our ability to use 
electrodes to detect specific chemicals, new electrode materials were being 
developed, in parallel, to create semi-conductor based, multisite microelectrodes 
as early as the 1970’s (Sreenivas et al., 1996, Burmeister, Moxon, and Gerhardt, 
2000). Multisite microelectrodes had many potential advantages over single 
electrodes including reproducible recording sites, spatially defined sites for 
layered brain structures, and the possibility of simultaneous electrophysiological 
and electrochemical recordings using the same microelectrode. They might also 
offer distinctly configured recording sites for multiple analytes or monitoring 
interferences. It also might be possible to supply investigators with a highly 
reproducible, affordable recording device. By the mid 1990’s, micromachining, 
integrated circuit technologies, thin-film deposition techniques, and 
photolithographic patterning had advanced the field tremendously. However, the 
initial silicon-based sputtered-carbon microelectrode arrays that our group 
developed suffered from an undesirable electrical conductance of the silicon 
substrate, which was likely the cause of a high background current and poor 
signal-to-noise characteristics seen in initial studies (Sreenivas et al., 1996). To 
remedy these problems, the silicon was replaced by an inert ceramic substrate 
with polyimide insulation, which was also used to improve strength, diminish 
cross talk, provide greater versatility, and lower production costs (Burmeister, 
Moxon, and Gerhardt, 2000). Because carbon will not stick to ceramic without 
extensive surface modifications, the recording site material was changed to 
sputtered platinum. This also provided a better surface to detect the products of 
enzyme-based chemical reactions. 
 In the late 1990’s and early 2000’s, our refined ceramic-based multisite 
microelectrode arrays demonstrated fast and reliable Glu detection with low 
detection limits (0.25 – 0.50 µM Glu), enhanced sensitivity, good selectivity 
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 (>100:1 versus ascorbic acid), fast response times (90% rise times = 1 second), 
and superior spatial and temporal resolutions (Burmeister, Moxon, and Gerhardt, 
2000, Burmeister and Gerhardt, 2001). We used procedures modified from Hu et 
al. (1994) to prepare our microelectrodes (full description in Chapter Two) and 
began using them routinely for in vivo studies (Burmeister et al., 2002, 
Pomerleau et al., 2003). Our lab’s commitment to technology development has 
continued to improve the quality and versatility of the recording capabilities. At 
the same time, we have broadened our focus to explore biological applications. 
Currently, our microelectrode arrays have been used to record Glu in 
anesthetized mice and rats, freely-moving rats, rat brain slices, anesthetized 
monkeys, and excised human brain tissue. They have also been used for 
electrophysiological and electrochemical (Glu) recordings in the awake, behaving 
monkey, and using other enzyme coatings, have been reconfigured to 
characterize other neurotransmitters using electrochemical detection including 
glucose, aspartate, choline, acetylcholine, and lactate (Burmeister and Gerhardt, 
2001, Parikh et al., 2004, Burmeister, Palmer, and Gerhardt, 2005). This 
dissertation documents my role in this team effort to advance how we can use 
this technology to investigate normal and disease-altered biology and contribute 
to both science and medicine. 
 
Microelectrode Arrays vs. Microdialysis for Studying L-Glutamate 
 
 Microelectrode-based recording techniques are not the only approaches 
used to monitor the chemical composition of the extracellular space of the brain. 
In fact, the most widely used techniques are based on intracranial microdialysis, 
which produces dialysate fluid samples for analysis (Khan and Shuaib, 2001). 
The main advantage of microdialysis methods is the ability to couple sampling 
with highly sensitive detection systems, such as high performance liquid 
chromatography and electrochemical or fluorescence detection. The detection 
limits of these systems for Glu are in the nanomolar to femtomolar range (Zhang 
7 
 et al., 2005, Smolders et al., 1995, Rowley, Martin, and Marsden, 1995). Another 
advantage of microdialysis is the ability to measure multiple chemicals from each 
sample. Often in vivo microdialysis studies will profile multiple amino acids (e.g. 
Glu, γ-aminobutyric acid (GABA), glycine, aspartate, taurine) or other 
neurochemicals over the time course of the experiment (Qureshi et al., 2003, Qu 
et al., 1998). These capabilities certainly make this technique attractive for many 
applications. 
 Nonetheless, there are disadvantages to microdialysis-based techniques 
that limit their usefulness in certain cases. Many of these limitations stem from 
the microdialysis probe and the way in which it creates samples for analysis. 
Microdialysis probes basically are constructed of two steel tubes (inlet and outlet) 
connected at the tip by a semipermeable dialysis membrane. Once implanted in 
the brain, perfusion fluid is slowly pumped through the probe (typical flow rate: 1-
2 µl/minute) allowing bidirectional exchange of small molecules across the 
membrane (Berners, Boutelle, and Fillenz, 1994). Because molecules will move 
along their concentration gradients, microdialysis probes can be used for local 
drug application (reverse microdialysis) as well as for sampling from the 
extracellular fluid (Khan and Shuaib, 2001). Volumes of dialysate are collected at 
the end of the outlet tube outside of the brain and typically frozen for off-line 
analysis. During sampling, concentrations of extracellular molecules do not 
completely equilibrate with the artificial medium. In fact, in vitro recovery testing 
is a routine part of most microdialysis studies. As a result, microelectrode 
recordings have the distinct advantage over microdialysis-coupled detection 
methods of actually measuring molecules in the extracellular fluid. 
 Other advantages of microelectrodes over microdialysis probes are their 
size and spatial resolution. A typical cylindrical microdialysis probe (CMA/11, 
CMA Microdialysis AB, North Chelmsford, MA) has a 1-4 mm long dialysis 
membrane with a 0.24 mm outer diameter. Comparatively, the implantable 0.005 
± 0.0005” (~130 ± 13 µm) thick ceramic portion of a microelectrode array is 10 
mm long, with a triangular shape that tapers from 1 mm at the base to 2-5 µm at 
the tip (Burmeister et al., 2002). The center of the array is positioned 1.0 mm 
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 from the tip, and the length of the array is 766 µm (length includes all four 15 x 
333 µm recording sites and 100 µm front-to-back spacing). Based on these 
dimensions, both the volumes of displacement and the surface areas at the 
sampling/recording interfaces can be calculated and compared. A typical 
microdialysis probe displaces approximately 5 to 18 times as much brain tissue 
along the interface length as compared to our microelectrode arrays (0.05 - 0.18 
mm3 vs. ~0.01 mm3). Furthermore, the described dialysis membrane makes 
contact with about 150 – 600 times as much brain tissue as one microelectrode 
recording site (0.75 – 3.02 mm2 vs. 4995 µm2). In the era of using 
electrophysiological data in conjunction with neurochemical detection, the 
impetus with respect to size has been to develop smaller devices and interfaces 
that will potentially be less disruptive, closer to the synapse, and in contact with 
fewer cells. This may be especially important for studying Glu, which is thought to 
be tightly regulated perisynaptically (Danbolt, 2001). Although both techniques 
measure extrasynaptic Glu, microelectrodes are smaller and have much better 
spatial resolution. 
 Probably the single greatest advantage of using microelectrodes over 
typical microdialysis is better temporal resolution (800 msec vs. typically 5-20 
min). The highly sensitive detection systems used for microdialysis require 
adequate sample volumes (~10-20 nl). Flow rates greater than 2 µl/minute would 
create these volumes more quickly, but this approach is impractical because of 
poorer relative recovery, potential for creating non-physiological conditions 
around the probe, and possible tissue damage (Rossell, Gonzalez, and 
Hernandez, 2003). As such, a typical off-line microdialysis study might perfuse 
fluid at 1-2 µl/minute with dialysate fractions collected every 5-20 minutes. 
Because it is widely recognized that small or rapid changes in neurochemicals 
might be missed altogether using microdialysis as described, proponents of the 
technique have pushed to improve the temporal resolution of the methods. 
Primarily, investigators have reported improved temporal resolution by combining 
dialysate outflow with on-line sample separation and subsequent small volume 
detection methods (both on- and off-line). The best example to date would be the 
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 use of capillary (zone) electrophoresis separation and laser-induced fluorescence 
detection (CE-LIFD) employed by several groups who report temporal resolution 
of only a few seconds (Tucci et al., 1997, Lada, Vickroy, and Kennedy, 1997, 
Rossell, Gonzalez, and Hernandez, 2003). The Hernandez group, in particular, 
couples microdialysis on-line with derivatization reactions in a cellulose-based 
capillary collection tube, which is cut into small sections, and claims 1 second 
time resolution corresponding to the length of each section. Under this logic, they 
could lower the temporal resolution of their method simply by cutting smaller 
sections of the collection tube. However, the true temporal resolution of 
microdialysis methods is limited by the number of seconds required for small 
molecule diffusion and equilibration across the microdialysis membrane. As such, 
temporal resolution of only a few seconds achieved by investigators such as the 
Kennedy group may realistically be the lower limit of microdialysis methods. In 
addition, microdialysis-based measurements are time-delayed from the actual 
intracranial events by minutes to days, even with on-line detection. In contrast, 
our microelectrodes sample the extracellular fluid and record Glu every 800 
msec. Furthermore, Glu signals are displayed as they happen in the brain on a 
second-by-second basis. In fact, we have recently developed software capable of 
recording average Glu measurements forty times per second, although 
recordings made at that speed are not yet routine. Clearly, our temporal 
resolution is much better than typical off-line microdialysis methods and 
continues to outperform the best on-line adaptations. 
 A commonly underreported aspect of using implanted devices for 
measuring small concentrations of molecules under physiological conditions is 
tissue trauma. This consideration is especially important for measuring Glu, 
which is present at very high amounts inside all brain cells (10 mM, Meldrum, 
Akbar, and Chapman, 1999), because traumatized cells could leak Glu into the 
extracellular space and obscure experimental findings. It is widely known that 
inflammation follows microdialysis probe implantation, and there is increased 
glucose metabolism and decreased blood flow around the probe within the first 
24 hours. Using both light and electron microscopy to observe microdialysis-
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 sampled brain tissue, several ultrastructural changes were reported. Tissue 
disruption was apparent up to 1.4 mm from the probe tract, there was 
asymmetric (glutamatergic) synapse loss and decreased neuron density up to 
400 µm from the implantation site, and swollen mitochondria and endoplasmic 
reticulum were observed (Clapp-Lilly et al., 1999, Khan and Shuaib, 2001, Drew 
et al., 2004). Although a full analysis of tissue damage related to implanting our 
microelectrode arrays has not been conducted, initial work has revealed minimal 
trauma even with microelectrodes implanted for 2 months. Strong indirect 
evidence comes from recent electrophysiological recordings made with our 
microelectrodes demonstrating that the neurons remain functionally intact 
following implantation for up to 6 months (Deadwyler and Gerhardt, unpublished 
data). Although further work is needed, these results support that our 
microelectrodes may produce less tissue trauma due to their size, tapered design 
with smooth edges, and means of operation. 
 The shortcomings of microdialysis for the measurement of Glu and GABA 
have come under particular scrutiny. Glu and GABA measures in microdialysis 
studies are often reported to have non-classical neurotransmitter characteristics. 
In short, tetrodotoxin (TTX) applications and calcium removal, conditions which 
should inhibit neuronal vesicular release of neurotransmitters, are widely 
reported to have no effect on basal Glu and GABA measures (Shiraishi et al., 
1997, Timmerman and Westerink, 1997). As a result, many investigators have 
concluded that basal levels of these neurochemicals originate purely from non-
neuronal sources such as uptake reversal and glial metabolism. However, 
Timmerman and Westerink (1997) and more recently Drew et al. (2004) have 
questioned the significance of these findings. This is in light of the knowledge 
that the molecules sampled by microdialysis are far removed from the synapse 
and mounting evidence that some neurotransmitters, such as Glu and GABA, are 
“faster” than others (i.e. more tightly regulated perisynaptically). They argue that 
the non-classical nature may not be purely biological but a failure of the 
microdialysis-coupled technologies to detect changes near the synapse, due to 
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 limitations with respect to size, spatial resolution, temporal resolution, and tissue 
trauma. 
 In summary, our ceramic-based microelectrode arrays with 
electrochemical detection have several advantages over microdialysis-coupled 
detection techniques for the measurement of Glu. Our microelectrodes are 
smaller and have better spatial resolution (15 x 333 µm vs. ~250 µm x 1-4 mm). 
They have better temporal resolution (800 msec vs. typically 5-20 min) and 
display the intracranial events as they happen on a second-by-second basis. 
They measure Glu in the extracellular space and not an artificial medium. They 
may also create less tissue trauma. Though our limit of detection (LOD: 0.25 – 
0.50 µM Glu) does not rival those of the highly sensitive detection systems used 
for microdialysis studies, current measures of basal and evoked Glu in the 
mammalian brain are in the micromolar range, above our LOD (Hu et al., 1994, 
Lada, Vickroy, and Kennedy, 1998, Kulagina, Shankar, and Michael, 1999, Baker 
et al., 2002, Burmeister et al., 2002, Pomerleau et al., 2003). These advantages 
are especially important for measuring fast neurotransmitters like Glu because, 
unlike microdialysis probes, our microelectrode arrays are designed to be closer 
to the synapse and maximize opportunities for detecting changes in 
extrasynaptic Glu that may reflect synaptic events. 
 
The Glutamatergic System in the Normal Mammalian CNS 
 
 The vast majority of synapses in the mammalian central nervous system 
use Glu as a neurotransmitter to create fast neuronal excitation. Glu neuron cell 
bodies can be found throughout the brain and spinal cord but are mainly 
concentrated in the cerebral cortex, hippocampus, cerebellum, thalamus, and 
dorsal horn of the spinal cord. Glutamatergic synapses are widely distributed 
throughout the mammalian CNS with the highest density found in the 
hippocampus, cortex, lateral septum, striatum, and molecular layer of the 
cerebellum (Nakanishi, 1992, Hudspith, 1997, Siegel et al., 1994). While the 
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 neuroanatomy of Glu neurons was emerging, investigators were also exploring 
the function of Glu in the brain. Today we understand that Glu plays a central role 
in a wide variety of normal CNS functions including cognition, learning, memory, 
sensation, and movement (Meldrum, 2000, Feldman et al., 1997, Riedel et al., 
2003). 
 Despite its ubiquitous nature, Glu is able to contribute to many different 
CNS functions in part because of multiple Glu receptors, broadly classified as 
ionotropic and metabotropic (Figure 1.1). Ionotropic Glu receptors (iGluRs) are 
ligand-gated ion channels represented by N-methyl-D-aspartate (NMDA), α-
amino-3-hydroxy-5-methyl-4-isoxazole-proprionic acid (AMPA), and kainate (KA) 
receptors, named according to their specific agonists. In addition to being ligand-
gated, NMDA receptors are also voltage-gated (to relieve magnesium blockade) 
and require the co-agonist glycine. The iGluRs are responsible for fast synaptic 
transmission with the fast component of the excitatory post-synaptic current 
(EPSC) attributed to sodium influx through AMPA receptors and the slow 
component of the ESPC resulting from the slightly delayed inward movement of 
both sodium and calcium through NMDA receptors. NMDA receptors have also 
been shown to be important for intracellular calcium signaling responsible for 
synaptic plasticity (long-term potentiation (LTP) and long-term depression (LTD)). 
The role of KA receptors is less well known; however, they are densely 
distributed in the CA3 region of the hippocampus and have been demonstrated 
to participate in non-NMDA receptor-dependent LTP there (Bortolotto et al. 
2003). IGluR subunits are encoded by different genes, have splice variants, 
undergo post-transcriptional (mRNA) editing, and assemble in multiple 
combinations for additional functional diversity (Siegel et al., 1994, Feldman et 
al., 1997). 
 In addition, there are three groups of ligand-gated G-protein-coupled Glu 
receptors called the metabotropic Glu receptors (mGluRs). These receptors are 
not involved in fast neurotransmission but are thought to modulate the activities 
of neurons and glia through intracellular second messenger signaling. Group I 
mGluRs (mGluR1,5) couple with Gq11 proteins to increase phospholipase C  
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Figure 1.1 The Glutamatergic Synapse 
Both ionotropic Glu receptors (orange chevrons) and metabotropic Glu receptors 
(mGluR) contribute to the diversity of functions attributed to the major excitatory 
neurotransmitter Glu in the mammalian CNS. Glu released from the presynaptic 
nerve terminal is primarily removed from the extracellular space by EAAT’s 
(yellow cylinders). See text for further details. 
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 activity, phosphoinositide hydrolysis, and intracellular inositol triphosphate (IP3) 
and diacylglycerol (DAG) signaling. This group has been shown to increase Glu 
release. Groups II and III mGluRs (mGluR2,3 and mGluR4,6-8, respectively) link 
with Gi/Go proteins to decrease adenylate cyclase activity and lower cyclic AMP. 
Both groups, but especially group II mGluRs, have autoreceptor function, 
providing inhibitory feedback to Glu presynaptic nerve terminals to decrease Glu 
release. Several studies on the mGluRs to learn more about their distribution, 
additional neuronal and glial functions, and potential as therapeutic targets are 
currently underway (Watkins, 2000, Cartmell and Schoepp, 2000, Danbolt, 
2001). 
 Glu neurotransmission is terminated by sodium-dependent excitatory 
amino acid transporters (EAATs) (Figure 1.1). Three different EAATs are present 
in the rat brain (Glu Aspartate Transporter (GLAST), Glu Transporter-1 (GLT-1), 
and Excitatory Amino Acid Carrier 1 (EAAC1)), while five have been discovered 
in humans (EAAT1-5). Most Glu uptake is accomplished by glial Glu transporters 
(rat GLAST and GLT-1, homologous to human EAAT1 and EAAT2, respectively), 
while some is performed by postsynaptic neuronal transporters (rat EAAC1, 
homologous to human EAAT3). The presence of a presynaptic EAAT has long 
been postulated; however, its identity and physiological relevance remain 
disputed. In the rat forebrain, glial Glu uptake is dominated by GLT-1, while 
GLAST is the predominant Glu transporter in the rat cerebellum (Meldrum, 
Akbar, and Chapman, 1999). EAAC1 can be trafficked to the membrane surface, 
and this action has been associated with protein kinase C activity. 
Perisynaptically, these transporters can be present in densities on the order of 
104/µm3 membrane and account for the rapid return of extracellularly released 
Glu to basal levels. Glu uptake is important to maintain low basal levels for fast 
signaling (good signal-to-noise) and to avoid overexposing cells to Glu, which 
has been shown to be neurotoxic (excitotoxicity) (Danbolt, 2001). 
 Microelectrode arrays configured to record Glu allow us to investigate Glu 
neurotransmission close to the synapse where Glu receptors and transporters 
are localized. As an action potential travels along a glutamatergic axon, 
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 propagated by voltage-gated sodium channels, the wave of depolarization 
ultimately reaches the presynaptic nerve terminal. There, voltage-gated calcium 
channels are activated, and calcium moves into the terminal allowing the docking 
of Glu-filled synaptic vesicles. Glu is released into the synaptic cleft where it 
binds AMPA and NMDA receptors in the post-synaptic density to create fast 
neuronal excitation (Hudspith, 1997, Meldrum, 2000). The concentrations in the 
synaptic cleft rise very quickly (estimated ~1 mM, Meldrum, Akbar, and 
Chapman, 1999) and almost immediately Glu begins to diffuse into the 
extrasynaptic extracellular space. Glu transporters, located primarily on glial 
processes opposed to the synaptic cleft and perisynaptically on the postsynaptic 
neuron, quickly begin to actively remove Glu from the extracellular space 
(Danbolt, 2001). Some Glu molecules escape immediate uptake and diffuse 
farther extrasynaptically where they can act on both ionotropic and metabotropic 
Glu receptors located on nearby neurons and glia. It is most likely this fraction of 
vesicular Glu which we currently have methods to study. However, information 
gained from studying extrasynaptic Glu may reflect Glu signaling in the synaptic 
cleft. 
 The considerable knowledge that already exists about Glu biology has 
stimulated intense interest in directly measuring Glu signaling in the intact brain. 
In some of the present studies, we focused on investigating normal Glu 
neurotransmission in the anesthetized rat and monkey brain and had very 
straightforward aims. We questioned how basal Glu is regulated, what we could 
learn about its origin, and how we could measure its levels. We also wanted to 
study evoked Glu kinetics, or in other words, to directly measure endogenous Glu 
as it is released from the presynaptic terminals and cleared from the extracellular 
space by the Glu transport system. In some studies, we extended this aim by 
applying exogenous Glu and specifically investigating the limits and 
responsiveness of the uptake system. We wanted to conduct these studies 
because no technology has ever before been able to reliably make these 
measurements in the intact brain as fast or as close to the synapse. We also 
wanted to define some of the normal characteristics of Glu signaling to provide a 
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 basis to hypothesize and test for alterations in Glu neurotransmission which may 
underlie many brain disorders. 
 
The Role of L-Glutamate in Parkinson’s Disease 
 
 While much of this work attempts to understand Glu regulation at the 
synaptic level, it may be equally important to place those findings in context of a 
large neural network with much higher levels of complexity. In fact, this is always 
the case in the intact brain where, in any particular brain region, there are 
multiple neurotransmitter and neuromodulatory influences not just on dendrites 
and soma to manipulate membrane potentials but also on presynaptic terminals 
and glial cells to affect neurotransmitter release and uptake kinetics. The 
connectivity of networks is perhaps best demonstrated when there is a failure, 
sometimes of just one circuit, which disrupts the entire system. Parkinson’s 
disease unfolds in a similar fashion, and studying the many changes that occur in 
the brain following disease onset is an interesting and important task. 
 Idiopathic PD is an age-related chronic neurodegenerative disorder that is 
classically characterized by resting tremor, cogwheel muscular rigidity, and 
slowness or loss of movement (bradykinesia or akinesia) (Lang and Lozano, 
1998). PD patients also tend to have postural instability, a shuffling gait, and 
masked facies (facial expression). The pathophysiology of Parkinson’s disease 
clearly begins with the loss of dopamine neurotransmission along the nigrostriatal 
pathway from the substantia nigra pars compacta (SNc) to the striatum (caudate 
and putamen) (Wichmann and DeLong, 2003). However, from a network 
perspective, the downstream effects of dopamine denervation on brain circuitry 
are far reaching, affecting Glu, GABA, acetylcholine, and many other 
neurotransmitter systems (Starr, 1995, Wichmann and DeLong, 2003) (Figure 
1.2). With the role of dopamine and dopamine-based treatments exhaustively 
investigated, many investigators have turned to studying other neurotransmitter  
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Adapted from Wichmann and DeLong (2003) 
 
Figure 1.2 Normal and Disease-Altered Basal Ganglia-Thalamocortical 
Circuitry 
In the normal brain, excitatory influences (gray arrows) and inhibitory influences 
(black arrows) act in a balanced fashion to help control movement. In the 
parkinsonian brain, the loss of DA from the SNc along the nigrostriatal pathway 
alters many neuronal pathways within the basal ganglia-thalamocortical loops. 
Progressively, this results in an inhibition of voluntary movement consistent with 
the symptoms of PD. Alterations in Glu regulation include hyperactivity along the 
corticostriatal and subthalamopallidal pathways. Abbreviation not defined in the 
text: globus pallidus external segment (GPe). 
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 changes in hopes of a greater understanding of PD and finding new therapeutic 
targets. 
 One of the results stemming from this change of focus has been the 
widely accepted redefinition of PD as a disease of secondary Glu hyperactivity 
along a number of involuntary motor pathways. Specifically, glutamatergic 
projections from the cortex (the corticostriatal pathway) and thalamus (THAL) 
provide the major driving force to the medium spiny neurons and cholinergic 
interneurons, respectively, in the striatum, which embodies the major input nuclei 
of the involuntary motor pathways. Furthermore, the subthalamic nucleus (STN) 
transmits Glu to the major output structures of the involuntary motor pathways, 
namely the internal segment of the globus pallidus (GPi) and the substantia nigra 
pars reticulata (SNr) (Wichmann and DeLong, 2003). Evidence supports that 
both the corticostriatal pathway and subthalamic nucleus projections are 
overactive in PD (Bergman, Wichmann, and DeLong, 1990, Calabresi et al., 
1993, Greenamyre, 2001). Understanding Glu signaling in the parkinsonian brain 
may provide insight into the pathophysiology and progression of PD, the 
mechanism of action of currently used medications and surgical treatments, and 
potentially new therapeutic approaches. 
 We were interested in using our microelectrodes to study differences in 
Glu regulation in an animal model of PD, namely the 6-hydroxydopamine (6-
OHDA)-lesioned rat, which is thought to model the late stages of PD. We 
recorded potassium-evoked endogenous Glu release and uptake kinetics in the 
striatum, nucleus accumbens, and frontal cortex of both unilaterally-lesioned 
hemiparkinsonian rats and normal rats in the same age range. We then 
compared results between the groups and within the lesioned group for 
significant differences. This study largely focused on the corticostriatal pathway. 
We would liked to have also investigated Glu signaling near the cell bodies and 
terminals of the subthalamic nucleus; however, it is a much more difficult target in 
the rat brain and more suitable for future studies. 
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The Role of L-Glutamate in Epilepsy 
 
 Epilepsy is a brain disorder characterized by multiple seizures, each of 
which is an episodic motor, sensory, and/or psychic disturbance caused by 
abnormal cerebral electrical activity that can be recorded using 
electroencephalography (EEG). The study of epilepsy may benefit from the 
second-by-second monitoring made possible by our microelectrodes because 
Glu neurotransmission is central to its pathophysiology. Alterations in excitatory 
and inhibitory influences may underlie this brain disorder (During and Spencer, 
1993). Throughout the mammalian CNS and especially in the cerebral cortex, 
Glu is the major excitatory neurotransmitter and GABA is the major inhibitory 
neurotransmitter. Changes in the regulation of either of these chemicals in an 
epileptic brain can alter the balance toward uncontrolled excitation and the 
potential for seizure onset. The prominent role of these neurochemicals is 
evidenced by the fact that many anticonvulsant medications work by enhancing 
GABA activity while most animal models of epilepsy work by chemically, 
electrically, or genetically altering Glu regulation. 
 Both animal and human studies support the strong relationship between 
Glu and epilepsy. Intracellular recordings from rat hippocampal slices 
demonstrate that Glu is responsible for paroxysmal depolarizing shifts 
characteristically associated with epileptic burst discharges (Meldrum, Akbar, and 
Chapman, 1999). Glu receptor agonists (e.g. kainate and NMDA) can chemically 
induce seizures in rats and mice. Genetically altering Glu receptor subunits or 
transporters in mice can create epileptic phenotypes, and Glu receptors and their 
subunits often display changes in protein levels in electrically or chemically 
induced rat models of epilepsy. Studies of resected epileptic brain tissue from 
humans reveal alterations in mRNA and protein levels of Glu receptors and Glu 
receptor subunits (Meldrum, Akbar, and Chapman, 1999). Of particular interest to 
our group are recent data collected from human subjects demonstrating that 
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 there are increases in extracellular Glu levels that occur immediately before and 
during seizures and higher basal Glu in the epileptogenic foci of some patients in 
the time period between seizures (During and Spencer, 1993, Ronne-Engstrom 
et al., 1992, Wilson et al., 1996, Thomas et al., 2003, Cavus et al., 2005). 
 Considering the future of intracranial Glu recording microelectrodes, it has 
become clear that the first human applications would most likely come from the 
neurosurgical arena and specifically from human epilepsy research, where 
implanted devices are commonly used intra- and post-operatively to monitor 
electrical activity and neurochemicals (During and Spencer, 1993, Engel, Jr., 
1998, Fried et al., 1999, Cavus et al., 2005). Our attempts to bridge the worlds of 
basic science, technology development, and patient-oriented research have 
proven to be a difficult task, however, and not enough experimental work was 
completed to merit a full chapter. Nonetheless, important progress and many 
plans for the future have been made. The appendix documents how we may 
introduce our microelectrode arrays into the human operating room, presents 
preliminary recordings from excised human tissue from an epileptic brain, 
discusses additional technological changes that need to be implemented, and 
explains how we believe microelectrode arrays may someday benefit patients 
who suffer from epilepsy and potentially many other brain disorders. 
 
Copyright © Brian Keith Day 2005 
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 Chapter Two: Methods 
 
Microelectrode Array Design 
 
 Fabrication 
 Microelectrode arrays were constructed in conjunction with Thin-Film 
Technologies, Inc. (Buellton, CA, USA). For a full description of microelectrode 
array fabrication, see Burmeister, Moxon, and Gerhardt, 2000 and Burmeister 
and Gerhardt, 2001. Because the microelectrode arrays are fabricated using 
photolithography, multiple geometries (number, size, shape, and arrangement) of 
the microelectrode array’s recording sites are routinely available. For 
consistency, most studies used the S2 geometry defined as microelectrode 
arrays with four platinum (Pt) recording sites (15 x 333 µm) geometrically 
arranged as two pairs of recording sites with 100 µm spacing between pairs and 
30 µm spacing between paired sites (Figure 2.1). Microelectrode arrays with a 
different geometry (serial recording sites, see Appendix Figure A.1) were 
provided to our collaborators at the Brigham Hospital in Boston. 
 
 Layer-Dependent Glu Selectivity 
 Two chemical layers were applied to make the microelectrode array 
selective for Glu, one for exclusion and one for sensitivity. First, the Pt recording 
sites were coated with Nafion™, which electrostatically repels anionic interferents 
such as L-ascorbic acid (AA) and DOPAC (Gerhardt et al., 1984). Thereafter, the 
sites were coated with a protein matrix layer (bovine serum albumin 
(BSA)/glutaraldehyde (GLUT)) containing the enzyme L-glutamate oxidase 
(GluOx). The GluOx layer permits the detection of Glu by enzymatically 
degrading it into α-ketoglutarate and H2O2. As H2O2 diffuses through the Nafion™  
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100 µm 
 
Figure 2.1 Ceramic-Based Pt Microelectrode Array (S2 Geometry) 
The ceramic-based microelectrode array (pictured) has four Pt recording sites 
(15 x 333 µm ea.), which are designed as two pairs of adjacent recording sites 
(30 µm spacing) arranged 100 µm apart. 
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 layer and contacts the Pt surface, it is oxidized at an applied voltage of +0.7 V 
versus Ag/AgCl reference. This reaction frees 2 electrons per H2O2 molecule to 
flow through our electrochemical detection system and record the presence of 
Glu (Figures 2.2 and 2.3). 
 Self-Referencing Configuration 
 To configure a microelectrode array to record Glu in self-referencing 
recording mode, the recording sites were prepared as previously described 
except one pair of recording sites was coated with an enzyme-free protein matrix 
layer (BSA/GLUT) to provide similar small molecule diffusion and detection 
characteristics without the ability to detect Glu (Figure 2.4). Signals on self-
referencing or “sentinel” recording sites may be used qualitatively to verify the 
identity of signals as Glu on Glu recording sites or quantitatively to subtract away 
background signals, noise, interferences, or artifacts. 
 
Electrode Preparation and Use 
 
 Silver/Silver Chloride (Ag/AgCl) Reference Electrodes 
 All of our studies were conducted using constant potential amperometry in 
2 electrode configuration to record Glu in vitro (calibration) and in vivo. This 
method requires both a working electrode (microelectrode array) and a 
silver/silver chloride (Ag/AgCl) reference electrode. Reference electrodes are 
critical for several reasons. First, applying a potential (voltage) at the working 
electrode requires having an electrical reference point, which is provided by the 
reference electrode. Second, to measure electrical current related to 
electrochemical events occurring at the working electrode, there must be a 
physical path of electron flow connected to a balanced (equal and opposite) 
electrochemical event at the reference electrode. Finally, the relationship 
between the working electrode and the reference electrode is thermodynamically 
stable, which is necessary for electrochemical recordings. 
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Figure 2.2 The FAST-16 Electrochemical Recording System 
Front and rear views of the FAST-16 potentiostat box are shown. Additonal 
information about features, controls, and connections is included. The FAST-16 
is used to create a potential difference between the working electrode 
(microelectrode array) and the reference electrode to promote electrochemical 
reactions. In conjunction with other hardware elements, including the headstage 
(pre-amplifier) and PCI card in the computer, the FAST-16 also amplifies the 
signal (electrical current) and digitizes it. The FAST-16 software creates second-
by-second data files based on this information. 
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Figure 2.3 Layer-Dependent Glu Selectivity 
Microelectrode arrays are made selective for Glu by coating layers of polymers 
on the Pt surface. NafionTM is first applied to electrostatically repel anionic 
interferents (e.g. AA and DOPAC). Then, a protein matrix layer 
(BSA/glutaraldehyde) containing the enzyme GluOx is applied. GluOx degrades 
Glu to produce H2O2 and α-ketoglutarate. H2O2 can be electrochemically 
detected on Pt (+0.7 V vs. Ag/AgCl reference). Other abbreviations: oxygen (O2) 
and proton (H+). 
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Figure 2.4 Microelectrode Array Configured for Self-Referencing Glu 
Recordings 
Refer to Figure 2.3 for a detailed explanation of layer-dependent Glu selectivity 
on Glu recording sites. A protein matrix layer (BSA/glutaraldehyde (GLUT)) with 
GluOx was coated on one pair to configure Glu recording sites (a). A similar 
protein matrix layer without GluOx was coated on the other pair to create self-
referencing or “sentinel” sites (b). Enzyme-free sites are not configured to detect 
Glu. Other abbreviations: α-ketoglutarate (α-KG), electron (e-). 
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  Two types of Ag/AgCl reference electrodes were used. Glass-bodied 
reference electrodes (RE-5b, Bioanalytical Systems, Inc.) require minimal 
preparation. On arrival, these electrodes are stored in 3 M NaCl. The quality of 
these electrodes can be tested against a known good Ag/AgCl reference 
electrode using a voltmeter; the potential difference should not exceed ±10 mV. 
This type of reference electrode is routinely used during microelectrode array 
calibration. The glass-bodied type is also preferred for some in vivo 
electrochemical recordings because an implanted bare wire Ag/AgCl reference 
electrode can damage brain tissue. An RE-5b was used to allow Glu recordings 
in the anesthetized nonhuman primates. This is possible because during each 
experiment the reference electrode maintained ionic contact with the animal’s 
brain. 
 Bare wire Ag/AgCl reference electrodes were prepared for acute 
anesthetized rat experiments. Teflon-coated silver wire was cut to length (10-20 
cm), and roughly 5 mm of Teflon was stripped from both ends. One end was 
soldered to an amphenol gold pin connector. The other end was placed in a 
saturated chloride solution (1 M HCl supersaturated with NaCl) along with a 
stainless steel wire. A modified power supply (9 V DC) was plugged into a 120 V 
wall outlet, the negative lead was connected to the stainless steel wire, and the 
positive lead was connected to the silver wire. AgCl was allowed to electroplate 
onto the exposed silver wire for 5-10 minutes. The prepared Ag/AgCl end of the 
reference electrode was implanted in the rat’s brain, and the amphenol connector 
was plugged into the FAST-16 hardware. 
 
 Microelectrode Arrays 
 The microelectrode arrays were coated to make them selective for Glu. 
Clean microelectrode arrays were dipped into fresh, stock Nafion™ and oven-
dried at 175 oC for 4 minutes. A 10 µL solution containing 1% (w/v) GluOx, 1% 
(w/v) BSA, and 0.125% (w/w) glutaraldehyde in ddH2O was prepared.  Under a 
dissecting microscope, a microsyringe (model 80100, Hamilton Co.) was used to 
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 coat the recording sites with the enzyme solution.  A small drop of the solution 
(~0.1 µL) suspended at the tip of the microsyringe needle was put in contact with 
the recording sites and removed. The coating was allowed to air dry, and 2-4 
additional coatings were applied at one minute intervals to achieve appropriate 
thickness. When required, microelectrode arrays were configured for self-
referencing recordings by leaving one or more adjacent recording sites uncoated 
and similarly applying an enzyme-free solution containing 1% BSA and 0.125% 
glutaraldehyde to these sites as a second coating step (Figure 2.4). All coatings 
were permitted to cure (overnight to two weeks) at room temperature in a clean 
environment prior to in vitro testing. 
 To calibrate the microelectrode arrays, constant voltage amperometry was 
performed using a FAST-16 high-speed electrochemistry instrument (Quanteon, 
L.L.C.) using software (Fast Analytical Sensor Technology (FAST), Quanteon, 
L.L.C.) written for simultaneous four-channel recordings.  Typically, 
measurements were carried out using an applied potential of +0.7 V vs. Ag/AgCl 
reference (Bioanalytical Systems, Inc., RE-5b). Some microelectrodes were 
calibrated at +0.7 V and separately at +0.25 V for particular experiments. For 
calibrations, the microelectrode recording sites were soaked for 45-60 minutes in 
a solution of 0.05 M phosphate-buffered saline (PBS) at room temperature, pH 
7.4. The microelectrode was then connected to the FAST-16 hardware, and the 
recording sites were lowered into 40 ml of PBS at 37 °C in a 50 ml beaker.  The 
PBS was slowly stirred without creating a vortex, using a 10 x 3 mm magnetic stir 
bar. A battery-operated stir plate (Barnant Co.) was used to mix the solution and 
to reduce AC (60 Hz) interference.  The buffer’s temperature was maintained 
using a recirculating water bath (Quanteon, LLC).  A combination headstage gain 
(2 nA/V) and secondary gain of 10X (200 pA/V final gain) was used for all 
amperometric recordings.  Aliquots of stock solutions of 20 mM AA, 20 mM Glu, 
2 mM DA, and 8.8 mM H2O2 were sequentially added to the buffer to produce the 
following final concentrations: 250 µM AA, 20, 40, 60 & 80 µM Glu, 2 µM DA, and 
8.8 µM H2O2. Amperometric measurements were taken for each addition. 
Selectivity ((∆I/ µM Glu):( ∆I/ µM AA), where I = current), slope (sensitivity, (∆I/ 
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 µM Glu)), limit of detection (LOD, signal-to-noise = 3), and linearity (R2) of the 
regression line of current vs. Glu concentration were calculated for each 
recording site. We have high confidence in the accurate measurement of Glu 
concentrations below the lower limit of our calibration range (i.e. <20 µM Glu) 
because of the excellent linearity of the response to the Glu reporter molecule 
H2O2 by Nafion™-coated microelectrode array recording sites (R2 > 0.999 ± 
0.000, Burmeister, Moxon, and Gerhardt, 2000). 
 Most experiments required delivering drugs or chemicals intracranially. 
When not required, the following steps were omitted. A Kopf model 700C pipette 
puller (David Kopf Instruments, Tujunga, CA) was used to pull single barrel glass 
capillary micropipettes (1.0 mm × 0.58 mm, 6", A-M Systems, Inc., Everett, WA, 
USA). The pulled glass micropipettes were bumped until the inner tip diameter 
was 10-15 µm. The micropipette tip was placed central to all recording sites and 
between 50 µm and 100 µm from the recording surface and attached to the 
microelectrode array’s ceramic paddle using Sticky Wax (Kerr Brand). 
 With or without an attached micropipette, the microelectrode was stored 
with the recording sites in PBS until the in vivo studies. Rats were anesthetized 
and surgically prepared for electrochemical recordings as described in the 
Animal Preparation for In Vivo Electrochemical Recording section (below). For 
intracranial ejections, a solution was loaded into the single-barrel micropipette 
using a custom-made, pulled stainless steel needle (30 gauge, Popper and Sons, 
Inc., New Hyde Park, NY, USA) attached to a sterile syringe filter (0.22 µm pore 
size, Costar, Corning, NY, USA) and a 1 cc syringe. The fully prepared 
microelectrode array was implanted into the animal’s brain. A fifteen minute 
equilibration period per brain region was allowed prior to beginning each 
experiment. Volumes of the solutions were ejected from the micropipette using a 
Picospritzer III (Parker Hannifin Corp., General valve operation, 5 to 40 PSI over 
0.2 to 2.0 seconds) and monitored using a stereomicroscope fitted with a reticule 
(Friedemann and Gerhardt, 1992). The FAST-16 recording system was used to 
record in vivo Glu. Specific details regarding recorded brain structures and their 
coordinates, intracranially applied drugs and chemicals, changes in recording 
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 parameters, and data analysis are included with the corresponding experiments 
described in chapters three, four, and five and the appendix. See Burmeister et 
al. (2002) for additional details (e.g. microelectrode fabrication, microelectrode 
cleaning and re-use). 
 
 The Durability of L-Glutamate Oxidase 
 It is important for in vivo applications of enzyme-based detection 
technologies that the enzyme used is resistant to being denatured by changing 
experimental conditions. Reduced enzyme activity by the loss or altered 
conformation of enzyme active sites would impair the microelectrode array’s 
sensitivity and limit of detection. Though we had never noted experimental 
findings that lead us to hypothesize that GluOx activity was changing due to 
denaturation, we did not appreciate the durability of this enzyme until we 
attempted to denature it ourselves to create an inactivated form of GluOx 
(iGluOx). These efforts were made in an attempt to match our protein matrices 
on Glu recording and sentinel/referencing sites more closely (BSA/Glut/GluOx vs. 
BSA/Glut/iGluOx, respectively). L-glutamate oxidase (EC 1.4.3.11) is a 140 kD 
protein composed of three subunits arranged in a hexameric structure (α2β2γ2) 
(Kusakabe et al., 1983). Several attempts to inactivate the enzyme were 
conducted as follows. 
 In initial testing, 5 µl (5 units) of stock enzyme solution were placed in a 
microcentrifuge tube and heated in a water bath at 80 °C for 15 minutes. The 
resulting condensed pellet, which was lighter in color and reduced in volume, 
was reconstituted with ddH2O to a final volume of 5 µl to bring it back to stock 
solution concentration. This solution was used in place of the normal GluOx stock 
solution to create a potentially heat-inactivated enzyme coating for the sentinel 
recording sites. Two microelectrode arrays were prepared using this coating and 
calibrated as described in the preceding section. It should be noted that the 
potentially-inactivated enzyme coating contained visible aggregates of enzyme 
unlike the typical homogenous appearance of normal enzyme coatings. Sentinel 
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 recording sites on both microelectrode arrays responded well to Glu additions 
during calibration demonstrating that the heated enzyme had retained activity. 
 Four additional methods were attempted to inactivate samples of the 
enzyme. Four 2 µl samples (2 units each) of stock enzyme solution were placed 
in separate microcentrifuge tubes and subjected to one of the following 
conditions: heated in a water bath at 100 °C for 15 minutes, heated by heat block 
at 100 °C for 15 minutes, microwaved at maximum power in a 1.1 kW output 
microwave oven for 1 minute, and cycled through one freeze-thaw cycle (-80 °C 
to room temperature). All samples were capped and sealed with both Parafilm 
and tape to prevent the escape of water vapor from the sample. Heated samples 
were immediately cooled down in an ice-cold water bath and allowed to rest for 
at least 15 minutes prior to activity testing. All samples were tested for activity 
using an uncoated microelectrode array as a H2O2 detector. The FAST-16 
hardware and software was used to perform a H2O2 calibration (a.k.a. peroxide 
test) of the microelectrode array exactly as calibrations are described in the 
preceding section except no AA, Glu, or DA was used and 8.8 mM H2O2 was 
added to create the following sequence of final volumes: 8.8, 17.6, 26.4, and 
35.2 µM H2O2. This peroxide test was not done specifically to produce a 
calibration factor but qualitatively to confirm that the microelectrode array had 
good sensitivity for H2O2. Also, the microelectrode tip was rinsed thoroughly with 
ddH2O between enzyme activity tests. 
 To prepare each sample for testing, the tape and Parafilm were removed, 
any water vapor that had condensed in the top was shaken down, and the tube 
was uncapped. Then, the sample was diluted with ddH2O (1:10) to a final volume 
of 20 µl to provide an adequate volume and vertical clearance for the 
microelectrode tip. The enzyme sample was agitated by a pipettor and/or spun 
using a vortexer if it did not readily mix with the added water. Portions of the 
microcentrifuge tube were carefully cut and removed until there was only a ~1 cm 
portion of the bottom of the tube remaining, which was the reservoir for the 
sample. This miniature reservoir was securely held in place by modeling clay to 
hold it upright. A bare wire Ag/AgCl reference electrode, prepared as described 
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 in the preceding section, was placed in the enzyme sample solution, and the 
microelectrode tip was lowered stereotaxically until all sites were submerged. 
Amperometric recordings (+0.7 V vs. Ag/AgCl reference) were made in the 
solution as up to 5 additions of Glu (20 mM, 1 µl) were added. This procedure 
has been used to verify GluOx activity in the past to troubleshoot non-responsive 
prepared microelectrodes, and it was known that normal stock enzyme would 
produce maximum detectable current with one addition of Glu even without 
stirring. 
 None of the methods used to inactivate GluOx completely eliminated 
enzyme activity. The enzyme subjected to the 100 °C water bath displayed 
activity at the third addition of Glu, and after 5 additions showed ~30% of 
maximum detectable current. The enzyme placed in the 100 °C heat block did 
not show activity until the fifth addition, which produced ~50% of maximum 
response. Both microwaved and freeze-thawed enzyme samples showed 
maximal detectable current after the first addition of Glu. In summary, we have 
not developed methods to inactivate GluOx for use on sentinel recording sites of 
microelectrode arrays configured for self-referencing. Instead, we have found 
that GluOx is an extremely durable enzyme, which is an advantage for acute use, 
chronic implantation, and future sterilization procedures. The long-term stability 
of purified or solubilized GluOx has not been fully determined by any research 
group or commercial entity. Initial studies conducted by our group investigating 
exogenous Glu detection in the brains of chronically implanted freely-moving rats 
indicate that GluOx in our cured protein matrix is active for up to 50 days in vivo. 
 
Animal Preparation for In Vivo Electrochemical Recordings 
 
 All animals were handled and cared for using protocols approved by the 
institutional animal care and use committees (IACUC) of the University of 
Kentucky Chandler Medical Center (UKMC) and the Medical University of South 
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 Carolina (MUSC). Both institutions are fully accredited by AAALACI (Association 
of Assessment and Accreditation of Laboratory Animal Care International). 
 
 Normal Young Fischer 344 Rats 
 Male Fischer 344 rats (3-6 months old, 200-300 g) were used to study 
normal Glu regulation and as non-lesioned control animals for the unilateral 6-
OHDA lesion study. The Fischer 344 rat, an inbred strain of rats, was chosen for 
these studies to limit the biological variability between animals. Coordinates used 
for stereotaxic surgery and microelectrode implantation were calculated from 
bregma using the rat brain atlas of Paxinos and Watson (1986). Rats were 
anesthetized with urethane (1.25 mg/kg, i.p.) in three divided doses. First, a 
loading dose approximately equal to one-half of the total dose was administered; 
the remaining urethane was given in two more injections over the course of up to 
1 hour as the rat became sedated. Partially anesthetized rats were weighed 
shortly before the second injection to ensure proper dosing. Urethane-injected 
rats were rested on a 37 °C heating pad as they approached the surgical plane of 
anesthesia. A rat was considered to be fully anesthetized when he was non-
responsive to toe pinch; rats reflexive to noxious stimuli two hours after the initial 
loading dose were given additional doses of urethane (0.1 cc of 25% (w/v), i.p.) 
at 15 minute intervals until they no longer responded to toe pinch. Anesthetized 
rats were placed in a stereotaxic frame (incisor bar: -2.3 mm) and rested on a 37 
°C heating pad. 
 The top of the rat’s head was visualized through a zoom-capable 
stereomicroscope (10x eyepiece, 0.5x objective, 0.7 to 4.5 zoom) on a boom 
stand. A midline, longitudinal incision (~4 cm) was made through the scalp 
overlying the skull. The skin and fascia were reflected bilaterally and held in 
retraction by clamps. Throughout the surgery, bleeding was controlled by 
cauterization, and the surgical field was cleaned of blood and loose tissue using 
physiological (0.9%) saline irrigation, surgical gauze (2 x 2’s), and cotton-tipped 
applicators. Identification of skull landmarks (sagittal suture, coronal suture, 
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 lambdoidal suture, bregma, and lambda) helped guide surgical bone removal; in 
particular, bregma was permanently marked prior to drilling. Section(s) of skull 
overlying the brain areas of interest were outlined. Perimeters were cut nearly or 
completely to the dural surface using a Dremel hand-held drill (Model 395, 
Racine, WI) with an engraving cutter drill bit (Dremel bit #105, 106, or 107, 
Racine, WI). The resulting bone flap was removed. The dura was carefully 
incised and dissected away to expose the cortical surface of the rat brain. A 
small burr hole was drilled through the skull at a remote location from the primary 
surgical area(s) for Ag/AgCl reference electrode implantation. Starting from 
bregma, prepared microelectrode arrays were stereotaxically aligned and 
lowered until the center of the recording sites were at the cortical surface. 
Microelectrode arrays were advanced into the brain to record different depths by 
a microdrive (Narishige, MO-8) (Figure 2.5). 
 
 Unilateral 6-Hydroxydopamine-Lesioned Young Fischer 344 Rats 
 Unilateral 6-hydroxydopamine (6-OHDA)-lesioned male Fischer 344 rats 
(5-9 months old, 250-350 g) were used to study the effects of striatal dopamine 
denervation on potassium-evoked Glu kinetics. Coordinates used for stereotaxic 
surgery and microelectrode implantation were calculated from bregma using the 
rat brain atlas of Paxinos and Watson (1986). 
 Lesioning and rotational testing were performed by Lauren Willis in the lab 
of Anne-Charlotte Granholm, Ph.D. (Department of Physiology and 
Neurosciences, Medical University of South Carolina). Rats were anesthetized 
with chloral hydrate (400 mg/kg in 0.9% NaCl, i.p.) and stereotaxically lesioned in 
the right medial forebrain bundle with 9 µg/4 µl of 6-OHDA in normal saline 
containing 0.02% ascorbate (coordinates -4.4 mm AP, +1.3 mm ML, and -7.8 mm 
DV from the dural surface; see Granholm et al., 1997). The 6-OHDA neurotoxin 
was administered over 4 minutes followed by a 2-minute delay period prior to 
needle withdrawal to allow for toxin absorption into the brain tissue. Animals were  
35 
  
 
Figure 2.5 The In Vivo Glu Recording Setup for Anesthetized Rat Studies 
36 
 provided with acetaminophen in their drinking water for 24 hours to alleviate 
potential post-surgical discomfort.  
 Lesioned animals were evaluated for apomorphine-induced rotational 
behavior beginning one week following 6-OHDA administration and tested once a 
week thereafter for a total of 4 weeks. Briefly, animals were placed in rotometer 
bowls (Hudson et al., 1993) and secured to the counting sensor by a thoracic 
harness. Subjects were allowed to acclimate to the environment for 10 minutes, 
and then administered a subcutaneous injection of apomorphine (0.05 mg/kg). 
Subsequent rotational behavior was recorded for one hour. Following rotational 
testing, animals were released from their harnesses, removed from the rotometer 
bowls, and returned to their cages. 
 A group of rats which responded to apomorphine with average 
contralateral rotations ≥300 times/hour were transferred to the University of 
Kentucky for in vivo electrochemical recordings. At least three months was 
allowed for the lesion to stabilize before recordings were made. Animals were 
anesthetized, surgically prepared, and implanted with electrodes exactly as 
described in the preceding section. 
 
 Normal Anesthetized Rhesus Monkeys (Macaca mulatta) 
 Three female normal rhesus monkeys (8, 25, and 28 years old) were used 
to characterize normal Glu regulation in the motor cortex and frontal cortex of 
young and aged nonhuman primates. Several methodological modifications were 
required to conduct recordings in the veterinary operating room. Because method 
refinement was part of the aims of conducting this study, a full methodological 
description is presented in Chapter Four. 
 
Drugs and Chemicals 
  
 All chemicals were used as received unless otherwise stated. All solutions 
were prepared using distilled, deionized water. 
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 Chemicals for Microelectrode Preparation and Calibration 
 Nafion™ (5% (w/v) in a mixture of aliphatic alcohols and water), BSA, 
glutaraldehyde (25% (w/w) in water), AA, Glu monosodium salt, and DA were 
obtained from Sigma-Aldrich Corp. (St. Louis, MO, USA) (Figure 2.6). GluOx was 
purchased from Seikagaku America, Inc. (East Falmouth, MA, USA). The 3% 
H2O2 solution was purchased from a local retailer. Sodium chloride, sodium 
phosphate monobasic, and sodium phosphate dibasic (used to make 0.05 M 
PBS) were obtained from Fisher Scientific (Fair Lawn, NJ, USA). The DA stock 
solution was prepared in 1% perchloric acid for prolonged stability. 
Glutaraldehyde was stored at -20 ºC. Special care was taken to ensure that the 
stock Nafion™, BSA, and glutaraldehyde solutions were only used for 1-2 
months. 
 
 Intracranially-Applied Drugs and Chemicals 
 Solutions used for intracranial injections were prepared in 0.9% saline, 
adjusted to pH 7.2-7.4, and filtered before use using a sterile syringe filter (0.22 
µm pore size, Costar, Corning, NY, USA). Sodium chloride, potassium chloride, 
and calcium chloride dihydrate (used for 0.9% saline and high potassium 
solutions) were obtained from Fisher Scientific (Fair Lawn, NJ, USA).  Glu 
monosodium salt and tetrodotoxin (TTX) were obtained from Sigma-Aldrich Corp. 
(St. Louis, MO, USA). D,L-threo-β-benzyloxyaspartate (TBOA) was obtained 
from Tocris Cookson Inc. (Ellisville, MO, USA) (Figure 2.6). 
 
 Anesthetics and Special-Use Drugs and Chemicals 
 Injectable anesthetics used in rat studies were prepared in 0.9% saline; 
sodium chloride was obtained from Fisher Scientific (Fair Lawn, NJ, USA). 
Urethane, chloral hydrate, 6-OHDA, apomorphine, and AA (used to delay the 
oxidation of the previous two drugs in solution) were obtained from Sigma-Aldrich 
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Figure 2.6 Molecular Structures of Selected Drugs and Chemicals 
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 Figure 2.6 (continued) 
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 Corp. (St. Louis, MO, USA) (Figure 2.6). While recovering, 6-OHDA-lesioned rats 
were given acetaminophen, which was provided by the hospital pharmacy at the 
Medical University of South Carolina (Charleston, SC). The following drugs and 
chemicals were used to prepare the nonhuman primates for anesthesia, 
magnetic resonance imaging, and surgery. Ketamine hydrochloride and 
chlorhexidine diacetate were obtained from Fort Dodge Animal Health (Fort 
Dodge, IA). Atropine sulfate was obtained from Butler Company (Columbus, OH). 
Sodium pentobarbital was obtained from Ovation Pharmaceuticals, Inc. 
(Deerfield, IL). Isoflurane was obtained from Baxter Healthcare Corporation 
(Deerfield, IL). Betadine® was obtained from Purdue Frederick Company 
(Stamford, CT). The 70% isopropyl alcohol solution was obtained from Hydrox 
Laboratories (Elgin, IL). Chronically-studied nonhuman primates were also given 
post-operative pain medication and prophylactic antibiotics. Buprenorphine was 
obtained from Reckitt Benckiser Health Care (Richmond, VA). Penicillin G 
Benzathine and Penicillin G Procaine were obtained from G. C. Hanford 
Manufacturing Company (Syracuse, NY). 
 
Data Analysis 
 Glu Signal Parameters 
 Glu signals, produced by evoked Glu release or exogenous Glu 
applications, are described by concentration and time measurements, which are 
then used to calculate additional signal parameters. Figure 2.7 depicts an 
example of a spike-shaped signal and some of the signal parameters that may 
be used to describe it. These include amplitude (the maximum change in 
concentration (µM Glu)), rise time (TR, the time from onset (stimulation or 
exogenous application of Glu) until peak amplitude (sec)), and total signal 
duration (TTotal, the time from onset until complete return to baseline (sec)). Other 
signal parameters are time measurements related to signal decay. Although 
abbreviated similarly, they should be considered separately from TR and TTotal.  
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Figure 2.7 Glu Signal Parameters 
A schematic example of a spike-shaped Glu signal is shown to illustrate how 
different signal parameters are measured and calculated. See text for details. 
Typically Glu signals are plotted as concentration versus time. The y-axis has 
been changed to percent response to clarify the definitions of certain signal 
parameters. 
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 These often include T50, T80, and T100, and follow the general format of TD (sec), 
where T refers to the time from peak amplitude for the signal to decay by D 
percent. Next, k-1 (sec-1) is a rate constant (first-order exponential rate of fit) 
related only to the decay portion of the curve. The constant k-1 is the slope of the 
linear regression of the natural log transformation of this data over time. Finally, 
uptake rate (µM Glu/sec) is calculated by multiplying peak amplitude by k-1. 
 Repeated potassium-evoked Glu releases and Glu ejection signals were 
collected at one or more depths within each brain region of interest. Individual 
parameters for each signal were pooled across animals by brain region. Each 
signal is considered an independent event under the assumption that the 
variability of responses within an animal is much greater than the variability of 
responses between animals, as has been stated for similar studies of other 
neurotransmitters, such as DA (see Cass et al., 1995). The number of data 
points (n) used for statistical analyses is the number of Glu signals recorded; 
however, the number of animals is also reported for consideration (e.g. n=40 
signals in 4 rats). 
 
 Other Analytical Approaches 
 Data analyses with respect to basal Glu regulation (effects of TTX and 
TBOA) and basal Glu measures are described in detail in Chapter Three. 
 
Copyright © Brian Keith Day 2005 
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 Chapter Three: Normal L-Glutamate Regulation in the Anesthetized Rat 
Brain 
 
Introduction 
 
 The work presented in this chapter focuses on basal and potassium-
evoked Glu release in the brains of normal young anesthetized rats. Previous 
work by our group had established many characteristics of in vivo Glu dynamics 
including fast signaling driven by rapid Glu uptake, limited dose-dependence of 
potassium-evoked Glu responses, robust dose-dependence of locally-applied 
exogenous Glu, and the reproducible nature of potassium-evoked Glu responses 
(Burmeister, Moxon, and Gerhardt, 2000, Burmeister and Gerhardt, 2001, 
Burmeister et al., 2002). Nonetheless, the speed and reproducibility of 
potassium-evoked Glu signals needed to be more extensively analyzed and fully 
documented. In particular, the effects of varying the concentration of potassium 
and shortening the time interval between potassium stimulations are reported. 
 Though we had conducted many Glu kinetics studies, work had not yet 
been completed to study basal Glu. Conducting basal Glu studies was especially 
important because our technology works much faster and closer to the synapse 
than microdialysis and might reveal significant and novel findings. These studies 
were delayed, in part, because our technology is especially good at detecting 
relative changes in Glu concentration from a defined baseline, an advantage 
which we readily used to study basal Glu regulation, but determining the 
concentration of Glu that contributed to that baseline is more difficult and 
required both technological refinement and new analytical approaches. The 
baseline signal (iB) presented a challenge because it is composed of multiple 
components, the background current (iBKD) and the current generated by 
electrochemical detection of molecules on the Pt surface (iB = iBKD + iX + iY + iZ + 
…). The background current may differ between microelectrodes and changes 
over time during an amperometric recording. After equilibration, it is nearly 
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 constant over a short period of time for all similarly designed, fabricated, and 
prepared recording sites within a microelectrode array, but you cannot know 
exactly what it is at a particular time point. The latter fact explains why we could 
not simply subtract away the background current from the baseline signal to 
ultimately calculate basal Glu concentrations. In fact, we conceptually had a 
solution for many years, which was self-referencing, but we had not yet carried 
out the experiments to test the hypothesis that we could use self-referencing 
subtraction methods to quantitate basal Glu levels. 
 The studies presented in this chapter were conducted in the striatum and 
frontal cortex to expand our knowledge of potassium-evoked Glu release and 
break new ground into investigations of basal Glu. The high temporal and spatial 
resolution of our microelectrode arrays allowed us to study in vivo Glu faster and 
closer to synaptic events than previously possible. Furthermore, the self-
referencing capabilities of our microelectrode-based technology produced data 
that we could use in new experimental and analytical approaches to determine 
basal Glu measures. One of these new approaches utilized the versatility of our 
technology by varying the applied voltage (versus Ag/AgCl reference electrode) 
at the recording surface. Finally, we used the combination of a self-referencing 
recording mode and varying the applied voltage to further confirm that Glu is the 
source of our amperometric signal because signal identity is the most cited 
potential disadvantage of voltammetric-based microelectrode studies (see 
Gerhardt and Burmeister, 2000, Obrenovitch and Zilkha, 2001). 
 
Methods 
 
 Refer to Chapter Two for full details. In the Animal Preparation for In Vivo 
Electrochemical Recordings section, the Normal Young Fischer 344 Rats 
subsection is relevant to studies presented in this chapter. 
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  Stereotaxic Implantation and Glu Recordings 
 Microelectrode arrays, with or without attached single-barrel micropipettes, 
were stored with the recording sites in PBS until the in vivo studies. For 
experiments in which one or more intracranial ejections were required, an 
appropriate solution (described below) was loaded into the micropipette. After 
aligning the center of the recording sites at the cortical surface, the 
microelectrode array was advanced into the brain using a hydraulic microdrive 
(Narishige MO-8). Recordings were made in the striatum (AP +1.0, ML -2.5, DV -
5.0 mm) and in the frontal cortex (AP +2.7, ML -1.5, DV -2.0 mm). The 
microelectrode tip was thoroughly rinsed with physiological saline between 
regional recordings. A fifteen minute equilibration period per brain region was 
allowed prior to beginning each experiment. The FAST-16 recording system, 
software, and recording parameters previously described were used to record in 
vivo Glu unless otherwise noted. To study basal Glu regulation, one of the 
following solutions was loaded into the micropipette for ejection: physiological 
(0.9%) saline, a 100 µM TTX solution, or a 100 µM TBOA solution (barrel 
concentrations). To measure basal Glu, microelectrodes configured for self-
referencing Glu recordings were typically used without attached micropipettes. 
Passive recordings were made to determine basal Glu at a constant potential 
(+0.7 V vs. Ag/AgCl) and varied potentials (+0.25 V compared to +0.7 V, vs. 
Ag/AgCl reference). To study evoked Glu release, a potassium solution (70 mM 
KCl, 79 mM NaCl, 2.5 mM CaCl2?2H2O, pH 7.4 or 120 mM KCl, 29 mM NaCl, 2.5 
mM CaCl2?2H2O, pH 7.4) was locally applied at 10 second to 5 minute intervals. 
 
 Data Analysis 
 For the basal Glu regulation data, a single channel subtraction approach 
was used. Following a 15 minute equilibration period to allow the signal to 
establish a baseline, pretreatment and post-treatment baselines were defined as 
the baseline signals during the 5 minute periods immediately before and after 
local intracranial drug applications. An averaged 10 second portion of the 
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 pretreatment baseline was compared to the maximum averaged 10 second 
portion of the post-treatment baseline to determine the change in signal due to 
treatment. The change in signal was converted into apparent change in Glu 
concentration using a recording site-specific calibration factor. Apparent changes 
in Glu concentration due to TTX or TBOA were compared to apparent changes in 
Glu concentration due to normal saline for each brain region by an unpaired, two-
tailed t-test (α=0.05). Average TTX- and TBOA-dependent Glu levels were 
calculated by subtracting the average apparent change in Glu concentration due 
to saline from each apparent change in Glu from individual TTX and TBOA 
experiments. Descriptive statistics were used to characterize the new data sets. 
 To determine basal Glu measures, paired channel subtraction approaches 
were used. A 15 minute equilibration period was allowed for the signals to attain 
their baselines. Simultaneously recorded signals on paired channels of the 
microelectrode array (enzyme-coated (+GluOx) versus enzyme-free (-GluOx)) 
were compared. Using a constant voltage method (+0.7 V vs. Ag/AgCl 
reference), resulting differences were converted to Glu concentration using the 
+GluOx calibration factor (slope m+GluOx = ∆I/µM Glu) from the enzyme-coated 
site, calculated from a typical calibration at +0.7 V vs. Ag/AgCl reference. We can 
use this slope because the slope calculated from the enzyme-free sentinel site 
during the same calibration was approximately zero for all microelectrodes that 
were used to measure basal Glu (Figures 3.1 and 3.2). Additionally, using a 
varied voltage method, each brain region was recorded at +0.25 V and +0.7 V 
(both vs. Ag/AgCl reference) and the voltage-dependent signal changes across 
individual channels were compared between +GluOx and -GluOx channels. 
Signal differences were converted to Glu concentration using a calibration factor 
equal to the difference in +GluOx calibration factors calculated at both +0.25 V 
and +0.7 V (both vs. Ag/AgCl reference) (Figure 3.3). Resulting measures from 
the two paired channel subtraction methods as well as average calculated TTX-
dependent changes in Glu concentrations were compared by a 1-way ANOVA 
with Bonferroni post-hoc tests (α=0.05) for each brain region. 
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Figure 3.1 Typical Calibration of a Microelectrode Array Configured for Self-
Referencing Glu Recordings 
During calibration, a standard sequence of chemicals was added to determine 
each recording site’s sensitivity to Glu, selectivity for Glu over AA, and 
responsiveness to other non-anionic electroactive molecules (e.g. DA and H2O2). 
An enzyme-coated Glu recording site (+GluOx) responds well to Glu and some 
electroactive molecules. An enzyme-free sentinel site (-GluOx) does not respond 
to Glu but shows similar responses to the same electroactive molecules. Final 
concentrations of each addition shown above: 250 µM AA, 20, 40, 60, and 80 µM 
Glu, 2 µM DA, and 8.8 µM H2O2. 
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Figure 3.2 Slopes of Glu Recording Sites and Sentinel Sites under Normal 
Calibration Conditions 
Data from a representative calibration are shown. Though calibrations can be 
graphed as current versus time (Figure 3.1), the data can also be replotted to 
show the average current at each Glu concentration. The slope of the linear 
regression of this plot produces our calibration factor (∆I/µM Glu) for each 
recording site. When we subtract raw current data between paired channels to 
use self-referencing recordings quantitatively (i.e.  I+GluOx minus I-GluOx), the proper 
calibration factor to determine Glu concentration is the difference between the 
slopes from the paired channels (i.e. m+GluOx minus m-GluOx). Because enzyme-
free sites do not respond to Glu, m-GluOx ≈ 0, and the calibration term simplifies to 
m+GluOx. In short, ∆Glu = (I+GluOx - I-GluOx)/ m+GluOx, where ∆Glu = the change in Glu 
concentration between the two paired channels at constant potential (+0.7 V vs. 
Ag/AgCl reference). 
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Figure 3.3 Slopes of Glu Recording Sites Calibrated at Two Different 
Applied Potentials 
To use a varied voltage analytical approach to measure basal Glu, we calibrated 
the same microelectrode arrays at two different applied potentials (vs. Ag/AgCl 
reference). Current versus Glu concentration plots are shown for a representative 
enzyme-coated recording site calibrated at +0.7 V (diamonds) and +0.25 V 
(squares). A voltage-dependent change in current on an enzyme-coated channel 
(∆I+GluOx(∆V) = I+GluOx(+0.7 V) - I+GluOx(+0.25 V)) minus a voltage-dependent change in 
current on an enzyme-free channel (∆I-GluOx(∆V) = I-GluOx(+0.7 V) – I-GluOx(+0.25 V)) 
produces the change in current due to Glu revealed by a change in applied 
potential (∆IGlu(∆V)). The proper calibration factor to convert this current into Glu 
concentration is the difference between the slopes calculated for an enzyme-
coated recording site calibrated at the different applied potentials (m+GluOx(+0.7 V) – 
m+GluOx(+0.25 V) = m+GluOx(∆V), circles). Again, enzyme-free slopes are very close to 
zero and do not contribute to the calculations. In summary, ∆Glu(∆V) = ∆IGlu(∆V)/ 
m+GluOx(∆V), where ∆Glu(∆V) = the change in Glu concentration between the two 
paired channels (enzyme-coated and enzyme-free) using a varied applied 
potential approach. 
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  Each potassium-evoked Glu signal was described by the following 
parameters: amplitude (µM Glu), rise time (TR (sec)), and total signal duration 
(TTotal (sec)). Refer to the Data Analysis section of Chapter Two for detailed 
explanations of these signal parameters. Average parameters were compared for 
each potassium concentration using an unpaired, two-tailed t-test with Welch’s 
correction (α=0.05). 
 
Results 
 
 Basal Glu Regulation: Effects of TTX and TBOA 
The potent voltage-dependent sodium channel blocker tetrodotoxin (TTX) 
was locally applied to inhibit action potential-dependent vesicular release in the 
recording area (Figure 3.4A).  TTX applications (100 µM barrel concentration, 
~100 nl) produced a rapid drop in our signal in both the rat striatum (n=17 
recordings in 5 rats) and frontal cortex (n=17 recordings in 5 rats). The observed 
decreases were significantly greater than the dilution artifact produced by 
physiological saline ejection (striatum: n=11 recordings in 4 rats, frontal cortex: 
n=10 recordings in 4 rats). The average TTX-dependent changes in Glu 
concentration were 1.9 ± 0.7 µM and 2.0 ± 0.8 µM (mean ± SEM) in the striatum 
and frontal cortex, respectively (Figure 3.4B). We also investigated the effects of 
the potent, competitive, non-transportable excitatory amino acid transporter 
(EAAT) inhibitor D,L-threo-β-benzyloxyaspartate (TBOA). Local applications of 
TBOA (100 µM barrel concentration, ~100 nl) caused a transient but detectable 
signal increase compared to physiological saline ejection within 5 minutes in both 
the rat striatum (n=54 recordings in 3 rats) and frontal cortex (n=44 recordings in 
4 rats) (Figure 3.5A). The average TBOA-dependent changes in Glu 
concentration were 1.6 ± 0.1 µM and 2.8 ± 0.4 µM (mean ± SEM) in the striatum 
and frontal cortex, respectively (Figure 3.5B). 
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Figure 3.4 The Effects of TTX on Basal Glu Recordings 
A) The composite trace demonstrates the typical effects of locally applied 
physiological saline and TTX (100 µM, ~100 nl) in the rat brain. B) The average 
decrease in apparent Glu concentration was significantly larger for TTX (dark 
gray bars) than saline applications (light gray bars) in the striatum and frontal 
cortex (inset, *p<0.05). Subtracting the apparent change in Glu due to saline 
(dilution artifact) from the apparent change in Glu due to TTX, the TTX-
dependent Glu concentration was approximately 2 µM in both brain regions. 
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Figure 3.5 The Effects of TBOA on Basal Glu Recordings 
A) The recording trace demonstrates a transient increase in signal following local 
application of the potent, general EAAT inhibitor TBOA (100 µM, ~100 nl). B) The 
average maximal change in apparent Glu concentration was significantly different 
following TBOA application (dark gray bars) compared to saline (light gray bars) 
in the striatum and frontal cortex (inset, **p<0.0001).  Correcting for dilution, the 
average TBOA-dependent Glu concentration ranged from 1-3 µM in these brain 
regions. 
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  Basal Glu Measures 
 Based on the TTX-dependent Glu levels that we observed, we were 
interested in determining overall steady-state basal Glu levels in the anesthetized 
rat striatum and frontal cortex. Investigating this question by analyzing channels 
individually is not possible because the baseline signal on each enzyme-coated 
channel is not a pure measurement of basal Glu. Instead, we recorded Glu in a 
self-referencing mode (see Burmeister and Gerhardt, 2001) to quantify basal Glu 
levels. We used two different methods based on comparing signals from paired 
enzyme-coated (+GluOx) and enzyme-free (-GluOx) channels; hereafter referred 
to simply as paired channels. First, we compared paired channel recordings at a 
constant applied potential (+0.7 V vs. Ag/AgCl) (Figure 3.6A). Calculated average 
signal differences were then converted to Glu concentration using an appropriate 
calibration factor (Figures 3.2 and 3.6B). Using this method, we measured an 
average basal Glu level of 1.4 ± 0.2 µM (n=16 recordings in 8 rats) in the striatum 
and 1.6 ± 0.3 µM (n=13 recordings in 8 rats) in the frontal cortex (Figure 3.6C). 
We also used a second approach that employed our ability to record at different 
applied potentials. By calibrating and conducting in vivo recordings separately at 
two different applied potentials (+0.25 V vs. +0.7 V, vs. Ag/AgCl reference), we 
could compare voltage-dependent signal changes between paired channels. 
Differences on enzyme-free channels primarily reflect changes in the background 
current due to the change in applied voltage. This change in background current 
also occurs on enzyme-coated channels. However, the voltage-dependent 
differences also reflect an increased ability to detect Glu (Figure 3.7A). Once 
again, average signal differences are converted to Glu concentration using an 
appropriate calibration factor (Figures 3.3 and 3.7B). Using this approach, we 
measured an extracellular Glu level of 1.8 ± 0.3 µM (n=16 recordings in 8 rats) in 
the striatum and 1.8 ± 0.4 µM (n=15 recordings in 8 rats) in the frontal cortex 
(Figure 3.7C). There was no significant difference in brain region-specific 
average basal Glu measures between the constant potential and varied potential 
methods. Recall that our TTX-saline comparisons revealed a TTX-dependency of  
54 
 A.      B. 
0.00
0.02
0.04
0.06
0.08
0 20 40 60 80
Time (sec)
C
ur
re
nt
 (n
A
)
+GluOx
-GluOx
-
-
-
-
0.0
0.5
1.0
1.5
2.0
2.5
0 20 40 60 8
Time (sec)
L-
G
lu
ta
m
at
e 
( µM
)
0
 
 
C. 
0.0
0.5
1.0
1.5
2.0
2.5
3.0
Striatum Frontal Cortex
L-
G
lu
ta
m
at
e 
( µM
)
 
 
Figure 3.6 Basal Glu Measures Using a Constant Applied Potential Method 
Passive simultaneous recordings from paired channels (enzyme-coated and 
enzyme-free) were compared and signal differences were converted to average 
Glu concentrations using appropriate calibration factors (see Figure 3.2). A) 
Recording in a self-referencing mode at a constant potential (+0.7 V vs. Ag/AgCl) 
allowed the detection of basal Glu on the enzyme-coated channel (+GluOx) 
which increases the baseline signal compared to the simultaneous response on 
the enzyme-free channel (-GluOx). B) The product of sychronized signal 
subtraction and conversion to Glu concentration is demonstrated. C) Average 
basal Glu measures for the striatum and frontal cortex were 1.4 ± 0.2 and 1.6 ± 
0.3 (µM Glu, mean ± SEM), respectively. 
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Figure 3.7 Basal Glu Measures Using a Varied Applied Potential Method 
A) Self-referencing signal analysis was used in conjunction with varied applied 
potential (+0.25 V vs. +0.7 V, vs. Ag/AgCl) to measure basal Glu. Recording at 
+0.25 V nearly eliminated the detection of the Glu reporter molecule H2O2. At 
+0.7 V, H2O2 detection is restored. Aligned voltage-dependent signal changes 
from paired channels showed a universal increase due to heightened 
background current. The +GluOx channel increase was larger due to additional 
Glu detection. B) The result of sychronized signal subtraction and conversion to 
Glu concentration is shown. The appropriate calibration factor was previously 
described (Figure 3.3). C) Average basal Glu measures for the striatum and 
frontal cortex were 1.8 ± 0.3 and 1.8 ± 0.4 (µM Glu, mean ± SEM), respectively. 
Basal Glu measures did not significantly differ by method (c.f. Figure 3.6). 
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 1.9 ± 0.7 µM in the striatum and 2.0 ± 0.8 µM in the frontal cortex (Figure 3.4). 
These differences did not significantly differ from our paired channel subtraction 
determinations of average basal Glu measures for either brain region. Taken 
together, our data support the hypothesis that basal Glu levels in two regions of 
the urethane-anesthetized rat brain are fully TTX-dependent and likely arise from 
neuronal vesicular release. 
 
 Potassium-Evoked Glu Release 
 To further explore potassium-evoked Glu release, we examined Glu 
responses under different depolarizing conditions and focused on their 
reproducibility. Pressure ejections of both 70 mM and 120 mM KCl solutions (50-
275 nl, average volume 113 nl) evoked reproducible Glu release in the 
anesthetized rat striatum and frontal cortex (Table 3.1). The 120 mM KCl 
stimulations produced Glu signals with larger peak amplitudes (µM Glu) than 70 
mM KCl in both the striatum (13.3 ± 0.9 vs. 5.7 ± 0.3, mean ± SEM, p<0.0001) 
and frontal cortex (15.9 ± 0.9 vs. 8.4 ± 0.5, p<0.0001). Rise times (TR in seconds) 
were slightly longer for 120 mM KCl versus 70 mM KCl in the striatum (2.8 ± 0.2 
vs. 1.6 ± 0.1, mean ± SEM, p<0.0001) but were not significantly longer in the 
frontal cortex (2.0 ± 0.1 vs. 1.7 ± 0.1, N.S.). Signal durations (TTotal in seconds) 
were also significantly longer after 120 mM KCl compared to 70 mM KCl in the 
striatum (13.0 ± 0.3 vs. 9.7 ± 0.3, mean ± SEM, p<0.0001) and frontal cortex 
(13.4 ± 0.3 vs. 9.6 ± 0.3, p<0.0001). In Figure 3.8A, local stimulations (70 mM 
KCl, 100 nl) in the anesthetized rat striatum produced signals that rose to peak 
amplitude in 1-4 seconds and lasted approximately 10-20 seconds. Evoked Glu 
signals in the frontal cortex maintained similar amplitudes and durations at 
stimulation intervals as short as 15 seconds (120 mM KCl, 100 nl, Figure 3.8B) 
and began to overlap with extracellular Glu accumulation at intervals of 10 
seconds (Figure 3.8C). Other neurotransmitters, such as DA, fail to show readily 
reproducible potassium-evoked responses when stimulated at rapid intervals 
(see Gerhardt, Rose, and Hoffer, 1986). 
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 Table 3.1 Potassium-Evoked Glu Kinetics 
Average peak amplitudes in both the striatum and frontal cortex significantly 
differed (p<0.0001) between responses to 70 and 120 mM potassium solutions. 
Typical Glu responses rose to peak amplitude in 1-2 seconds and lasted 
approximately 10-20 seconds. Reported values for peak amplitude, TR, and TTotal 
represent the mean ± SEM. 
 
 
 Striatum Frontal Cortex 
 70 mM KCl 120 mM KCl 70 mM KCl 120 mM KCl 
Number of rats 4 3 4 3 
Number of responses 160 80 140 90 
Peak amplitude (µM Glu) 5.7 ± 0.3 13.3 ± 0.9 8.4 ± 0.5 15.9 ± 0.9 
Rise time (TR (sec)) 1.6 ± 0.1 2.8 ± 0.2 1.7 ± 0.1 2.0 ± 0.1 
Signal Duration (TTotal (sec)) 9.7 ± 0.3 13.0 ± 0.3 9.6 ± 0.3 13.4 ± 0.3 
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Figure 3.8 The Speed and Reproducibility of Potassium-Evoked Glu Signals 
A) The 70 mM potassium ejections (100 nl, black arrows, 20 second ejection 
intervals, striatum) evoked rapid Glu releases. Following each release, the robust 
Glu transport system quickly cleared the extracellular space back to basal Glu 
levels. B) and C) Responses to local 120 mM potassium applications (75 nl each, 
black arrows, frontal cortex) provide evidence for tremendous reserve and/or 
rapid replenishment within the Glu neurotransmitter pool in the rat brain. Multiple 
serial stimulations with decreasing ejection intervals produced signals that were 
readily reproducible. Each application stimulated Glu release and uptake events 
that showed a high degree of similarity within the series but remained distinct 
with as little as 15 seconds between applications. Glu began to accumulate and 
distinct signals were lost at 10 second stimulation intervals. 
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  Further Confirmation that Glu is the Source of the Potassium-Evoked 
Glu Signals 
 To further address the identity of our potassium-evoked signals, we 
designed experiments to study Glu in a self-referencing recording mode (see 
Burmeister and Gerhardt, 2001). Enzyme-free sites can detect all of the 
molecules that enzyme-coated sites can detect except Glu. Qualitatively, these 
sites act as “sentinels”, alerting us to the presence of interferences. When there 
are no signal changes recorded on enzyme-free channels, we have very high 
confidence that detected signals on enzyme-coated sites result purely from the 
presence of extracellular Glu. Figure 3.9 shows a Glu recording in the 
anesthetized rat striatum at +0.7 V and +0.2 V (both vs. Ag/AgCl reference). At 
the higher potential, an enzyme-coated site (+GluOx) recorded potassium-
evoked Glu signals (70 mM KCl, 125 nl) while the adjacent enzyme-free site (-
GluOx) showed no change in signal. At the lower potential, we repeated the 
stimulations but observed no responses on either channel. The Glu reporter 
molecule H2O2 oxidizes efficiently at an applied potential of +0.7 V but poorly at 
+0.2 V. By contrast, many interferents, such as DA, can produce a detectable 
signal at the lower potential (Pomerleau et al., 2003). Taken together, the 
potassium-evoked Glu releases that we recorded were both enzyme-dependent 
and voltage-dependent, supporting that the major source of the potassium-
evoked signals is Glu. 
 
Discussion 
 
 Using enzyme-coated multisite Pt-based microelectrode arrays to study in 
vivo Glu regulation in the anesthetized rat brain, we have found that Glu levels 
are tightly regulated in the mammalian CNS, making the dynamics of Glu release 
and uptake very rapid. Basal Glu is regulated by active release and uptake 
mechanisms, including TTX-dependent vesicular release. A self-referencing 
recording mode can be used to further verify the identity of our signal. We also  
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Figure 3.9 Selectivity of Glu Measures 
The upper trace shows the signals recorded from an enzyme-coated recording 
site (+GluOx). The lower trace represents a simultaneous recording on an 
adjacent enzyme-free recording site (-GluOx). At an applied potential at which 
H2O2 will readily oxidize on platinum (+0.7 V versus Ag/AgCl reference 
electrode), 70 mM potassium ejections (black arrows) evoked signals detected 
only on the enzyme-coated channel. This indicates that our signal is enzyme-
derived. To further test the theory that the enzyme-derived Glu reporter molecule 
H2O2 is responsible for our signal, we lowered the applied voltage to +0.2 V and 
repeated the stimulations. At +0.2 V, H2O2 oxidizes very poorly on platinum, 
unlike other electroactive species such as DA. At +0.2 V, we detected no evoked 
signal on any channel. 
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 used this recording mode to determine absolute basal Glu levels, which were 
approximately 2 µM in the rat striatum and frontal cortex. These levels did not 
significantly differ from TTX-dependent Glu concentrations, supporting the 
hypothesis that basal Glu likely originates from neuronal vesicular release in two 
regions of the urethane-anesthetized rat brain. Following short burst local 
potassium stimulations, most Glu signals rose to peak amplitude in 1-2 seconds 
and lasted approximately 10-20 seconds, creating a characteristic spike pattern 
of evoked Glu release and uptake kinetics. Both neuronal vesicular Glu release 
and the Glu uptake system were robust, as potassium-evoked Glu signals were 
readily reproducible at stimulation intervals as short as 15 seconds. 
 In the present studies, we used multiple approaches to study basal Glu 
including examining drug effects on underlying release and uptake mechanisms 
and implementing new analytical approaches and technological refinements to 
measure basal Glu levels. Basal measures of Glu may reflect an extracellular 
steady-state, controlled by active Glu release and uptake mechanisms (Herrera-
Marschitz et al., 1996, Lada, Vickroy, and Kennedy, 1998). Known release 
mechanisms include neuronal vesicular release, excitatory amino acid 
transporter (EAAT) uptake reversal, and metabolic Glu exchange for other 
molecules (e.g. cystine) (Fillenz, 1995, Anderson and Swanson, 2000, Baker et 
al., 2002). In fact, the relationship between basal Glu and the Glu-cystine 
antiporter has been studied in the rat striatum by Baker et al. (2002). They found 
that blocking neuronal release had a relatively small effect (0-30% decrease) on 
microdialysis measures of extracellular Glu compared to inhibition of the Glu-
cystine antiporter (60% decrease). Independent TTX and TBOA applications 
allowed us to inhibit voltage-gated sodium channel-dependent vesicular Glu 
release and glial and neuronal Glu uptake to reveal the significance of these 
processes in maintaining steady-state basal Glu levels. We observed a 
significant but transient increase in our signal following TBOA, supporting that 
there are steady-state Glu release mechanisms that require active Glu uptake to 
keep basal Glu levels well-controlled. TBOA was chosen for its potency and non-
transportable properties. TBOA inhibits EAAT’s by blocking the transporters 
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 without inducing transport currents or heteroexchange for Glu, unlike competitive 
transporter substrates such as D,L-threo-β-hydroxyaspartate (THA) or L-trans-
2,4-pyrrolidine dicarboxylate (PDC) (Shimamoto et al., 1998, Shigeri et al., 2001). 
The transient nature of these signal changes may be explained by the fact that 
local TBOA application leaves a large number of EAAT’s unaffected at the 
periphery of the relatively small drug-affected area. These EAAT’s may be 
clearing Glu as it diffuses along its concentration gradient. Also, because TBOA 
is a competitive inhibitor, some of the Glu may have been cleared by EAAT’s in 
the recording area if rising levels of extracellular Glu sufficiently increased to 
dislodge TBOA from the transporters. The TTX-dependent signal decreases that 
we recorded were significantly greater than the dilution artifacts created by 
intracranial saline ejections, demonstrating that basal Glu levels are maintained 
to some extent by action potential-dependent vesicular release. We extended our 
saline-TTX comparison to quantify how much of the signal change observed 
following TTX was drug-dependent by subtracting the effects of dilution and 
arrived at approximately 2 µM Glu in both the striatum and frontal cortex. 
 However, the prior approach does not necessarily reveal the overall basal 
Glu levels, and the question of what percentage of total basal Glu is TTX-
dependent remained. We configured our microelectrode arrays in a self-
referencing recording mode and took two additional approaches based on 
constant potential and varied potential paired channel recordings to measure 
total basal Glu. We observed no significant differences in brain region-specific 
Glu measures between the methods; the average basal Glu was ~2 µM Glu in 
both the striatum and frontal cortex. Comparing this to our TTX studies, we 
discovered that basal Glu levels in two regions of the urethane-anesthetized rat 
brain are fully TTX-dependent and likely arise from neuronal vesicular release. 
Interestingly, all three subtraction methods that we used to quantify measures of 
total or neuronally-derived basal Glu yielded very similar results. Basal Glu in the 
chloral hydrate-anesthetized rat brain has previously been studied using 
microsensors with electrochemical detection (Kulagina, Shankar, and Michael, 
1999). This study used similar investigational strategies including comparing 
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 enzyme-coated and enzyme-free adjacent electrodes and local TTX applications. 
Both their measures of resting (29.0 ± 9.0 µM Glu) and TTX-dependent Glu 
levels were larger than our measures possibly due to differences in anesthetic 
drugs or their recording methods; however, they observed significant signal 
decreases following TTX applications (100 µM, 200 nl, resulting in a 25-85% 
decrease vs. original baseline signals), which were similar to our results. 
Alternatively, published studies support that less than 50% of basal Glu 
measured by microdialysis is TTX-dependent (Herrera-Marschitz et al., 1996, 
Timmerman and Westerink, 1997, Baker et al., 2002). The differences that we 
observed in our assessments of the magnitude and TTX-dependency of basal 
Glu levels compared to prior electrochemical and microdialysis studies may stem 
from altered basal Glu regulation related to the anesthetic drug urethane. There 
are reports of decreased Glu release (Hudspith, 1997) and increased Glu uptake 
(Danbolt, 2001) due to other anesthetics such as halothane and isoflurane. 
Highly relevant ongoing Glu recordings in our lab in the awake, freely-moving rat 
(unpublished data) have started to reveal differences in basal Glu regulation, 
which support a significant effect of urethane anesthesia on basal Glu measures. 
We may discover with further investigation that basal Glu levels are much higher 
in the awake rat brain than those measured in the urethane-anesthetized rat 
brain, that other anesthetics alter basal Glu regulation to different degrees, and 
that the fraction of basal Glu that is TTX-dependent differs under awake or 
alternatively anesthetized conditions. 
 Previously reported in vivo measures have supported the hypothesis that 
potassium-evoked Glu has fast kinetics of release and uptake (Hu et al., 1994, 
Burmeister et al., 2002, Burmeister and Gerhardt, 2003). Our experiences with 
evoked Glu dynamics have consistently resembled the fast release and uptake 
parameters observed by Hu et al. (1994) who used similar enzyme-based 
amperometric recording techniques that were highly selective for Glu. Their 
studies demonstrated Glu responses to potassium stimulations (100 mM KCl, 
1000 nl) that rose to peak amplitude in a few seconds and lasted roughly 1 
minute, which were reproducible given a 20 minute rest interval. They also 
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 demonstrated fast responses to Glu ejections (1 mM, 200-1000 nl) that peaked in 
a few seconds and returned to baseline in ~20 seconds, which is consistent with 
some of our previous observations using Glu selective microelectrode arrays 
(Burmeister and Gerhardt, 2001). In this chapter, we expanded our studies of 
potassium-evoked Glu kinetics using two different concentrations of potassium 
solutions and further investigated the reproducibility of potassium-evoked Glu 
release. There were potassium concentration-dependent effects on the peak 
amplitudes, rise times, and total signal times. Interestingly, the rise time data sets 
did not appear to have normal Gaussian distributions. Instead, at our current 
sampling rate (1 Hz), the data appeared to follow a Poisson distribution, with over 
half of the recorded rise times at 1 second (70 mM KCl in both brain regions, 120 
mM KCl in the frontal cortex) or within 2 seconds (120 mM KCl in the striatum). 
These observations emphasize not only that evoked Glu release is rapid, but that 
even with second-by-second monitoring, we still do not have an accurate 
measure of the speed of all of our potassium-evoked Glu signals. Overall, the 70 
mM potassium solution evoked Glu signals that were slightly smaller and faster 
than the 120 mM potassium-evoked Glu signals. Potassium-evoked Glu signals 
stimulated at 20 second intervals displayed a high level of reproducibility. In fact, 
we were able to stimulate highly reproducible Glu signals at intervals as short as 
15 seconds. Most evoked Glu signals lasted approximately 10-20 seconds, so 
that if we reduced the time interval to 10 seconds, we could stimulate a Glu 
signal and then evoke additional Glu release before the first Glu signal was 
cleared (Figure 3.8C). This is an important difference compared to potassium-
evoked Glu measures reported by Hu et al. (1994). Our data do not support the 
hypothesis that there is a lengthy refractory period for evoked Glu release, which 
was the explanation offered by the authors for the 20 minute rest interval that 
they observed between reproducible potassium-evoked Glu signals. Though the 
potassium concentration was similar, their volumes of potassium were higher 
(1000 nl vs. 50-275 nl) which may explain their larger average signal amplitudes 
(60.5 ± 9.1 µM Glu), but this does not necessarily explain the lengthy rest period. 
They were also recording potassium-evoked Glu release in the hippocampus of 
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 urethane-anesthetized rats, while our recordings were reported for the striatum 
and frontal cortex. However, we have observed rapid reproducibility of 
potassium-evoked signals in the rat hippocampus (unpublished data), so that the 
difference is likely not brain region-specific and may relate to their electrode 
design or other differences in experimental variables. High levels of extracellular 
potassium and Glu have both been reported to initiate spreading depression in 
cortical areas (Somjen, 2001), which might explain their findings. The 
reproducibility of our potassium-based methods for measuring evoked Glu 
release demonstrate that spreading depression likely does not occur in the brains 
of the animals that we record. Overall, we have shown that evoked Glu release 
and uptake are very fast, potassium concentration-dependent, and reproducible. 
Our results highlight how our microelectrode-based sampling and detection 
technology with superior spatial and temporal (second-by-second) resolution is 
well-suited to study Glu kinetics. 
 We have previously demonstrated that our enzyme-based microelectrode 
recording technique can reliably measure Glu (Burmeister et al., 2000, 
Burmeister et al., 2001). However, it is necessary to critically evaluate underlying 
basal and evoked signals in vivo because other electroactive species might 
interfere with our recordings (Gerhardt and Burmeister, 2001, Robinson et al., 
2003). Generally, the major interferent for voltammetric recordings at lower 
potentials in the extracellular space of the mammalian CNS is AA (Hu et al., 
1994, Fillenz, 1995, Kulagina, Shankar, and Michael, 1999, Cui et al., 2000, 
Gerhardt and Burmeister, 2000). To date, we have successfully used Nafion™ 
coated on the recording sites to repel anionic interferents such as AA and 
DOPAC and virtually eliminate their contribution to the overall signal. 
Furthermore, GluOx is critical to measuring Glu and provides additional 
specificity. In many brain areas, these coatings allow us to use constant potential 
amperometry at +0.7 V (vs. Ag/AgCl reference) to measure Glu with confidence 
in the identity of our signal. However, high potassium stimulation in some brain 
areas can cause the release of interfering electroactive species. The 
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 demonstrated enzyme- and voltage-dependence of our potassium-evoked 
measures further support that the major source of our signal is Glu. 
 Measuring basal and potassium-evoked release of Glu is a beginning to 
understanding tonic and phasic release of Glu in the mammalian CNS. Tonic Glu 
is the steady-state extracellular Glu levels thought to be maintained at a low 
concentration range by the activities of neurons and glia within a brain region 
(Herrera-Marschitz et al., 1996, Lada, Vickroy, and Kennedy, 1998, Baker et al., 
2002). Tonic Glu may be maintained in part by neuronal vesicular release, even 
basal level burst firing of neurons; however, the tonic Glu concentration is 
currently not thought to dramatically change on a second-by-second basis. 
Compared to tonic Glu release, phasic Glu release is a more entrained 
phenomenon in which synchronized or temporally overlapping neurotransmitter 
releases raise extracellular Glu higher than background tonic Glu levels. Phasic 
Glu release is followed by robust active neurotransmitter uptake, which returns 
the extracellular concentration to basal levels, and the entire process may 
change the extracellular Glu concentration very rapidly (Timmerman and 
Westerink, 1997, Danbolt, 2001). Basal and evoked Glu measures may simulate 
tonic and phasic Glu characteristics. Studies of both basal and evoked Glu 
regulation are important for understanding the normal glutamatergic system and 
the role of Glu in brain disorders. In this chapter, the development of methods to 
measure basal Glu levels using microelectrode arrays was inspired in part by 
microdialysis techniques, which have the capabilities to measure unstimulated 
levels of Glu in microdialysate fractions. A strength of microelectrodes coupled 
with electrochemical detection over microdialysis, however, is better temporal 
resolution (800 msec vs. commonly 5-20 minutes for microdialysis), which 
allowed us to monitor both basal and evoked Glu release on a second-by-second 
basis. Proponents of microdialysis have recognized the need to improve the 
temporal resolution of their measures and made considerable progress using on-
line separation and detection technologies (i.e. CE-LIF), which have reduced the 
temporal resolution to 5-12 seconds (Lada, Vickroy, and Kennedy, 1997, Lada, 
Vickroy, and Kennedy, 1998, Kennedy et al., 2002). Ultimately, the temporal 
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 resolution of microdialysis techniques is limited by sampling extracellular 
neurochemicals through a microdialysis membrane in a medium that is removed 
from the brain. This may be an important constraint for correlating both basal and 
evoked measures with electrophysiological events because such investigations 
may need second-by-second to subsecond temporal resolution to distinguish 
some of the roles of Glu. 
 In summary, the present studies using microelectrode arrays configured to 
record Glu signals on a second-by-second basis have helped us begin to 
understand basal and potassium-evoked Glu release in two areas of the 
anesthetized rat brain, the striatum and frontal cortex. We found that basal Glu is 
actively regulated by TTX-dependent release mechanisms and EAAT-dependent 
uptake. Quantifying the TTX-dependent portion of the signal changes revealed 
that a significant, measurable portion of the overall basal Glu levels were TTX-
sensitive. Two self-referencing Glu recording methods (constant and varied 
applied potential) measured the total average basal Glu at roughly 2 µM in both 
brain regions. These measures did not significantly differ by method, nor were 
they significantly different from the average TTX-sensitive measures. These 
findings support that basal Glu is completely TTX-dependent and is likely due to 
neuronal vesicular release. The spatial resolution, direct sampling, and low 
micrololar limit-of-detection of our technology are advantageous for both basal 
and evoked Glu studies, which may simulate tonic and phasic Glu, respectively. 
Potassium-evoked Glu release and uptake are robust, transient, potassium 
concentration-dependent, and highly reproducible at intervals as short as 15 
seconds. 
  
Copyright © Brian Keith Day 2005 
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 Chapter Four: Alterations in L-Glutamate Regulation in the Unilateral 6-
Hydroxydopamine (6-OHDA)-Lesioned Rat Brain 
 
Introduction 
 
 The studies in this chapter build on our knowledge of normal Glu signaling 
in the rat brain and extend the applications of our microelectrode-based 
technology to include studies of Glu in an altered rat brain. Although there are 
several rat models of diseases in which Glu measures may be altered, our group 
is most interested in neurodegenerative disorders. Keeping with our dual role as 
members of both the Center For Sensor Technology (CenSeT) and one of 
currently eleven Morris K. Udall Centers of Excellence For Parkinson’s Disease 
Research nationwide, we enthusiastically focused on studying Glu 
neurotransmission in a rat model of PD, the hemiparkinsonian unilateral 6-
hydroxydopamine (6-OHDA)-lesioned rat. As previously described in Chapter 
One, PD has been examined more closely over the last decade as a disease of 
secondary Glu hyperactivity. Two major glutamatergic pathways associated with 
the involuntary motor system are strongly implicated, the corticostriatal pathway, 
which is largely the focus of the studies presented in this chapter, and projections 
from the subthalamic nucleus, which are also extremely interesting but more 
suitable for future studies. 
 The rat corticostriatal pathway emanates diffusely from all areas of the 
cortex to make synaptic connections bilaterally in the striatum (caudate and 
putamen) (Calabresi et al., 1996, Mitchell, Cooper, and Griffiths, 1999, Calabresi 
et al., 2000) (Figure 4.1). The caudate and putamen represent the major input 
nuclei of the involuntary motor pathways, which contain predominantly (95%) cell 
bodies of GABAergic medium spiny neurons (MSN) as well as some 
interneurons (INT, large aspiny neurons, 5%) which transmit several 
neurotransmitters including acetylcholine (Centonze et al., 1999, Mitchell, 
Cooper, and Griffiths, 1999). The MSN’s project along two distinct pathways: the 
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Figure 4.1 The Corticostriatal Pathway and the Basal Ganglia-
Thalamocortical Circuitry 
Predominantly, Glu descends to the striatum from all areas of the cortex along 
the corticostriatal pathway (red arrow). The direct and indirect pathways 
described in the text are also illustrated. See also Figure 1.2 for more details 
regarding the basal ganglia-thalamocortical pathways. 
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 direct pathway, which facilitates voluntary movement, and the indirect pathway, 
which inhibits it (Mitchell, Cooper, and Griffiths, 1999, Marino et al., 2002). 
Glutamatergic projections descending from the cortex are thought to synapse on 
the heads of the dendritic spines of MSN’s. Glu along the corticostriatal pathway 
provides the major excitatory driving force for the firing patterns of these neurons 
(Calabresi et al., 1996, Centonze et al., 1999, Calabresi et al., 2000). In the 
normal rat brain, DA ascends to the striatum from the SNc along the nigrostriatal 
pathway which is thought to synapse on the dendritic shafts of MSN’s, closely 
apposed to Glu synapses, to modulate cell firing (Figure 4.2). It is also known 
that both Glu and DA heteroreceptors exist on these presynaptic terminals, so 
that DA can directly affect presynaptic Glu release events, and vice versa 
(Calabresi et al., 1996, Bamford et al., 2004). 
 In the unilateral 6-OHDA-lesioned rat model of PD, the synthetic 
neurotoxin 6-OHDA is injected into the medial forebrain bundle on one side 
where it is selectively taken up through the DA transporter into dopaminergic 
neurons. The 6-OHDA destroys both nerve terminals through axonal disruption 
and cell bodies through retrograde transport and the production of reactive 
oxygen species (Hudson et al., 1993, Reader and Dewar, 1999, Schober, 2004). 
The nigrostriatal pathway on the side of injection may be fully lesioned by this 
neurotoxin, resulting in unilateral DA denervation in the striatum. As the loss of 
DA neurotransmission along the nigrostriatal pathway is known to be central to 
human idiopathic PD, so does this loss of DA neurotransmission in the rat brain 
produce hemiparkinsonian motor abnormalities. These deficits are revealed in a 
stably lesioned rat brain by the administration of drugs which act on the DA 
system such as apomorphine, which is more effective in the supersensitized 
striatum ipsilateral to lesion and promotes movement in an imbalanced fashion 
that results in the rat exhibiting contralateral rotations (Perese et al., 1989, 
Hudson et al., 1993, Deumens, Blokland, and Prickaerts, 2002, Schober, 2004). 
Rats are considered to be >90% lesioned when they exhibit low dose 
apomorphine-induced contralateral rotations at a rate of >300/hour (>5/minute) 
(Hudson et al., 1993). 
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Figure 4.2 Glu-DA Interactions in the Striatum 
Glu and DA can influence the firing of striatal projection neurons through direct 
activation of their receptors on the dendrites of MSN’s. Synaptic spillover of these 
neurotransmitters may also occur, so that both Glu and DA can influence their 
own or each other’s presynaptic release. For example, striatal DA inhibits Glu 
release through activation of D2-like receptors located on the glutamatergic 
presynaptic terminals. 
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  The motor deficits in animal models of PD may begin with DA denervation 
in the striatum, but a large number of neurotransmitter systems are affected 
including Glu neurotransmission along the corticostriatal pathway (Albin et al., 
1989). Such Glu alterations have been reported by several investigators 
(Tossman, Segovia, and Ungerstedt, 1986, Lindefors and Ungerstedt, 1990, 
Calabresi et al., 1996, Meshul et al., 1999); however, we had a unique 
opportunity to examine the dynamics of Glu release and uptake in the 6-OHDA-
lesioned rat brain with greater temporal and spatial resolution than prior methods. 
We focused our studies on potassium-evoked Glu kinetics in the frontal cortex 
and striatum to collect information about the corticostriatal pathway. We 
additionally investigated potassium-evoked Glu release and uptake in the 
nucleus accumbens. Although the nucleus accumbens is cellularly organized 
almost identically to the striatum, DA is primarily transmitted from a different brain 
region, the ventral tegmental area (Mitchell, Cooper, and Griffiths, 1999, Lancia 
et al., 2004). Furthermore, although these structures have overlapping functions 
(Mitchell, Cooper, and Griffiths, 1999), the nucleus accumbens is primarily a 
limbic structure whereas the striatum may be more dedicated to movement; thus, 
there may be interesting regional differences in Glu measures. Potassium-
evoked Glu signals from two groups of rats (unilateral 6-OHDA-lesioned and 
similarly-aged, non-lesioned rats) were characterized by signal parameters and 
compared by hemisphere both between groups and within the lesioned group. 
Our hypotheses were that evoked Glu kinetics would differ between lesioned and 
non-lesioned rats and that there would be ipsilateral and contralateral differences 
in Glu kinetics within the 6-OHDA-lesioned group. 
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 Methods 
 
 Refer to Chapter Two for full descriptions. In the Animal Preparation For In 
Vivo Electrochemical Recordings section, the Normal Young Fischer 344 Rats 
and Unilateral 6-Hydroxydopamine-Lesioned Young Fischer 344 Rats 
subsections are relevant to the studies presented in this chapter. 
 
 Stereotaxic Implantation and Glu Recordings 
 Prior to implantation, a 45 mM potassium solution (45 mM KCl, 104 mM 
NaCl, 2.5 mM CaCl2?2H2O, pH 7.4) was loaded into the single-barrel 
micropipette attached to the microelectrode array. The 45 mM potassium solution 
was tested in pilot animals and reliably evoked highly reproducible Glu signals 
with very few instances of simultaneously evoked DA release. The fully prepared 
microelectrode/micropipette assembly was implanted into the striatum (AP +1.0, 
ML ±2.1, DV -3.5 to -6.0 mm), the nucleus accumbens (AP +1.0, ML ±2.1, DV -
6.5 to -7.0 mm), and the frontal cortex (AP +2.7, ML ±1.5, DV -2.0 to -4.0 mm). 
The striatum and nucleus accumbens were recorded in one pass. The 
microelectrode was removed from the brain, rinsed with 0.9% (physiological) 
saline, and stereotaxically implanted in the frontal cortex in a second pass. From 
the initial depth, the microelectrode was advanced into the brain using a 
hydraulic microdrive (Narishige MO-8) in 0.5 mm steps. This was repeated for 
the opposite hemisphere. A fifteen minute equilibration period per implantation 
was allowed prior to initial potassium stimulation, and a two minute equilibration 
period was allowed between depths. If spontaneous neurotransmitter release 
occurred when entering a new depth, additional time was permitted for the signal 
to return to basal levels before applying potassium. Ejections of 45 mM KCl 
(~300 nl) were made at one minute intervals at each depth to obtain five Glu 
responses evoked within the acceptable dose range (250 to 350 nl). Evoked Glu 
signals were recorded on a second-by-second basis by the FAST-16 recording 
system. At the end of the recording sessions of lesioned rats, the microelectrode 
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 was removed from the brain and rinsed as before. Then, the 45 mM potassium 
solution was removed from the micropipette and replaced with a 70 mM 
potassium solution (70 mM KCl, 79 mM NaCl, 2.5 mM CaCl2?2H2O, pH 7.4). The 
microelectrode/micropipette assembly was implanted in the striatum (AP +1.0, 
ML ±2.1, DV -5.0). Following equilibration, ejections of 70 mM KCl (~1800 nl) 
were made, and the resulting Glu and/or DA signals were recorded by the FAST-
16 recording system. 
 
 Data Analysis 
 Each potassium-evoked Glu signal was analyzed and characterized by the 
following parameters: amplitude (µM Glu), uptake rate (µM Glu/sec), and T80 
(sec). Refer to Chapter Two for a full description of signal parameters. Average 
signal parameters were compared between hemisphere-matched signals 
recorded in the 6-OHDA-lesioned animals and age-matched, non-lesioned 
control animals. They were also compared between signals recorded ipsilateral 
to lesion and contralateral to lesion within the unilateral 6-OHDA-lesioned group. 
Statistical comparisons were made using a one-way ANOVA with Bonferroni 
multiple-comparisons post-hoc test (α=0.05, α*=0.0083). Values for signal 
parameters identified as outliers (values greater than 3 standard deviations from 
the mean) were excluded from analysis. Signals from the first brain area 
recorded per hemisphere (AP +1.0 ML ±2.1, DV -3.5, slightly superficial to the 
striatum) were primarily recorded to fine tune our pressure ejection system to 
deliver volumes of potassium solutions within the accepted dose range. As such, 
these signals were not considered in the data analysis. 
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 Results 
 
 Contralateral DA Release 
 Unilateral 6-OHDA-lesioned rats were included in this study only if they 
met established criteria for a full (>90%) lesion of the nigrostriatal pathway on the 
side of injection (apomorphine-induced contralateral rotations ≥300 turns/hour). 
To verify this indirect measure of DA depletion, we ejected an extremely high 
dose of potassium (70 mM, ~1800 nl) bilaterally in the striatum of lesioned rats at 
the end of the recording sessions to depolarize all of the nerve terminals and 
directly measure some of the released neurotransmitters. As configured for the 
present studies, our microelectrode arrays are selective for Glu over anionic 
interferents such as AA and DOPAC, but display poor selectivity for Glu over the 
cation DA, which can also be detected (See Figure 3.1). DA is transmitted along 
the non-myelinated nigrostriatal pathway (Cooper, Bloom, and Roth, 1996), 
which requires much higher stimulation than myelinated (e.g. glutamatergic) 
pathways to evoke neurotransmitter release (unpublished data). Figure 4.3 
shows that at a level of potassium stimulation approximately 10 times the typical 
amount used in these studies, we were able to stimulate and detect the release 
of both Glu and DA on the contralateral side (characteristic spike-dome signal 
shape). Furthermore, enzyme-free sentinel sites, which are not configured to 
detect Glu, recorded the DA release only on the contralateral side. Finally, Glu 
but not DA kinetics were recorded in the ipsilateral striatum (characteristic spike 
signal shape). Taken together, these results support that there was a full lesion 
on the ipsilateral side and functional DA terminals on the contralateral side. 
 
 Potassium-Evoked Glu Signals in the Striatum 
 Glu signaling in the striatum originates predominantly from cortical regions 
along the corticostriatal pathway which provides the primary excitatory influence 
on MSN cell firing behavior. We bilaterally recorded potassium-evoked (45 mM, 
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Figure 4.3 Contralateral DA Release 
We used an extremely high dose of potassium (70 mM, ~1800 nl, black arrow) to 
evoke neurotransmitter release from both myelinated (e.g. glutamatergic) and 
non-myelinated (e.g. dopaminergic) projections. The upper trace (dashed line) 
shows a typical response on the ipsilateral side, a signal with rapid (spike) 
kinetics that are characteristic of Glu. The lower trace (solid line) shows a typical 
biphasic (spike-dome) response to the same stimulation on the contralateral side. 
The shape of this signal demonstrates simultaneous detection of Glu and DA 
release and uptake. Inset: A simultaneous recording from an enzyme-free 
(sentinel/referencing) site shows only the DA kinetics on the contralateral side. 
77 
 ~300 nl) Glu signals in the striatum (5 signals/Glu recording site/depth for 5 
depths) of unilateral 6-OHDA-lesioned and non-lesioned rats within the same age 
range. The recorded signals were analyzed by average signal parameters that 
provide information about Glu release and uptake events and mechanisms 
(Table 4.1). Figure 4.4 shows representative traces of potassium-evoked Glu 
signals in the striatum of both groups of rats. Average Glu signal amplitudes (µM 
Glu) and uptake rates (µM Glu/sec) were significantly increased bilaterally in 
lesioned rats compared to hemisphere-matched, non-lesioned rats. Average 
T80’s (sec) were slightly but significantly faster on the ipsilateral side and did not 
differ on the contralateral side compared to matched hemispheres in non-
lesioned rats. Within the lesioned rat group, there were no significant differences 
between hemispheres in any of the reported signal parameters (Figure 4.5). 
 
 Potassium-Evoked Glu Signals in the Frontal Cortex 
 Glu terminals in the frontal cortex originate bilaterally from the thalamus 
and cortex (corticocortical pathways). We bilaterally recorded potassium-evoked 
(45 mM, ~300 nl) Glu signals in the frontal cortex (5 signals/Glu recording 
site/depth for 5 depths) of unilateral 6-OHDA-lesioned and non-lesioned rats (5-9 
months old). Reported values for average signal parameters are included in 
Table 4.1. Representative traces of potassium-evoked Glu signals for both 
groups of rats are shown in Figure 4.6. Average amplitudes, uptake rates, and 
T80’s of Glu signals from lesioned animals were significantly increased bilaterally 
compared to matched hemispheres from non-lesioned rats. Within the lesioned 
group, there were no significant differences between hemispheres for any of the 
reported signal parameters (Figure 4.7). 
 
 Potassium-Evoked Glu Signals in the Nucleus Accumbens 
 The nucleus accumbens is organized similarly to the striatum and receives 
Glu projections from similar areas. We bilaterally recorded potassium-evoked (45  
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 Table 4.1 Potassium-Evoked Glu Signal Parameters 
All Glu signal parameters are reported as mean ± SEM (*p<0.05, **p<0.01, 
***p<0.001, vs. matched hemisphere in non-lesioned rat). The numbers of 
signals analyzed are indicated in parentheses below each average value. 
Amplitude, uptake rate, and T80 are expressed in µM Glu, µM Glu/sec, and sec, 
respectively. Within the lesioned group, there were no significant differences in 
average signal parameters between hemispheres ipsilateral and contralateral to 
lesion with the following exceptions. In the nucleus accumbens, the average 
amplitude (†p<0.05) and uptake rate (‡p<0.001) were increased on the ipsilateral 
side. 
 
 Right Side/Ipsilateral Left Side/Contralateral 
 
Non-lesioned 
Group 
Lesioned 
Group 
Non-lesioned 
Group 
Lesioned 
Group 
 Striatum 
Amplitude 2.8 ± 0.1 5.4 ± 0.3*** 3.2 ± 0.1 5.9 ± 0.3*** 
 (199) (251) (172) (247) 
Uptake Rate 0.4 ± 0.0 2.0 ± 0.1*** 0.7 ± 0.1 2.1 ± 0.1*** 
 (193) (251) (169) (247) 
T80 5.9 ± 0.2 4.6 ± 0.1*** 4.9 ± 0.2 4.8 ± 0.1 
 (194) (249) (194) (248) 
  Frontal Cortex 
Amplitude 2.8 ± 0.2 4.9 ± 0.3*** 3.8 ± 0.3 4.9 ± 0.3* 
 (198) (252) (175) (245) 
Uptake Rate 0.8 ± 0.1 1.6 ± 0.1*** 1.3 ± 0.1 1.9 ± 0.2** 
 (187) (244) (173) (243) 
T80 4.1 ± 0.1 5.3 ± 0.1*** 3.9 ± 0.1 5.2 ± 0.1*** 
 (202) (245) (202) (243) 
  Nucleus Accumbens 
Amplitude 2.2 ± 0.2 5.0 ± 0.5***,† 4.7 ± 0.4 3.6 ± 0.3 
 (77) (98) (69) (98) 
Uptake Rate 0.4 ± 0.1 1.7 ± 0.2***,‡ 1.5 ± 0.2 0.9 ± 0.1* 
 (75) (98) (67) (97) 
T80 11.3 ± 1.4 5.3 ± 0.2*** 4.0 ± 0.1 5.2 ± 0.1 
 (74) (98) (80) (100) 
  All Brain Regions 
Number of rats 4 4 4 4 
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Figure 4.4 Representative Potassium-Evoked Glu Signals in the 6-OHDA-
lesioned and Non-lesioned Rat Striatum 
Potassium-evoked Glu signals (45 mM KCl, ~300 nl, black arrows) in the striatum 
of lesioned animals were significantly larger bilaterally compared to non-lesioned 
rats. Within the unilaterally lesioned rat group, Glu signals in the striatum were 
similar bilaterally despite the extensive loss of DA transmission only on the 
ipsilateral side (see Figure 4.3). 
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Figure 4.5 Average Potassium-Evoked Glu Kinetics in the Striatum of 
Unilateral Lesioned and Non-lesioned Rats 
The average A) peak amplitudes and B) uptake rates of potassium-evoked Glu 
signals were significantly longer in the striatal hemispheres of lesioned rats 
bilaterally (vs. non-lesioned matched hemispheres) but did not differ between 
hemispheres within the unilaterally lesioned group. C) The average elapsed time 
from signal peak until 80% signal decay (T80) showed a small but significant 
decrease in 6-OHDA-lesioned rats on the ipsilateral side (compared to non-
lesioned matched hemispheres) but did not differ within the lesioned group. The 
average T80 did not differ between lesioned and non-lesioned rats on the 
contralateral (left) side. 
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Figure 4.6 Representative Potassium-Evoked Glu Signals in the 6-OHDA-
lesioned and Non-lesioned Rat Frontal Cortex 
Potassium-evoked Glu signals (45 mM KCl, ~300 nl, black arrows) in the frontal 
cortex of lesioned animals were significantly larger bilaterally compared to non-
lesioned rats. Once again, within the lesioned group, Glu signals in the frontal 
cortex were similar bilaterally. 
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Figure 4.7 Average Potassium-Evoked Glu Kinetics in the Frontal Cortex of 
Unilateral Lesioned and Non-lesioned Rats 
The average A) peak amplitudes, B) uptake rates, and C) T80’s of potassium-
evoked Glu signals were significantly higher in the cortical hemispheres of 
lesioned rats bilaterally (vs. non-lesioned matched hemispheres) but did not differ 
between hemispheres within the unilateral lesioned group. 
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 mM, ~300 nl) Glu signals in the nucleus accumbens (5 signals/Glu recording 
site/depth for 2 depths) of lesioned and non-lesioned rats. Reported values for 
average signal parameters are shown in Table 4.1. Representative traces of 
potassium-evoked Glu signals for both groups of rats are shown in Figure 4.8. 
Within the right (ipsilateral) nucleus accumbens of both lesioned and non-
lesioned rats, the previously reported trends were maintained. Average amplitude 
and uptake rate on the ipsilateral side of 6-OHDA-lesioned rats were significantly 
increased compared to the right side of non-lesioned rats. In contrast, the 
average T80 on the right side was significantly decreased in lesioned vs. non-
lesioned rats. Considering the left (contralateral) nucleus accumbens between 
lesioned and non-lesioned rats, the average amplitude and T80 did not 
siginificantly differ, but the uptake rate was significantly slower. Looking 
specifically within the lesioned group, the average amplitude and uptake rate 
were increased on the ipsilateral side, while the average T80 did not differ. Within 
the nucleus accumbens especially in these studies, there is evidence for 
hemispheric differences within the normal non-lesioned rat group. Note that the 
average amplitude for Glu signals was significantly increased on the left side, 
and the average T80 showed a roughly 2 to 3-fold increase on the right side (non-
lesioned right vs. left side) (Figure 4.9). 
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Figure 4.8 Representative Potassium-Evoked Glu Signals in the 6-OHDA-
lesioned and Non-lesioned Rat Nucleus Accumbens 
Potassium-evoked Glu signals (45 mM KCl, ~300 nl, black arrows) in the nucleus 
accumbens of lesioned animals did not completely follow the trends seen in the 
other brain areas. As previously observed, evoked Glu signals on the side 
ipsilateral to lesion were significantly larger when compared to matched (right-
sided) non-lesioned rat hemispheres. In contrast, evoked Glu signals on the side 
contralateral to lesion were significantly decreased compared to signals from 
both the ipsilateral hemispheres within the lesioned group and the matched (left-
sided) non-lesioned rat hemispheres. In addition, normal potassium-evoked Glu 
signals were significantly larger on the left side within the non-lesioned rat group. 
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Figure 4.9 Average Potassium-Evoked Glu Kinetics in the Nucleus 
Accumbens of Unilateral Lesioned and Non-lesioned Rats 
A) and B) In the nucleus accumbens on the right (ipsilateral) side, the average 
peak amplitude and uptake rate of potassium-evoked Glu signals were 
significantly higher in lesioned rats (vs. non-lesioned). These measures were 
also significantly higher compared to the contralateral side within the lesioned 
group (†p<0.05, ‡p<0.001). The average contralateral amplitude and uptake rate 
tended to be decreased in lesioned rats (vs. hemisphere-matched, non-lesioned 
rats). C) The average T80 showed a significant decrease on the ipsilateral side 
(compared to non-lesioned matched hemisphere) but did not differ within the 
lesioned group. Significant hemispheric differences (R vs. L) of evoked Glu 
signaling in the non-lesioned (normal) rat nucleus accumbens are apparent. 
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 Discussion 
 
 The present studies were conducted in Fischer 344 rats to evaluate 
alterations in potassium-evoked Glu kinetics resulting from loss of DA 
neurotransmission to the right striatum. The unilateral 6-OHDA-lesioned rat is a 
commonly used model of PD, and the hemiparkinsonian effects observed in this 
model are considered desirable because the non-lesioned (contralateral) 
hemisphere can serve as an “internal control structure” (Schober, 2004). We also 
investigated Glu dynamics in the non-lesioned rat brain bilaterally to serve as 
another control group, especially to determine if there were changes in Glu 
regulation in brain regions contralateral to lesion that would go undetected 
otherwise. Based on the current understanding of Glu alterations in the 
parkinsonian brain, we expected to see significant changes on the ipsilateral side 
compared to both the contralateral side and the hemisphere-matched right side 
in non-lesioned rats. We also considered that there might be changes on the 
contralateral side of lesioned rats compared to the hemisphere-matched left side 
of non-lesioned rats. Animals were recorded at approximately the same age (5-9 
months old) to minimize age-related changes that might affect the results. Work 
conducted in our lab has shown that Glu regulation in normal rats does not 
dramatically differ from our age group (~6 months old) until after 18 months old 
(Nickell et al., 2005). 
 Interpreting hemispheric comparisons both within and between rat groups 
hinges largely on the assumption that, within a unilateral lesioned rat, there is 
little or no DA in the striatum on the ipsilateral side and good DA 
neurotransmission on the contralateral side. This assumption is commonly tested 
by administering drugs that act on the DA system and evaluating their effects on 
locomotion. In response to DA denervation, there is an increased number and 
surface expression of DA receptors, creating a supersensitivity to DA agonist 
drugs such as apomorphine (Deumens, Blokland, and Prickaerts, 2002). Thus, 
the administration of low dose apomorphine to a unilateral 6-OHDA-lesioned rat 
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 will act in an imbalanced fashion (ipsilateral > contralateral striatum) to stimulate 
movement. The gold standard used to determine the lesion status of a unilateral 
6-OHDA-treated rat is an average number of apomorphine-induced contralateral 
rotations greater than or equal to 300 turns per hour. Post-mortem analyses have 
confirmed that rats that display this drug-induced response have full (>90%) 
ipsilateral lesions (Hudson et al., 1993). The unilateral 6-OHDA-lesioned rats 
used in this study were lesioned and subjected to rotational testing at the Medical 
University of South Carolina. Only rats which met or exceeded this criterion were 
shipped to the University of Kentucky for electrochemical recordings. 
 Our use of the animals was somewhat unique, in that we used technology 
that was capable not only of recording extracellular Glu kinetics but also of 
detecting DA (See Figure 3.1). This afforded us the opportunity to further verify 
the lesion status of the 6-OHDA treated group through direct measurement of 
evoked DA neurotransmission, which we conducted at the end of the recording 
sessions for each lesioned rat. Figure 4.3 demonstrates that we were able to use 
a high dose of potassium (approximately ten times the stimulation typically used 
in these studies) to stimulate and detect DA only on the contralateral side (solid 
lines). Glu recording sites simultaneously recorded Glu and DA kinetics (spike-
dome) while sentinel sites, which are not configured to detect Glu, only recorded 
the DA kinetics (inset). Figure 4.3 also shows that on the ipsilateral side, no DA-
like kinetics were observed, only spike-like signal kinetics that are consistent with 
pure Glu release and uptake. These results support the full ipsilateral lesion 
status of the animals predicted by apomorphine testing with no evoked DA 
signaling on the side of lesion and good DA release and uptake on the 
contralateral side. Note that the use of very high potassium stimulation was 
important to stimulate the non-myelinated DA fibers and to fully test the ipsilateral 
side, which likely had few, if any, DA terminals. 
 Although in Figure 4.3, the simultaneous detection of Glu and DA was 
useful, typically we are interested in studying pure Glu signals, and DA is an 
undesirable interferent. Fortunately, recording DA interferences is not a problem 
in brain regions that are not DA-rich, such as the frontal cortex or the DA-
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 depleted striatum in these studies. In DA-rich areas, Glu uptake is very fast 
relative to DA uptake, which contributes to the characteristic signal shapes of 
evoked release and uptake (Glu spike vs. DA dome). Signals which reflect 
simultaneous release of Glu and large amounts of DA (spike-dome, see Figure 
4.3 and Burmeister et al., 2002) or smaller amounts of DA (uncharacteristic 
prolonged signal decay times) were easily recognized and excluded from Glu 
signal analysis. Furthermore, potassium-evoked DA signals do not show rapid 
reproducibility unlike Glu signals; this characteristic can also be used during the 
course of an experiment to evaluate any suspected DA signals (see Gerhardt, 
Rose, and Hoffer, 1986). 
 Efforts to discriminate between pure Glu and unwanted, DA-contaminated 
Glu signals in DA-rich areas have become rare, however, largely because of two 
methodological advancements. First, all but one of the microelectrode arrays 
used in this chapter’s studies were configured for self-referencing Glu recordings, 
and DA kinetics could easily be evaluated on sentinel sites. When Glu signals 
are detected on Glu recording channels while no signals are recorded on sentinel 
sites, we feel highly confident in the identity of our signal as Glu (see Figure 3.9). 
Secondly, DA is transmitted along non-myelinated axons that require higher 
stimulation than myelinated fibers (e.g. glutamatergic) to cause neurotransmitter 
release; thus, we are able to avoid eliciting DA release in many experiments 
simply by lowering the potassium concentration and/or volume. Prior to these 
studies, preliminary work was done in normal Fischer 344 rats testing the effects 
of 30 mM, 45 mM, and 70 mM potassium solutions. Whereas 30 mM potassium 
did not reliably evoke Glu release and 70 mM evoked DA release too often for 
the experimental design, 45 mM potassium reliably evoked Glu signals with good 
reproducibility and very few instances of simultaneous DA release. Thus, 
potassium stimulations used in these studies (45 mM, ~300 nl) were specifically 
chosen to evoke Glu release without stimulating DA release in areas like the 
striatum and nucleus accumbens. 
 Glu signal parameters, described in detail in Chapter Two, provide 
information about Glu release and uptake systems. Often we consider certain 
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 measures (e.g. rise time, amplitude) to be reflective of Glu release mechanisms 
while others (e.g. decay times, k-1) give us information about Glu uptake. In fact, 
this split has some validity for potassium-evoked Glu measures because the two 
divisions may be primarily influenced by the two respective systems. In reality, 
the rapid fluctuations in extracellular Glu recorded by our technology are driven 
by the balance between these systems. Glu concentrations rise when Glu 
release is greater than uptake, fall when Glu uptake is greater than release, and 
peak or plateau when release and uptake mechanisms are balanced. Often we 
must consider what multiple signal parameters are supporting to make 
conclusions about particular Glu systems. 
 In the striatum of unilateral 6-OHDA-lesioned rats, we found evidence for 
bilateral effects from a unilateral lesion, consistent with previous studies of 
hemiparkinsonian animal models (see Cass et al., 1995). Using the same level of 
potassium to stimulate all signals in both lesioned and non-lesioned rats in our 
studies, the average amplitudes of signals were significantly increased in the 
lesioned animals bilaterally compared by hemisphere to non-lesioned control 
rats. Higher amplitude is most often thought to reflect an increase in evoked Glu 
release, but could signify a decrease in Glu transport because the extracellular 
Glu level is determined by the balance between Glu release and uptake. 
Considering the average decay time T80, which is primarily a measure of Glu 
transporter function, striatal Glu signals on average did not extraordinarily differ. 
Even though the mean difference (~1 second) reached statistical significance on 
the ipsilateral/right side, this change in transport time may not be physiologically 
significant. Taken together, the higher amplitudes most likely reflect an increased 
ability to release Glu on stimulation. Bilaterally increased uptake rates were also 
observed and may seem to contradict the preceding statements; however, the 
uptake rate (calculated by multiplying the amplitude by the decay constant k-1) 
can be increased by either increased release or uptake. More Glu was likely 
released on stimulation, but it took roughly the same amount of time to be 
cleared from the extracellular space; thus, in this case, the increased uptake 
rates are most likely due to increased evoked Glu release, as the EAAT’s are not 
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 operating at their Vmax. Strikingly, there were no statistical differences between 
any of the measures between hemispheres ipsilateral and contralateral to the 
lesion within the treated group. 
 The increased Glu release ipsilateral to lesion can be explained by the DA 
denervation on that side. In the striatum of normal rats, DA is thought to act on 
D2-like receptors on presynaptic Glu terminals to inhibit Glu release (Calabresi et 
al., 1996, Bamford et al., 2004) (Figure 4.2). DA denervation would disinhibit Glu 
terminals and allow increased evoked Glu release. Increased Glu release 
contralateral to lesion cannot be explained in this manner because DA 
neurotransmission remains intact on that side (see Figure 4.3). Two possible 
explanations for contralateral effects include contralateral changes in DA 
regulation and bilateral effects stemming from the neuroanatomy of the 
corticostriatal pathway. First, DA levels have been reported to increase on the 
contralateral side possibly as a compensatory mechanism following unilateral 
nigrostriatal lesion (Nieoullon et al., 1977, Cass et al., 1995). Increased DA could 
cause receptor internalization in presynaptic Glu terminals, desensitizing them to 
the inhibitory effects of DA. In effect, there might be a functional disinhibition of 
evoked Glu release. Alternatively, the bilateral projections of the corticostriatal 
pathway may play a role in creating the contralateral effect. The corticostriatal 
pathway is not a discrete tract but rather a collection of projections that emanate 
from all areas of the cortex and synapse in the striatum. Nonetheless, two distinct 
corticostriatal pathways have recently been reported, a unilateral and a bilateral 
pathway. The unilateral pathway stems largely from lower layer V pyramidal 
neurons in the motor cortex, which travel along the corticospinal tract carrying 
commands of voluntary movement. Collateral striatal afferents peeling off this 
pathway make up the unilateral corticostriatal pathway. The bilateral 
corticostriatal pathway begins in layer III and upper layer V of the cortex and 
sends projections to the cortex and striatum ipsilaterally and across the corpus 
callosum to these structures contralaterally (Reiner et al., 2003, Lei et al., 2004). 
In association with the bilateral corticostriatal pathway, changes in Glu signaling 
in the DA depleted striatum may be able to affect Glu signaling on the opposite 
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 side. In fact, reproducing these experiments in conjunction with corpus 
callosotomy to further investigate the role of the bilateral corticostriatal pathway 
would be an especially interesting future study. Of course, other explanations are 
possible, and these hypotheses require further testing. 
 Bilateral effects on evoked Glu signaling were also seen in the frontal 
cortex. As explained for the striatum, the bilaterally increased amplitudes taken 
together with what may be physiologically insignificant changes in decay times 
(~1 second mean difference) lead to the conclusion that the increased 
amplitudes are most likely due to increased Glu release with stimulation. Also, as 
before, the bilaterally increased uptake rates probably reflect increased evoked 
Glu release. Once again, there are no significant differences in any of the 
reported parameters between signals recorded in the ipsilateral and contralateral 
cortical hemispheres within the lesioned rat group. The direct effects of DA loss 
likely do not explain these differences because there is no nigrostriatal and 
limited mesocortical DA signaling in the discrete areas of the frontal cortex that 
we recorded. However, the loss of DA neurotransmission along one of the 
nigrostriatal pathways creates alterations in several neurotransmitters within and 
connected to nuclei of the involuntary motor pathways. Impulse flow diagrams of 
network changes associated with PD often show decreased tone along the 
glutamatergic pathways from the thalamus to the cortex and from the cortex to its 
targets, including the striatum (Wichmann and DeLong, 2003). This might lead 
one to think that we should be observing decreased Glu release in both the 
striatum and frontal cortex. However, these diagrams are oversimplifications and 
do not consider all of the local effects of neurotransmitter alterations, such as 
receptor-coupled release and uptake modulations. Furthermore, although our 
data in both the striatum and frontal cortex support the hypothesis that there is 
increased evoked Glu release, which may simulate phasic Glu behavior, our 
electrochemical recordings do not give us information about cell firing patterns or 
frequency. Multiple single-unit recordings of ensembles of striatal neurons in 
freely moving unilateral 6-OHDA-lesioned rats have shown that basal cell firing of 
medium spiny-like neurons and large aspiny-like neurons increased on the 
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 lesioned side and on both sides, respectively (Kish et al., 1999). Together, these 
studies support the hypothesis that there is increased excitation bilaterally to the 
striatum. Similar electrophysiological studies of the frontal cortex under 
hemiparkinsonian conditions have not been reported. Increased Glu release in 
the frontal cortex may be a compensatory mechanism for decreased excitatory 
influences from the thalamus, predicted by impulse flow diagrams, or other 
cortical regions (ipsilateral and contralateral thalamocortical and corticocortical 
pathways) and could explain the bilateral effects. In addition, bilateral changes in 
cortical Glu regulation might affect cortical targets, such as the striatum, in both 
hemispheres. 
 In the nucleus accumbens, we did not observe similar bilateral effects 
when we compared matched hemispheres from the lesioned and non-lesioned 
groups, and for the first time, we observed significant differences in signal 
parameters between ipsilateral and contralateral hemispheres within the lesioned 
group. In the non-lesioned rat group (R vs. L nucleus accumbens), we found on 
average smaller amplitudes (<50%) and prolonged T80’s (200-300%) on the right 
side. The long decay time leads us to conclude that Glu transport is much slower 
on the right side, which would tend to increase amplitudes if there was robust 
release; however, the small average amplitude reveals that Glu release is 
instead decreased. Combined, low release and slow uptake explain the low 
uptake rate. On the left side of non-lesioned rats, we found evidence for much 
more robust evoked Glu signaling. A higher average amplitude and faster decay 
time support comparatively increased release and uptake, and a much faster 
uptake rate. These findings might support the hypothesis that there are normal 
hemispheric biases in Glu regulation in the nucleus accumbens. Alternatively, the 
high variability in signal parameters that we observed across the nucleus 
accumbens data sets may have resulted from difficulties in microelectrode 
placement. Unlike larger, more superficial intracranial targets such as the frontal 
cortex and striatum, the nucleus accumbens is a deeper structure with more 
complicated neuroanatomy. At the anterior-posterior coordinates of this study, 
the shell of the nucleus accumbens in the rat is medial and deep to the core of 
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 the nucleus accumbens. Although the trajectory of our coordinates should have 
placed our microelectrode recording sites only in the core, small deviations from 
this trajectory or biological variances in neuroanatomy may have altered our 
recording regions within this structure. Of particular concern is the presence of 
the anterior commissure (AC) traversing through the core ~0.2 mm medial to our 
final recording depth. Microelectrode placement in the AC dramatically lowers 
potassium-evoked DA signaling using carbon fibers (unpublished data), and 
would likely alter potassium-evoked Glu signaling. Without histological 
confirmation of the microelectrode tract, it is difficult to conclude that normal 
hemispheric biases truly exist. 
 If we assume that our recordings were made in the accumbens core, we 
can continue discussing the nucleus accumbens data, limiting our comparisons 
to matched hemispheres between lesioned and non-lesioned rats. It is tempting 
to posit that decreased DA neurotransmission along the lesioned side 
disinhibited presynaptic Glu release mechanisms, as explained for the ipsilateral 
effects in the striatum. This might increase Glu release and stimulate the Glu 
transporter system to function more efficiently, explaining the observed lowered 
average T80 and increased average uptake rate. Cortical afferents carrying Glu to 
the nucleus accumbens on the contralateral side largely showed no statistically 
significant changes in evoked Glu signaling compared to the left nucleus 
accumbens in non-lesioned rats. However, on average, amplitude tended to be 
lower and the T80 longer; slightly less Glu release and slightly slower Glu uptake 
combined to significantly decrease the Glu uptake rate. A slight decrease in Glu 
release might be explained by a compensatory increase in DA signaling to the 
contralateral side, which did not reach the level to internalize DA receptors on 
presynaptic Glu terminals. Following unilateral 6-OHDA injection in the medial 
forebrain bundle, the loss of DA to the ipsilateral nucleus accumbens is often less 
than the loss to the ipsilateral striatum (Lancia et al., 2004); thus, it is conceivable 
that contralateral DA compensation might also be less and have different effects. 
The decreased uptake rate on the contralateral side may be a glutamatergic 
compensatory mechanism in response to the slight lowering of Glu release. 
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 Overall, evoked Glu signaling in the unilateral 6-OHDA-lesioned rat nucleus 
accumbens showed a very different pattern of effects compared to the striatum, 
possibly due to inherent hemispheric differences in Glu regulation and/or 
differences in the loss of DA neurotransmission to these areas. 
 The striking bilateral effects seen in the striatum and frontal cortex put the 
use of the contralateral side as a control in unilateral 6-OHDA-lesioned rats in 
question, at least for some investigations. It has been recognized for a long time 
that patients with PD often are more severely affected on one side, and that 
treatments targeted to the more severely affected side have bilateral efficacy 
(Spencer et al., 1992, Molina et al., 1994). Bilateral projections exist throughout 
the involuntary motor nuclei and associated brain regions and may help explain 
these findings (Glowinski, Bessen, and Cheramy, 1984, Barbeito et al., 1989). 
The data presented in this chapter, in particular, strongly implicate Glu signaling 
from the cortex as a region and system that might play a central role in 
connecting unilateral lesion-induced alterations bilaterally. This also opens up the 
possibility that cortical Glu may be playing a role in the bilateral effects of 
unilateral PD treatments. 
 In summary, we investigated differences in potassium-evoked Glu kinetics 
(45 mM KCl, ~300 nl) in the striatum, frontal cortex, and nucleus accumbens of 
unilateral 6-OHDA-lesioned rats by comparing measured changes by 
hemisphere both within the lesioned group and to similarly aged non-lesioned 
rats. Contrary to one of our original hypotheses, we did not find significant 
changes within the lesioned rat group in the striatum or frontal cortex. Instead, 
we found strikingly matched bilateral effects of a unilateral lesion compared to 
non-lesioned rats. In these brain regions, Glu release was primarily affected, 
showing significant increases on the ipsilateral and contralateral sides. Ipsilateral 
effects in the striatum may be directly related to the loss of DA, while 
contralateral effects in the striatum and all of the effects in the frontal cortex may 
be due to parkinsonian changes in neurotransmitter signaling and/or the 
neuroanatomical bilateral connectivity of the involuntary pathways and 
associated brain regions. Evoked Glu signaling in the nucleus accumbens 
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 showed a similar effect on the ipsilateral side, while the contralateral side 
remained largely unchanged compared to hemisphere-matched recordings from 
non-lesioned rats. There was, however, evidence for hemispheric differences 
within the non-lesioned rat group, which made interpretation of this data difficult. 
Glu signaling from the cortex may play a central role in bilateral alterations 
observed in unilateral animal models of PD. 
  
Copyright © Brian Keith Day 2005 
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 Chapter Five: Normal L-Glutamate Regulation in the Nonhuman Primate 
(NHP) Cortex 
 
Introduction 
 
 In this chapter, we once again build upon our investigations of normal Glu 
neurotransmission in the anesthetized rat brain by developing and implementing 
methods to study normal Glu regulation in the brains of anesthetized nonhuman 
primates. Inherently, this is an interesting pursuit because much of the basic 
science that is conducted in lower mammalian species is assumed to be 
applicable to human conditions; however, important biological species 
differences may exist which can limit the relevance of experimental findings 
(Roth, Ingram, and Lane, 2001). Species which are more closely related to 
humans, such as the rhesus monkeys used in these studies, may be more 
suitable to model humans and represent a logical step along the pathway toward 
applying our technology in the clinical setting. As such, these studies are 
examples of our commitment to conducting translational research at the 
University of Kentucky. However, nonhuman primate studies are not just a 
stepping stone to human research but also stand alone as important 
investigations of basic biological processes in a presumably more relevant, 
higher mammalian species. As this idea relates to our particular research, we 
explored aspects of basic neurobiology in these animals by conducting 
microelectrode arrays studies of Glu regulation in the normal young and aged 
nonhuman primate cortex. 
 Glutamate has often been suspected to contribute to alterations in brain 
function in aging and age-related neurodegenerative conditions. The current 
leading theories of aging primarily implicate free radical formation, largely 
generated by mitochondria, and the resulting long term effects on cell function 
and viability (Harman, 1956, Linnane et al., 1989, Ozawa, 1997, Balaban et al., 
2005). In other words, cell aging may reflect the cumulative effects of 
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 metabolically-produced reactive oxygen species (ROS) on cellular 
macromolecules (Michaelis, 1998). Furthermore, calcium signaling has been 
shown to be altered with age (Foster and Kumar, 2002). Both changes in calcium 
signaling and ROS production may begin with alterations in the regulation of Glu 
neurotransmission; thus, extracellular Glu merits study in the aging brain. Such 
investigations are encouraged by some groups who have reported an increased 
susceptibility to Glu-induced excitotoxicity with age (Liu et al., 1996, Brewer, 
2000). Yet relatively few studies on the regulation of extracellular Glu in the aging 
brain have been conducted, and the results have been highly inconsistent with 
respect to basal Glu levels and Glu clearance capacity (Segovia et al., 2001). 
These inconsistencies may stem in part from some of the limitations of brain slice 
methods and microdialysis. These techniques do not have the spatial and 
temporal resolution to adequately characterize neurotransmitters with fast 
kinetics of release and uptake, such as Glu, and often do not differentiate 
between neuronal and glial Glu sources (Nickell et al., 2005). Our technology 
allows us to investigate basal Glu and evoked Glu dynamics in the intact brain 
closer to the synapse and faster than previously possible. 
 Faced with the opportunity to conduct research in rhesus monkeys, we 
were also presented with new challenges. Significant differences exist between 
working with acutely-studied rats in the laboratory setting and chronically-
investigated monkeys in the veterinary operating room. The tasks of general 
animal handling, anesthesia, surgery, and recovery fell on collaborating teams of 
experts, and our role was relegated to experimental and technological 
specialists. We were concerned primarily with how to design the study and 
modify our voltammetry-based techniques to transition as easily as possible into 
this new venue. One of our primary concerns was creating a mobile FAST-16 
electrochemical detection system that could easily be moved between settings 
and closely positioned to the anesthetized monkey in the operating room without 
compromising the sterile field. We also sought to make the system highly self-
contained to move all components as a single unit and require minimal setup or 
additional equipment. Further concerns were related to modifying our preparation 
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 procedures, providing external nitrogen to our pressure-ejection system, 
implanting a Ag/AgCl reference electrode, and handling sterility with respect to 
direct contact between our electrodes and surgically-exposed tissue from 
chronically-used animals. 
 Briefly, we designed our studies to investigate normal Glu regulation in the 
anesthetized monkey cortex in three ways. First, all microelectrode arrays used 
in these studies were configured for self-referencing Glu recordings. This allowed 
us to use a constant potential paired channel subtraction approach (described in 
Chapter Three) to monitor basal Glu. Secondly, we investigated potassium-
evoked Glu kinetics. In particular, we wanted to compare signal parameters of 
nonhuman primate evoked Glu release and uptake to the rapid Glu dynamics we 
had previously observed in the anesthetized rat brain. Next, we ejected 
exogenous Glu in the recording area to evaluate the Glu uptake system in a 
more isolated fashion. Finally, all of these experiments were performed in three 
monkeys from two different age groups, young and aged, to collect preliminary 
data regarding age-related changes in Glu regulation in the monkey cortex. 
 
Methods 
 
 Refer to Chapter Two for full descriptions of microelectrode array design, 
electrode preparation and use, drugs and chemicals, and data analysis. Any 
deviations from those procedures are noted below, and a full description of 
animal preparation for Glu recordings is also described. 
 
 Animals 
 One young (8 years old) and two aged (25 and 28 years old) female 
rhesus monkeys (Macaca mulatta) obtained from a commercial supplier 
(Covance, Alice, TX) were used in this study. The animals were maintained on a 
12-h light/12-h dark cycle and housed in individual cages measuring 9 square 
feet each, with an elevated perch, front access doors and side rear access doors. 
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 Each cage is a double over-under design containing two monkeys. Each pair of 
two housing cages has an activity module in the middle, connected to the 
housing cage via the side rear doors (Figure 5.1). Their diet consisted of certified 
primate biscuits in the morning (7:30 AM) supplemented daily in the afternoon 
(1:30 PM) with fresh fruit or vegetables, and water was available ad libitum. All 
procedures, except the MR imaging, were conducted in the Laboratory Animal 
Facilities of the University of Kentucky, which are fully accredited by the 
Association for Assessment and Accreditation of Laboratory Animal Care 
(AAALAC).  Veterinarians skilled in the health care and maintenance of 
nonhuman primates supervised all animal care, and all protocols were approved 
by the University of Kentucky’s Institutional Animal Care and Use Committee 
(IACUC). The 28 year-old monkey had congenital malformations of the head, 
including one ear, which made placement in the stereotaxic head frame difficult. 
For other health considerations, this animal was euthanized and underwent a 
necropsy following her Glu recording session. 
 
 Anatomical MRI Procedures 
 After being sedated with ketamine hydrochloride (~20 mg/kg; i.m.) plus 
atropine sulfate (~0.04 mg/kg; i.m.), the animals were anesthetized with sodium 
pentobarbital (~10 mg/kg; i.v.) and imaged to provide stereotaxic coordinates for 
implantation of the microelectrode arrays. At the end of the imaging sessions, the 
animals were recovered and returned to their housing. All MR images were 
obtained on a 1.5T clinical imager (Siemens Magnetom Vision) using a standard 
cross polarized extremity coil. The animal’s head was positioned in the extremity 
coil using an MRI compatible stereotaxic head frame (David Kopf Instruments, 
Model 1430M). This frame kept the animal’s head level and immobilized at the 
center of the radio frequency coil using ear and mouth bars. An initial set of 
coordinates (antero-posterior, dorsal-ventral, and midline) was taken using the 
earbars, toothbar and a zeroing bar targeted to the gum line between the two 
upper middle incisors to allow replication any time the animal was replaced in the  
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Figure 5.1 Nonhuman Primate Housing System 
Pairs of monkeys are housed together to promote social behavior. A variety of 
customized animal toys are included in the activity module (middle section with 
monkey) for environmental enrichment. 
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 stereotaxic apparatus. The coil/frame assembly was then positioned to place the 
animal’s head at magnet isocenter.  Following acquisition of scout images to 
confirm correct positioning, sets of T1-weighted 3D-FLASH images were 
collected for determination of the brain coordinates (TR/TE = 22/9 ms; FA = 35°; 
FOV = 96 × 96 × 90 mm; Matrix = 128 × 128 × 90; Nacq = 2; TA = 6 min 48 sec). 
All images were acquired as coronal slices of the brain. Antero-posterior, lateral 
and vertical coordinates for stereotaxic surgery were derived from the T1-
weighted coronal sections through the brain. The interaural line was identified on 
the scans by modified earbars containing Vitamin E. This provided a precise 
reference-point on the MRI and frame, which allowed for antero-posterior 
measurements. Lateral measurements were determined by measuring the 
distance from midline (defined by the sagittal sinus and/or third ventricle) to the 
target site. Vertical measurements were determined from the surface of the brain 
to the target at the lateral coordinate. 
 
 Electrochemical Recording System Preparations 
 We made several preparations in the weeks to months prior to the first 
experiment day. First, we assembled the mobile FAST-16 electrochemical 
detection system (Figure 5.2). Components included a computer (tower, monitor, 
keyboard, and mouse), a 4-channel FAST-16 setup (potentiostat, headstage 
(pre-amplifier), custom-made plexiglass headstage stand, and dip-socket 
connector), and a Picospritzer III pressure-ejection system. These components 
were secured onto a plastic push-cart, all of the data cables were connected, and 
the power cords were plugged into a central power strip. Additional equipment 
and materials necessary for conducting the experiment (some of which are 
shown in Figure 5.2) included a hydraulic microdrive (Narishige, MO-8), a 
stereotaxic holder, micropipette loading materials, a glass-bodied Ag/AgCl 
reference electrode (Bioanalytical Systems, Inc., RE-5b), and a 
stereomicroscope on a boom stand. Finally, fully prepared microelectrode/ 
micropipette assemblies were securely rested above a bath with the recording  
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Figure 5.2 Mobile FAST-16 Electrochemical Recording System 
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 sites soaking in PBS. All of the additional components were easily stowed on the 
push-cart along with the mobile FAST-16. To protect the delicate glass 
micropipette tips from movement-induced damage, either the microelectrode/ 
micropipette assemblies were separately hand-carried or the PBS was removed 
from the bath before transport and refilled when the push-cart was finally 
positioned in the operating room. 
 A nitrogen tank was secured in the central tank room for the veterinary 
surgical suites. It was dedicated to a spigot near the head of the operating table 
where the mobile FAST-16 was planned to be positioned. A custom-made 
coupling allowed us to connect our Picospritzer III directly to the spigot on the 
operating room wall. This setup was tested for gas delivery to the operating room 
and worked well without any apparent leaks. 
 
 Electrode Preparation and Use 
 Our electrode preparation and use was consistent with most established 
protocols (see Chapter Two for detailed descriptions); however, certain 
methodological approaches were refined as follows. Approximately one week 
prior to scheduled experiment day, we configured four microelectrode arrays to 
record Glu in self-referencing recording mode. The day before the experiment, 
single barrel micropipettes were pulled, bumped to an inner diameter of 10-15 
µm, and attached to the microelectrode arrays. Also, the mobile FAST-16 was 
set up and tested. Three and a half hours before the surgical technician team 
was scheduled to retrieve the rhesus monkey, microelectrode arrays were 
soaked in PBS for one hour and then calibrated in the laboratory using the 
mobile FAST-16 system positioned at the benchtop. Based on calibration data, 
the four microelectrode arrays were ranked by performance. The top two 
microelectrode arrays were assigned for use with potassium and Glu ejections, 
respectively. The other two microelectrodes were planned to be used as backups 
in case of accidental breakage or other unforeseen problems. At this point, the 
surgical technician team was contacted and told to begin their preparations for 
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 surgery. We purposefully scheduled the experiment day to progress like this, so 
that we could abort the experiment prior to animal handling in case of any Glu 
recording system problems. To date, we have recorded from three rhesus 
monkeys and have never needed to cancel the experiment. 
 
 Surgical Procedures 
 Following sedation with ketamine hydrochloride (~20 mg/kg; i.m.) plus 
atropine sulfate (~0.04 mg/kg; i.m.), each animal was intubated via the 
orotracheal method, and intravenous lines were secured. Then, the animal was 
anesthetized with isoflurane (1-3%) and placed in an MRI-compatible stereotaxic 
apparatus (David Kopf Instruments, Model 1430M) in a ventral-lateral position.  
The animal was maintained on a heated blanket and had cardiac and respiratory 
parameters monitored during the procedure. Coordinates for microelectrode 
array implantation were determined by MRI prior to the surgery as described 
above. After being shaved, the scalp area was cleaned with antiseptic. Starting at 
the incision site and moving circumferentially to the periphery, the shaved area 
was gently scrubbed with sterile 4 x 4 sponges soaked in chlorhexidine diacetate 
surgical scrub followed by 70% isopropyl alcohol. This procedure was repeated. 
After the alcohol dried, Betadine® prep was applied, and the animal was covered 
with sterile drapes (Figure 5.3). Then, a 5-7 cm incision was made through the 
scalp, and the skin and muscles were reflected to expose the skull. Small (2 mm 
diameter) holes were drilled in the skull directly over the targeted areas using a 
dental drill and a rounded drill bit, and the overlying meninges were removed to 
expose the surface of the brain. A lateral pocket was made in the fascia at the 
posterior extent of the incision using blunt dissection. A 70% isopropyl alcohol-
cleaned glass-bodied Ag/AgCl reference electrode (Bioanalytical Systems, Inc., 
RE-5b) was inserted into the pocket. Sterile saline irrigation was used to maintain 
ionic contact between the reference electrode and the exposed brain. 
Microelectrode/micropipette assemblies were slowly lowered into each target 
using a stereotaxic holder as described below. After completion of the recording  
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Figure 5.3 Recording Glu in the Operating Room 
Rhesus monkeys were anesthetized and prepared for electrochemical recordings 
under sterile field conditions. The mobile FAST-16 was positioned in the room at 
the head of the operating table. First, a small group of surgeons exposed small 
areas of cerebral cortex and helped implant the microelectrode/micropipette 
assembly. Then, a two-person team conducted the experiment, while a separate 
team of veterinary technicians maintained anesthesia and monitored the 
monkey’s vital signs throughout the procedures. 
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 session, bone wax was placed in the drill holes, and the scalp incision was 
sutured over the exposed areas per normal procedures. The animal was then 
given an analgesic (buprenorphine, 0.01 mg/kg, i.m.) and prophylactic antibiotics 
(combination Penicillin G Benzathine and Penicillin G Procaine, 20,000 U/kg, 
s.c.). Temperature, heart rate, respiratory rate, and femoral pulse were monitored 
until the animal recovered from anesthesia.  Full recovery was defined as self-
sustained balance and posture.  
 
 Stereotaxic Implantation and Glu Recordings 
 Prior to MRI-assisted implantation, a 70 mM potassium solution (70 mM 
KCl, 79 mM NaCl, 2.5 mM CaCl2?2H2O, pH 7.4) or a 5 mM Glu solution (5 mM 
Glu in physiological (0.9%) saline, pH 7.4) was loaded into the single-barrel 
micropipette attached to the microelectrode array. First, a custom-made, pulled 
stainless steel needle (30 gauge, Popper and Sons, Inc., New Hyde Park, NY, 
USA) was cleaned externally and rinsed internally with 70% isopropyl alcohol 
and allowed to air dry. Then, a solution was drawn into a 1 cc syringe, and a 
sterile syringe filter (0.22 µm pore size, Costar, Corning, NY, USA) and pulled 
needle were attached. The fully prepared syringe was used to load the sterile-
filtered solution into the micropipette. The fully prepared microelectrode/ 
micropipette assemblies were implanted into the frontal cortex (frontal eye field) 
and the motor cortex, based individually on coordinates measured from each 
monkey’s MRI. After initially advancing the center of a microelectrode array to the 
cortical surface (David Kopf Instruments, Model 1760 electrode manipulator), an 
assembly was sequentially moved through the recording depths (-1.0 mm to -2.0 
mm in 0.25-0.50 mm increments) using a microdrive (Narishige, MO-8) (Figure 
5.4). In the case of potassium-evoked signals in the frontal cortex, additional 
depths were recorded (-2.25 mm and -2.5 mm). Potassium-evoked Glu signals 
were recorded in one hemisphere, while exogenous Glu was ejected and 
recorded in the opposite hemisphere. For each solution, a separate 
microelectrode/micropipette assembly was used. For each hemisphere, the  
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Figure 5.4 The In Vivo Glu Recording Setup for Anesthetized Monkey 
Studies 
The microelectrode/micropipette assembly was stereotaxically lowered into 
cortical regions based on coordinates derived individually from each monkey’s 
MRI. A four-channel headstage (pre-amplifier) plugged into the FAST-16 was 
placed near the recording area and connected to the microelectrode array using 
a custom-made connector. A stereomicroscope on a boom stand, focused on the 
meniscus within the micropipette, was used to monitor the volumes of solutions 
that were pressure-ejected into the brain. 
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 frontal cortex was recorded in one pass, and then the microelectrode was 
removed from the brain, rinsed with 0.9% (physiological) saline, and 
stereotaxically implanted in the motor cortex in a second pass. A fifteen minute 
equilibration period per implantation was allowed prior to beginning the ejections, 
and a two to three minute equilibration period was allowed between depths. 
Basal Glu levels were assessed at each depth in real time, and additional time 
was allowed to record basal Glu activity when necessary prior to ejections. 
Ejections of 70 mM KCl or 5 mM Glu were made at one minute intervals at each 
depth until at least three to five reproducible Glu responses were recorded. For 5 
mM Glu ejections, we adjusted our ejection volumes to amplitude-match the 
signals between monkeys in the ~50-100 µM range for analytical purposes. 
Volumes were controlled by a pressure-ejection system and monitored using a 
stereomicroscope fitted with a reticule (see Friedemann and Gerhardt, 1996). Glu 
signals were recorded (+0.7 V vs. Ag/AgCl reference) on a second-by-second 
basis by the FAST-16 recording system. 
 
 Data Analysis 
 Average measures from one young monkey were compared to those from 
one aged monkey. A second aged monkey with congenital head malformations 
was recorded. On necropsy, we discovered that our recordings were too far 
anterior. Thus, measures from this animal are not presented with one exception. 
We observed extraordinary basal Glu activity in an area of this aged monkey’s 
brain that was identified as the frontal cortex during post-mortem examination. 
 Basal Glu measures were calculated for each depth by a constant applied 
potential paired channel subtraction approach (described in Chapter Three). Low 
basal Glu measures require within-array performances that exceed normal 
recording requirements. Microelectrode array recordings that displayed obvious 
mismatches in performance were omitted. Briefly, at the end of equilibration, a 
stable paired channel (enzyme-coated vs. enzyme-free) Glu recording of one 
minute duration was evaluated. For extraordinary basal Glu activity, longer 
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 comparison times (three to five minutes) were used. Paired channel signal 
differences were converted into Glu concentrations using an appropriate 
calibration factor. Average Glu concentrations over these time intervals were 
calculated for each depth, and the average Glu concentration for each brain 
region was also determined. Both potassium-evoked and Glu ejection-produced 
Glu signals were analyzed and characterized by the following parameters: 
amplitude (µM Glu), rise time (sec), TTotal (sec), T80 (sec), and uptake rate (µM 
Glu/sec). Refer to Chapter Two for full descriptions. The average amplitude per 
nanoliter of ejected solution (amp/nl, µM Glu/nl) was also calculated. Average 
basal Glu measures and Glu signal parameters were compared between the 
young and aged monkey using unpaired t-tests (α=0.05). Welch’s correction was 
used when required. 
 
 
Results 
 
 Potassium-Evoked Glu Signals in the Motor Cortex 
 We recorded fast kinetics of potassium-evoked Glu release and uptake in 
the motor cortex of both the young and aged monkey. These signals displayed a 
characteristic spike shape (Figure 5.5) and were very similar in character to the 
signals that we routinely observed in the normal young rat cortex. Glu signals in 
the normal young monkey (n=20) rose to peak amplitude in 2.0 ± 0.1 seconds 
and lasted 16.1 ± 1.0 seconds (mean ± SEM used throughout the Results 
section). This is comparable to potassium-evoked Glu signals in the young rat 
cortex, which rose to peak amplitude in 1-2 seconds and lasted 10-20 seconds 
(see Chapter Three). Glu signals in the normal aged motor cortex (n=30) rose 
more slowly (3.3 ± 0.1 sec, p<0.0001) but lasted approximately the same time 
(14.4 ± 0.3 sec, N.S.). Likewise, the average time from signal peak to 80% decay 
(T80) did not significantly differ between the young and aged monkey (10.4 ± 0.6 
sec vs. 11.2 ± 0.2 sec, N.S.). The average signal amplitude was significantly  
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Figure 5.5 Potassium-Evoked Glu Signals in the Motor Cortex 
Potassium ejections at one minute intervals (black arrows) in the monkey motor 
cortex evoked fast Glu release and uptake. Smaller amplitude signals were 
observed in the motor cortex of the young monkey (top trace (blue), responses to 
100 nl potassium volumes) compared to the aged monkey (bottom trace (red), 
responses to 250 nl potassium volumes). 
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 larger in the aged monkey (3.3 ± 0.4 µM Glu vs. 13.3 ± 0.3 µM Glu, young vs. 
aged, p<0.0001) as was the average uptake rate (0.21 ± 0.04 µM Glu/sec vs. 
1.37 ± 0.06 µM Glu/sec, young vs. aged, p<0.0001); however, the potassium 
dose (volume) was also much larger in the aged monkey (100.0 ± 0.0 nl vs. 
236.7 ± 17.9 nl, young vs. aged, p<0.0001). 
 
 Glu Ejections in the Motor Cortex 
 Glu ejection-produced Glu signals in the motor cortex of young and aged 
monkeys were well-matched (Figures 5.6 and 5.7). The average amplitude of 
these signals (young: n=30, aged: n=29) fell into our targeted 50-100 µM range 
(73.9 ± 2.5 µM Glu vs. 67.1 ± 3.4 µM Glu, young vs. aged, N.S.). The volumes of 
5 mM Glu required to achieve these amplitudes dramatically differed (48.3 ± 1.7 
nl vs. 531.7 ± 11.6 nl, young vs. aged, p<0.0001) as did the resulting amp/nl (1.6 
± 0.1 µM Glu/nl vs. 0.1 ± 0.01 µM Glu/nl, young vs. aged, p<0.0001). Average 
T80’s were significantly longer in the aged monkey (10.5 ± 0.3 sec vs. 14.4 ± 0.3 
sec, young vs. aged, p<0.0001), and the average uptake rate was significantly 
slower in the aged monkey (18.5 ± 0.6 µM Glu/sec vs. 7.1 ± 0.6 µM Glu/sec, 
young vs. aged, p<0.0001). 
 
 Potassium-Evoked Glu Signals in the Frontal Cortex 
 Glu signals with fast release and uptake kinetics were also observed in the 
young monkey frontal cortex but not in the aged monkey. These signals differed 
from the Glu signals that were recorded in the monkey motor cortex and in the rat 
cortex primarily with respect to size. Low amplitude Glu signals (1.8 ± 0.2 µM 
Glu, n=18) in the young monkey frontal cortex were recorded at an average 
potassium dose (152.8 ± 14.7 nl) that typically evokes robust Glu release and 
uptake. These signals rose to peak amplitude in 2.2 ± 0.1 seconds but lasted 
only 7.7 ± 1.2 seconds. Overall, most potassium-evoked Glu signals in the 
monkey frontal cortex were atypical low amplitude, slow release, slow uptake 
signals (young: n=6, aged: n=40). Figure 5.8 demonstrates that this population of  
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Figure 5.6 Glu Ejections in the Motor Cortex 
Ejections of 5 mM Glu (black arrows) were volume-adjusted to produce Glu 
signals of similar amplitudes for comparison. The top trace (blue) shows 
recorded ejections of 50 nl of Glu in the young monkey motor cortex while the 
bottom trace (red) shows Glu ejections in the same brain region of the aged 
monkey. Much larger volumes of Glu solution (550, 525, 550 nl) were needed in 
the aged animal to achieve amplitudes between 50 and 100 µM. Increased time 
for signal decay and decreased uptake rate are also apparent in the aged animal. 
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Figure 5.7 Measures of Glu Ejections in the Motor Cortex 
A) Glu ejection-produced Glu signals in the motor cortex were amplitude-
matched for comparison. B) Volumes of 5 mM Glu approximately ten times those 
used in the young monkey were required to achieve the same amplitudes 
(p<0.0001). C) The time from peak amplitude until 80% Glu signal decay was 
significantly increased in the aged monkey (p<0.0001). D) At similar average 
amplitudes, the average uptake rate was significantly decreased in the aged 
monkey (p<0.0001). 
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Figure 5.8 Potassium-Evoked Glu Signals in the Frontal Cortex 
We observed unusually slow potassium-evoked Glu signaling in the frontal 
cortex. These signals were seen at one depth in the young animal (top trace 
(blue), 175 and 50 nl ejections marked with arrows). Slow evoked Glu signals 
were seen at all depths in the aged animal (bottom trace (red), 250 nl ejections 
marked by arrows). 
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 Glu signals achieved average amplitudes of 1.5 ± 0.6 µM Glu and 1.3 ± 0.2 µM 
Glu (young vs. aged, N.S.), rose to peak amplitude very slowly (39.0 ± 6.5 sec 
vs. 22.8 ± 1.7 sec, young vs. aged, p<0.01), and decayed very slowly (young vs. 
aged, average T80: 99.3 ± 13.7 sec vs. 37.8 ± 2.1 sec, p<0.05; average uptake 
rate: 0.0038 ± 0.0008 µM Glu/sec vs. 0.0098 ± 0.0028 µM Glu/sec, p<0.05). The 
volumes of potassium used to stimulate these signals did not significantly differ 
between the differently aged monkeys. 
 
 Glu Ejections in the Frontal Cortex 
 We adjusted volumes of Glu ejections in the frontal cortex to produce Glu 
signals (young: n=30, aged: n=30) that were amplitude-matched (107.8 ± 7.4 µM 
Glu vs. 109.3 ± 6.3 µM Glu, young vs. aged, N.S.) (Figures 5.9 and 5.10). On 
average these signals were very similar in the young and aged monkeys (rise 
times: 2.7 ± 0.2 vs. 2.2 ± 0.1, p<0.05, T80’s: 9.9 ± 0.5 vs. 11.3 ± 0.5, N.S.). 
Average uptake rates were also nearly identical (19.8 ± 2.2 µM Glu/sec vs. 20.6 
± 1.6 µM Glu/sec, young vs. aged, N.S.). However, as we had previously 
observed in the motor cortex, the aged monkey required much larger volumes of 
5 mM Glu to achieve the same amplitudes (46.7 ± 2.3 nl vs. 413.3 ± 37.9 nl, 
young vs. aged, p<0.0001), and the amp/nl significantly differed (2.4 ± 0.2 µM 
Glu/nl vs. 0.3 ± 0.04 µM Glu/nl, young vs. aged, p<0.0001).  
 
 Basal Glu Measures 
 Basal Glu measures were made at three depths in the motor cortex (n=6 
for each monkey) and five depths in the frontal cortex (n=10 for each monkey) in 
both the young and aged monkey. Average basal Glu measures in the young 
monkey tended to be larger than those in the aged monkey in the motor cortex 
(5.3 ± 1.8 µM Glu vs. 0.7 ± 0.2 µM Glu, N.S.) and were significantly larger in the 
frontal cortex (10.3 ± 3.3 µM Glu vs. 2.7 ± 0.5 µM Glu, p<0.05). Significantly 
larger average basal Glu measures in the young monkey’s frontal cortex resulted 
in part due to extraordinarily large basal Glu measures (Figure 5.11) at two   
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Figure 5.9 Glu Ejections in the Frontal Cortex 
Adjusted volumes of 5 mM Glu were ejected in the monkey frontal cortex (black 
arrows) to produce similar Glu signals for comparison. Glu signals in the aged 
animal (bottom trace (red), 550, 525, 525) required larger volumes than the 
young animal (top trace (blue), 50, 50, 25 nl). Note that the signals have very 
similar release and uptake characteristics. 
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Figure 5.10 Measures of Glu Ejections in the Frontal Cortex 
A) Glu ejections in the monkey frontal cortex produced Glu signals that were 
amplitude-matched. B) The aged animal required nearly ten times the volume of 
5 mM Glu to achieve similar amplitudes (p<0.0001). C) and D) Measures of Glu 
uptake did not significantly differ. 
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Figure 5.11 Novel Basal Glu Activity in the Frontal Cortex 
(Figure legend on the following page) 
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 Figure 5.11 (continued) 
Microelectrode arrays configured for recording Glu in self-referencing mode were 
used in these studies. Each graph shows the apparent Glu concentrations from 
the paired channel traces (enzyme-coated (top-most trace, colored solid line) and 
enzyme-free (middle trace, colored dashed line)) which were subtracted to 
quantify basal Glu levels (bottom trace, solid black line). Black arrows indicate 
lowering the microelectrode array to a new depth. A) Upon lowering to -2.25 mm 
(DV) in a young monkey’s frontal cortex, we passively recorded a robust rise in 
basal Glu levels which leveled and oscillated around an average measure of 13.4 
µM Glu over 3 minutes and 20 seconds. This activity disappeared when the 
microelectrode array was lowered to the next depth (not shown). B) When we 
lowered to a depth of -1.25 mm (DV) in an aged monkey’s frontal cortex, we 
passively recorded a dramatic increase in basal Glu levels which irregularly 
oscillated around an average measure of 44.4 µM Glu over 5 minutes. Once 
again, this activity was not observed at the next depth. 
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 depths in this animal. Figure 5.11A shows an example of such measurements 
from the frontal cortex of the young monkey. As stated previously, Glu signals in 
a second aged animal were recorded. In this animal, we observed extraordinary 
basal Glu activity at two depths in a brain region that was visually confirmed to be 
the frontal cortex on post-mortem examination. Figure 5.11B shows an example 
of this novel basal Glu finding from an aged monkey. We observed dynamic 
basal Glu activity with oscillatory behavior in the frontal cortex of both a young 
and an aged rhesus macaque. Such activity has never been observed in the rat 
brain. 
 
Discussion 
 
 We successfully achieved our goal of applying our Glu detection 
technology in a higher mammalian species in an operating room setting. This 
would not have been possible without a professional team effort and careful 
planning based on the collective expertise of all involved. The rhesus monkey 
handling team, surgery team, and veterinary technicians were experienced and 
prepared to fulfill their responsibilities, so that the primary obstacles fell on the 
Glu recording team. Our main challenges were developing a mobile recording 
and experimental setup and modifying our methodologies so that both would be 
compatible with operating room conditions. Creating the mobile FAST-16 was 
simplified by the compact design and limited number of hardware elements 
required to conduct electrochemical recordings. A dry run was made from our 
laboratory to the veterinary operating room and back to assess the security of the 
components and the effects of movement vibrations on our connections. At the 
end of this run, the FAST-16 system was tested and performed without error. 
Once in the OR, all the mobile setup needed was electrical power and a nitrogen 
supply for our pressure-ejection system. Fortunately, modern operating rooms 
have central vacuum and gas supplies with wall spigots in the individual surgical 
suites. We simply had to transport a nitrogen tank to the central tank room one 
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 time in advance and develop a custom-made coupling to gain control over our 
supply of pressurized nitrogen for all experiments. This was an important 
challenge to overcome because transporting a nitrogen tank to the surgical suite 
and securing it in the room for each experiment would be a laborious, time-
consuming, and possibly dangerous task. 
 In addition to these advanced preparations, we also modified our methods 
to progress in a timely and logical fashion and adapted them for chronic animal 
use in a sterile OR setting. Potentially time-intensive elements such as 
micropipette attachments were performed the day before an experiment, and 
calibrations were started hours before the scheduled OR time to ensure that we 
had good functioning Glu recording devices prior to animal retrieval. We 
increased the number of prepared microelectrode arrays per experiment from 
two to four also for this reason and to have backups in case of accidental 
damage or other unforeseen problems. We also modified our Ag/AgCl reference 
electrode implantation protocol for the safety of the rhesus monkey because 
prolonged exposure to bare wire Ag/AgCl reference electrodes can damage brain 
tissue. The use of bare wire Ag/AgCl reference electrodes is highly acceptable 
for acute animal studies, but might be inappropriate for chronic animal use, 
especially when we have a good previously-tested alternative (see Gerhardt et 
al., 1995, Cass et al., 1995). We were able to implant the glass-bodied reference 
electrode under a saline-irrigated skin flap because the Ag/AgCl reference 
electrode works as long as it remains in ionic contact with the brain. The sterilely 
gowned and gloved surgery team handled the reference electrode by holding the 
non-sterile end with sterile gauze and rinsing the implanted portion with 70% 
isopropyl alcohol which was allowed to dry before making contact with the 
exposed monkey tissue. Sterilizing the implanted microelectrode arrays remains 
a challenge because both commonly-used heat and gas sterilization techniques 
disrupt the layered coatings that make the recording sites selective for Glu. It is 
common practice to use small, clean but non-sterile, implantable devices, such 
as microdialysis probes and carbon-fiber microelectrodes, in animal research 
including chronic nonhuman primate studies. Standard veterinary protocols 
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 already include prophylactic antibiotics following surgery in a chronically-used 
large animal. Neither of the recovered monkeys developed a post-experimental 
brain infection or any other poor outcome, so we feel confident that our 
techniques are safe. Nonetheless, we continue to research ways to sterilize our 
microelectrode arrays without compromising performance. 
 We applied this technology to a pilot study of normal Glu 
neurotransmission in the cerebral cortex of young and aged rhesus monkeys in a 
sterile field operating room setting. Most importantly, we were able to assemble 
collaborative teams of experts and modify our methods successfully to conduct 
Glu recordings in the intact brain of monkeys in a safe and efficient manner. This 
was our primary goal and achieving it creates opportunities for many important 
future studies using this technology in nonhuman primates and/or the operating 
room setting. We observed Glu signaling that was both very familiar and very 
different from our experiences with Glu regulation in the rat brain. These facts 
validate our research in lower mammals while also highlighting the need to 
advance this technology into higher mammals to improve our studies’ relevance 
to human conditions. All Glu measures were compared between one young and 
one aged animal. The low number of animals per age group and the lack of a 
middle-aged group limit the contributions of this study to aging research. 
Nonetheless, we were able to detect significant differences in Glu regulation in 
two cortical areas from individual monkeys of different ages. These results 
support that alterations in Glu regulation likely occur with aging, as has 
previously been reported in recent rat studies (Nickell et al., 2005); thus, a larger 
study is merited. 
 If the monkeys used in this study prove to be representative of their age 
groups, significant age-related alterations occur in Glu release and uptake 
mechanisms which affect evoked and basal Glu regulation. Within the motor 
cortex, we observed some of the most familiar evoked Glu signaling to our 
experiences with potassium-evoked Glu regulation from the young rat cortex. In 
particular, average potassium-evoked Glu signals in the young monkey motor 
cortex rose to peak amplitude in ~2 seconds and lasted ~16 seconds. This 
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 compares well with our 70 mM potassium-evoked signaling from the rat brain 
which rose to peak amplitude in 1-2 seconds and lasted 10-20 seconds (see 
Chapter Three). The same stimulations in the aged monkey motor cortex 
produced signals that closely matched these times. Larger signal amplitudes in 
the aged monkey represent the primary difference between the two animals. 
Higher amplitudes without significant differences in Glu transporter function (i.e. 
non-significant difference in T80’s) drove the significant increases that we 
observed in the uptake rate. The measures support that we were observing a 
difference in Glu release while uptake was unchanged at the low Glu release 
levels. We cannot, however, attribute this change solely to differences in age 
because the potassium doses were also significantly higher in the aged monkey 
motor cortex. We have previously observed a limited dose-response to 
increasing potassium volumes in the young (see Burmeister et al., 2002) and 
aged rat brain (unpublished data); thus, the higher amplitudes in the aged animal 
may simply be due to higher depolarizing stimulations. 
 While we could not detect significant differences in the Glu uptake system 
by studying low volume 70 mM potassium-evoked Glu signals, highly significant 
uptake changes were evidenced by the recordings of 5 mM Glu ejections. We 
adjusted the ejected volumes to match Glu signal amplitudes in a targeted range 
to better compare signal parameters, especially measures of the Glu uptake 
system (e.g. T80 and uptake rate). While uptake rate can reflect changes in Glu 
release or uptake (see above, Chapter Two Data Analysis, and Chapter Four 
Discussion), it is mainly reflective of the Glu uptake system when signals have 
the same amplitudes. The higher volumes of 5 mM Glu that were needed to 
produce target amplitudes in the aged monkey can be explained in at least two 
ways. First, there may be increased uptake in the aged monkey because more of 
the ejected Glu was being cleared from the extracellular space in the 50-100 µm 
distance between the micropipette tip and the microelectrode array recording 
sites. Second, there may be an age-related change in the excitability of Glu fibers 
(i.e. a change in the level of exogenous Glu-induced endogenous Glu release). 
Further analysis of our signals shows that Glu uptake-related signal parameters 
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 in the aged monkey (longer T80 and decreased uptake rate) support a decrease 
in Glu uptake. Recently, a series of studies in young (6 month old), late middle-
aged (18 month old), and aged (24 month old) rats have expanded our 
understanding of age-related changes in the mammalian Glu system. Consistent 
with our pilot work in monkeys, Nickell et al. (2005) showed that, in the aged rat 
brain, greater volumes of 5 mM Glu were required to produce amplitude-matched 
signals, and there was a decrease in the average uptake rate compared to 
younger rats. Additional Western blots analyses were completed to examine the 
amount and surface expression of rat Glu transporters (GLAST and GLT-1 (glial) 
and EAAC1 (neuronal)), which revealed that there were no age-related changes 
in total protein levels; however, the surface expression of GLAST was 
significantly decreased in the late middle-aged and aged rats. Thus, although 
gliosis (an increased number of glial cells, such as astrocytes that account for 
most of Glu uptake) has been reported in the aged mammalian brain (Unger, 
1998), data in rats support an age-related decrease in the number of Glu 
transporters available for Glu uptake. This may explain the decreased uptake 
rate seen in both the aged rat and monkey. Furthermore, there is no supporting 
evidence to conclude that increased uptake accounted for the increased volumes 
of 5 mM Glu needed to produce amplitude-matched signals in either the aged rat 
or monkey brain. Instead, this may reflect an age-related decrease in the 
excitability of Glu terminals. 
 We also recorded potassium-evoked Glu signals in the monkey frontal 
cortex, yet many of the characteristics of these signals differed from the typical 
evoked Glu kinetics that we observed in the motor cortex. First, we evoked both 
fast and relatively slow Glu signals in the young monkey, while only slower Glu 
signals were seen in the aged monkey. The fast Glu signaling differed from our 
typical signals primarily with respect to amplitude. It is interesting to consider that 
we also recorded extraordinarily high basal Glu activity in this brain region, which 
may have been tonically activating presynaptic metabotropic Glu autoreceptors 
that inhibit Glu release. This may explain the reduction in amplitude and 
decreased signal times. That we did not see fast Glu signaling at all in the aged 
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 monkey may have been due to the age difference; however, this animal was 
being maintained at a higher level of anesthesia (3% isoflurane, an induction 
level) than the young monkey during these recordings. Isoflurane has been 
reported to decrease Glu release and increase Glu uptake in mammals 
(Hudspith, 1997, Danbolt, 2001), and the higher dose in the aged animal makes 
definitive conclusions difficult. The anesthesia was lowered to a more typical 
maintenance level (2%) before additional Glu recordings were made. In both the 
young and aged monkey frontal cortex, we also observed unusual Glu signals 
which showed reproducible slow release and uptake characteristics. Once again, 
the higher basal Glu activity may explain the lowered Glu release but does not 
explain the decreased uptake. At least two possibilities can explain the 
decreased Glu uptake at these low levels of Glu release. First, the frontal cortex 
may be a more susceptible region to the effects of isoflurane on Glu regulation, 
which may have also contributed to decreased Glu release, and secondly, we 
may be observing novel normal Glu regulation. The complementary Glu ejections 
in the frontal cortex do not support that this region has diminished Glu transporter 
function. In fact, the Glu uptake rate was roughly equivalent or even higher than 
that seen following Glu ejections in the motor cortex. If this region is predisposed 
to higher, often oscillatory, basal Glu levels, an increase in extracellular Glu 
concentration of ~1-2 µM (average potassium-evoked Glu signal amplitudes 
seen in the frontal cortex) may not always elicit the fast uptake responses that we 
have previously characterized and may represent a new kind of Glu signaling in 
the brain. Interestingly, low level evoked Glu release and uptake was faster 
(faster rise times and T80’s) in the aged monkey frontal cortex. 
 Once more, when we challenged the Glu uptake system with much higher 
levels of exogenous Glu ejections, Glu uptake was robust and revealed a 
difference in Glu uptake between the young and aged animals. In nearly every 
measure, these Glu signals were very closely matched. The most striking 
difference was that average volumes of nearly ten times as much 5 mM Glu were 
needed to achieve the target amplitudes in the aged monkey, which may again 
be explained by an age-related change in glutamatergic excitability (decreased 
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 Glu-induced Glu release in the aged monkey). Unlike in the motor cortex, the 
average uptake rates and T80’s were not different, so that the Glu uptake system 
appears to remain functionally unchanged with age in the frontal cortex. 
 Average basal Glu measures were larger in both cortical regions of the 
young monkey compared to the aged monkey. The young monkey measures 
showed a statistically significant mean increase in the frontal cortex but only 
tended to be larger in the motor cortex despite a large mean difference 
(p=0.052). Basal Glu signals were recorded in a second aged monkey in two 
brain regions. Extremely high basal Glu measures (43.4 ± 14.9 µM Glu, n=10) 
were calculated for a brain region that was identified as the frontal cortex on 
post-mortem examination. These levels were much larger than the average 
frontal cortical levels from the young monkey and the other aged monkey (10.3 ± 
3.3 µM Glu and 2.7 ± 0.5 µM Glu, respectively). Thus, it is difficult to conclude 
that there is any age-related change in basal Glu levels in this region, as aged 
monkeys individually showed much lower and much higher basal Glu levels in 
the frontal cortex than a young monkey. This emphasizes that many of the 
comparisons discussed for the various Glu measures so far may not be due to 
age differences but simply biological variability between animals. As previously 
mentioned, this discussion of age-related differences in Glu regulation assumes 
that these animals are representatives of their age groups. This assumption can 
only be tested by conducting a much larger study. 
 Particularly interesting findings in two of the three monkeys were strikingly 
increased basal Glu levels at discrete depths within the frontal cortex. Both the 
temporal behavior and, in the case of the 28 year-old monkey, the magnitudes of 
the average basal Glu measurements (129.2 µM Glu and 44.4 µM Glu, both over 
5 minutes) had never been seen before in any Glu recording from a mammalian 
brain. As we lowered into these depths, the sentinel recording sites maintained 
baseline activities, while the Glu recording sites passively displayed high basal 
Glu levels that tended to oscillate over time. The periodicities of these oscillations 
were approximately 30 seconds to a minute, time periods much too long to 
correspond to other biological or mechanical interferences such as heart rate or 
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 ventilation. In fact, the aged monkey traces showed a smaller, superimposed 
higher-frequency oscillation on both the sentinel and Glu recording channels (see 
Figure 5.11B). These fluctuations may reflect the pulse pressure created by a 
typical anesthetized rhesus monkey heart rate, which leads us to hypothesize 
that, in the case of the aged monkey, we may have been recording basal Glu 
levels near a cortical blood vessel. In this animal, the average basal Glu level 
dropped in an almost logarithmic fashion as we lowered the microelectrode array 
further supporting the hypothesis that we began close to a concentrated source 
of Glu and moved away from it. In the young animal, however, we saw neither 
the superimposed frequency nor did the level drop in a predictable fashion. Both 
depths that showed extraordinary basal Glu activity in the young monkey were 
inferior and superior to depths that had much lower basal Glu levels. These new 
and exciting findings would not have been possible without the spatial and 
temporal resolution that implantable microelectrode arrays provide. 
 In summary, we achieved our primary goal of safely and efficiently 
advancing second-by-second microelectrode array Glu recordings into the 
nonhuman primate brain in the veterinary operating room. This began with 
careful planning on the parts of several collaborating teams of specialists who 
helped recognize the challenges of this task. Specifically, we developed a mobile 
Glu recording setup, made several advanced preparations, and adapted our 
protocols to maximize the likelihood of executing successful experiments. 
Accomplishing our primary goal creates many opportunities for future studies in 
nonhuman primates and/or in the OR setting. These efforts were also part of a 
pilot study of age-related changes in Glu regulation in the nonhuman primate 
cerebral cortex. Although we collected data from only three animals in two age 
groups, we were already able to see differences in Glu regulation in differently 
aged individual animals. Our Glu recordings in the rhesus monkey cortex 
displayed both the fast kinetics that we had previously characterized in the rat 
brain and novel potassium-evoked and basal Glu activities. Larger studies are 
merited to further explore differences in normal Glu signaling and age-related 
alterations in Glu regulation in the nonhuman primate brain. 
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 Discussion & Conclusions 
 
 Our development of ceramic-based enzyme-coated multisite 
microelectrode arrays that use electrochemical detection to selectively record Glu 
levels with high spatial and temporal resolutions (15 x 333 µm, 800 msec) 
created an exciting new research tool to examine direct Glu measures in the 
intact mammalian CNS. The premier conclusion that emerged from the initial 
work using Glu selective microelectrode arrays confirmed that in vivo measures 
of extracellular Glu displayed fast kinetics of release and uptake that required a 
fast monitoring technology (see Burmeister, Moxon, and Gerhardt, 2000, 
Burmeister and Gerhardt, 2001, and Burmeister et al., 2002). The second-by-
second recording capabilities are a distinct advantage of microelectrode array 
studies of Glu. In this dissertation, these capabilities were used repeatedly to 
investigate the dynamics of Glu release and uptake in the mammalian brain. 
However, we also expanded the use of this technology to study basal Glu 
regulation including achieving the important task of measuring basal Glu levels. 
In addition to technological advancements that expanded and improved our Glu 
recording capabilities, we also advanced the biological applications of 
microelectrode arrays to complement the initial in vivo recordings in the normal 
rat brain and pushed this technology into a rat model of PD and into young and 
aged normal rhesus monkeys in the veterinary operating room setting. Ultimately, 
as our technology and biological applications progress, we would like to conduct 
Glu recordings in the intact human brain in the clinical setting to advance our 
scientific understanding of Glu regulation and possibly benefit patient care. 
 In Chapter Three, we used microelectrode arrays to study basal and 
potassium-evoked Glu regulation in the normal anesthetized young rat brain. Glu 
kinetics studies had already been performed in the normal rat CNS using both 
potassium and Glu ejections; however, the speed and reproducibility of different 
concentrations of potassium had not been fully investigated, and no work had 
been carried out to explore basal Glu using microelectrode arrays. Our studies in 
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 the striatum and frontal cortex revealed that TTX lowered while TBOA increased 
signals across individual Glu recording channels to significantly different levels 
than physiological saline ejections alone, which lowered the signal slightly due to 
dilution of the recording area. The TBOA-dependent effects (1-3 µM Glu 
increase) support the hypothesis that active Glu release and uptake occurs at a 
basal level. The TTX-dependent effects (~2 µM Glu decrease) support the 
hypothesis that a significant measurable portion of basal Glu originates from 
action potential-dependent neuronal release. To determine what fraction of basal 
Glu was TTX-dependent, we had to further develop our technology to quantify 
overall basal Glu levels. We developed two methods using the self-referencing 
capabilities of our microelectrode arrays. The first method measured baseline 
signal differences between pairs of enzyme-coated and enzyme-free channels at 
constant applied potential (+0.7 V vs. Ag/AgCl reference). The second was a 
varied applied potential method that switched the potential between +0.25 V and 
+0.7 V (both vs. Ag/AgCl reference) and measured the differences in voltage-
dependent signal changes between the same paired channels. We applied these 
techniques in the rat striatum and frontal cortex to find that the overall basal Glu 
level was ~2 µM Glu in both regions with no significant difference between the 
methods. Taken with the previous TTX-saline comparisons, our data support that 
basal Glu is fully TTX-dependent in two regions of the urethane-anesthetized rat 
brain. Our results compare favorably in concept to another voltammetry-based 
investigation of basal Glu (Kulagina, Shankar, and Michael, 1999) except the 
magnitude of our TTX-induced signal changes and overall basal Glu levels are 
lower. Alternatively, our basal Glu levels are similar to reported microdialysis 
measures; however, microdialysis studies do not support greater than 50% TTX-
dependency of basal Glu levels. These differences may be related to our use of 
the anesthetic drug urethane, which may be lowering basal Glu levels and 
altering the TTX-dependent fraction. Investigations in the awake, freely-moving 
rat in our laboratory to resolve this issue are ongoing. We also investigated 70 
mM and 120 mM potassium-evoked Glu signals in the same brain regions and 
determined the speed of these signals. Overall, the potassium-evoked signals 
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 supported robust Glu release and uptake, rising to peak amplitude in 1-4 
seconds and lasting 10-20 seconds. The 70 mM potassium-evoked Glu signals 
were slightly smaller and faster than 120 mM and were less likely to show any 
signs of interference from other electroactive molecules such as the 
neurotransmitter DA. All potassium-evoked signals were routinely reproducible at 
20 seconds intervals and remained distinct at intervals as short as 15 seconds. 
These results are comparable to earlier studies of potassium-evoked Glu release 
using similar technology (Hu et al., 1994), especially with respect to the fast 
kinetics of Glu release and uptake. Finally, we responded to one of the most 
common criticisms of microelectrode-based detection systems, signal identity. To 
address this issue, we recorded potassium-evoked Glu responses in a self-
referencing mode to demonstrate that our evoked signals were both enzyme- 
and voltage-dependent, further confirming that the major source of our evoked 
signals is Glu. 
 In Chapter Four, we built on our previous investigations of normal Glu to 
advance this technology to study a rat model of PD. In the last decade, PD has 
been reexamined as a disease of secondary Glu hyperactivity along pathways 
related to the disease-altered involuntary motor system, namely the 
glutamatergic corticostriatal and subthalamopallidal pathways. Conducting 
microelectrode array studies in the brains of unilateral 6-OHDA-lesioned young 
rats, we focused on the corticostriatal pathway, recording in both the striatum and 
frontal cortex. We also examined evoked Glu signaling in the nucleus 
accumbens, a brain area that is cellularly organized almost identically to the 
striatum but receives DA primarily from a different area of the midbrain. Like 
many investigators, we used the unilateral lesioned rat model so that we could 
make comparisons to the contralateral side as a within-animal control. We also 
recorded non-lesioned rats in the same age range as another control group. Our 
hypotheses entering the study were that there would be ipsilateral and 
contralateral differences in evoked Glu kinetics within the 6-OHDA-lesioned 
group and that evoked Glu kinetics would differ between matched hemispheres 
of lesioned and non-lesioned rats. Potassium ejections (45 mM KCl, ~300 nl) 
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 were used to stimulate Glu signals in all animals. At the end of the recording 
sessions, we used roughly ten times higher potassium stimulation in the striatum 
to record simultaneous Glu and DA release to further confirm the unilateral lesion 
status of the 6-OHDA-treated animals. In the striatum and frontal cortex, there 
were no significant differences in any of the reported average signal parameters 
(amplitude, uptake rate, T80) between hemispheres within the unilaterally 
lesioned group; however, Glu signal measures were significantly altered in both 
lesioned hemispheres compared to matched hemispheres in non-lesioned rats. 
Taken together, we observed a striking bilateral effect of a unilateral lesion on 
Glu signaling in the striatum and frontal cortex. Closer examination of the signal 
parameters supported that the primary difference in lesioned rats was increased 
Glu release on stimulation. In the normal rat striatum, DA release tends to inhibit 
Glu release through D2-like receptors on the presynaptic Glu nerve terminals. In 
the DA denervated striatum on the ipsilateral side, the presynaptic Glu terminals 
may be disinhibited so that they release more Glu when evoked. In the DA 
innervated striatum on the contralateral side, the same disinhibition cannot occur 
because DA is present; however, an increased DA compensation on this side, as 
previously reported (Nieoullon et al., 1977, Cass et al., 1995), might internalize 
some DA receptors and cause a functional disinhibition of Glu release. 
Alternatively, a distinct bilateral corticostriatal pathway has been reported (Reiner 
et al., 2003, Lei et al., 2004), which may play a role in sychronizing events 
between the ipsilateral and contralateral striatum due to bilateral connectivity 
through the cortex. In fact, bilaterally increased potassium-evoked Glu release in 
the frontal cortex was also measured in the unilateral lesioned rat group. These 
findings may result from the downstream effects of lesioning the nigrostriatal 
pathway as the cortex is known to be involved in parkinsonian motor 
abnormalities. Again, the bilateral effects may relate to the high connectivity of 
the cortex to the striatum and to other cortical areas within both hemispheres. In 
the nucleus accumbens, we measured significant differences in evoked Glu 
signaling within the lesioned rat group; however, we also found compelling 
evidence for normal hemispheric differences within the non-lesioned rat group 
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 that may have reflected greater difficulties in microelectrode array placement in 
this brain region. Restricting our discussion to hemisphere-matched comparisons 
between lesioned and non-lesioned rats, the increased evoked Glu release was 
maintained in the ipsilateral nucleus accumbens; however, there was also a 
significant increase in Glu uptake. In the contralateral nucleus accumbens, there 
was no significant effect of lesion on evoked Glu measures except for a slight but 
significant decrease in Glu uptake. Interestingly, DA depletion to the nucleus 
accumbens is relatively spared following 6-OHDA treatment (Lancia et al., 2004), 
which may have contributed to some of the differences that we measured 
compared to similar brain areas like the striatum. Overall, this work puts the use 
of the contralateral side in the unilateral 6-OHDA-lesioned rat as a control into 
question for some measures, as we would not have recognized any difference in 
evoked Glu kinetics in the striatum and frontal cortex of lesioned animals without 
another control group. Furthermore, the effects that we measured in both 
hemispheres in lesioned rats place the cortex and the neurotransmitter Glu as 
prime candidates for modulating bilateral effects of unilateral treatments, 
including 6-OHDA-lesions and possibly PD therapies. 
 In Chapter Five, we returned to investigating normal Glu regulation by 
advancing our technology to study both young and aged rhesus monkeys. Our 
primary goal was to modify our technology and methods to safely and efficiently 
conduct nonhuman primate Glu recordings in the veterinary operating room. We 
also wanted to compare characteristics of normal Glu regulation between our 
initial rat work and the higher mammalian species, determine if there were 
regional changes within the monkey cortex, and collect preliminary data to 
evaluate whether there were age-related differences in Glu regulation. 
Accomplishing our primary goal began with extensive planning between the 
collaborating teams and a number of modifications to our standard Glu recording 
approach. First, we created the mobile FAST-16, a self-contained 
electrochemical recording system that could be easily moved between the 
laboratory and operating room with minimal setup requirements. In advance, we 
supplied the surgical facilities with pressurized nitrogen and created a custom-
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 made coupling so that our pressure-ejection system would be compatible with 
typical OR gas supply lines. We also modified our experimental preparations to 
conform to the timeline of nonhuman primate surgery and improve our chances 
for successful Glu recordings. First, we increased the number of microelectrode 
arrays prepared per animal from two to four. Then, we moved time-intensive 
steps such as micropipette attachment to the day before surgery. Finally, we 
calibrated the microelectrode arrays several hours before surgery to evaluate 
their quality prior to the start of pre-surgical monkey preparation. We did this so 
that, if necessary, the experiment could be cancelled in a timely manner to avoid 
inefficient animal use. With these new methods in place, we successfully 
recorded Glu signals in three rhesus monkeys (8, 25, and 28 YO) with no 
experiments cancelled. We measured basal Glu levels and studied Glu signals 
resulting from local ejections of 70 mM potassium and 5 mM Glu solutions. In the 
motor cortex of all monkeys, we observed the fast kinetics of Glu release and 
uptake that we had previously characterized in the rat brain. Fast Glu uptake was 
also seen in the frontal cortex of all monkeys following exogenous Glu challenge; 
however, potassium-evoked Glu responses were unusual in this brain region. All 
potassium-evoked signals were low amplitude (<2 µM Glu), and both fast (young 
monkey) and slow (both young and aged monkey) Glu release and uptake 
kinetics were recorded. Interestingly, novel basal Glu activity was also observed 
in this brain region in both a young and an aged monkey, which might contribute 
to some of the atypical release and uptake characteristics. The average basal 
Glu levels in the isoflurane-anesthetized monkeys were higher in the frontal 
cortex than those we have measured in the urethane-anesthetized rat frontal 
cortex, and both species and anesthetic changes may play a role in these 
differences. More strikingly, average basal Glu levels at discrete depths were 
often very high (~10-120 µM Glu) and displayed dynamic oscillatory behavior. 
These basal Glu magnitudes and activities had never before been recorded in 
the anesthetized mammalian brain. The primary age-related difference that we 
observed was related to Glu uptake. In both cortical regions, we had to deliver 
roughly ten times the volume of 5 mM Glu in the aged monkey to match the 
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 amplitudes we achieved in the young monkey. This may be due to an age-related 
decrease in the excitability of Glu fibers in the monkey cortex. We also saw an 
age-related decrease in uptake rate in the motor cortex. The low number of 
animals per group limits the relevance of these findings to aging research; 
however, we already have data supporting differences in Glu regulation in young 
and aged individual monkeys, and a larger study is merited. 
 Overall, we have made good progress to both advance and refine the 
technology and expand its biological applications to better study Glu in the 
mammalian brain. Beginning with the characteration of basal and potassium-
evoked Glu regulation in the anesthetized rat brain, we moved the technology 
forward to study disease-altered Glu regulation in the hemiparkinsonian rat brain 
and normal Glu neurotransmission in young and aged rhesus monkeys. Based 
on our experiences to date, we would like to continue pushing our technology 
forward to record Glu in the intact human brain. This dissertation began by 
introducing the idea that using implantable microelectrode arrays to advance 
science and medicine is neither science-fiction nor radical, but potentially a 
common and valuable tool that might be used by physicians to improve patient 
care. The appendix documents our first experience with excised human brain 
tissue and how we might logically proceed to introduce Glu selective 
microelectrode arrays into clinical applications. 
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 Appendix: Investigating Glu Neurotransmission in the Human Brain 
 
Introduction 
 
 Throughout the graduate studies of my combined M.D./Ph.D. training, I 
have been especially interested in advancing our technology toward clinical 
applications. Because the initial use of microelectrode arrays to study normal Glu 
dynamics in the intact rat brain shortly predated the start of my dissertation 
research, my role in this effort began at the benchside. Though we had published 
data supporting the rapid nature of extracellular Glu signaling, many aspects of 
Glu neurotransmission required further investigation. In response, I conducted 
several additional studies of normal Glu regulation in the rat brain, focusing on 
both basal and potassium-evoked measures. Building on these studies, we also 
investigated Glu signaling alterations in the unilateral 6-OHDA-lesioned rat model 
of PD. Together, these acute investigations provided biological, methodological, 
and analytical bases for moving our technology into chronically-used nonhuman 
primates in the veterinary operating room. This effort represented a logical step 
in the advancement of our technology toward human applications and an 
important opportunity for us to begin modifying our methods to transition into a 
clinically-relevant setting. In a parallel fashion, actual human brain tissue 
recordings have begun at the benchside, and hopefully they will ultimately be 
applied in the clinical arena to benefit patient care. 
 
Preliminary Human Tissue Study 
 
 In collaboration with neurosurgeon Craig van Horne M.D., Ph.D. and his 
laboratory team at the Harvard Institutes of Medicine (HIM, Boston, MA), we 
attempted to record Glu from a piece of excised human brain tissue. We began 
working toward this goal in the Spring of 2003 when I traveled to the Brigham 
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 Hospital and the HIM to deliver, set up, and test his FAST-16 electrochemical 
detection system. During this trip, I also supplied his laboratory with many of the 
materials and equipment necessary to conduct independent microelectrode array 
studies and trained his staff. With these basic requirements satisfied, we allowed 
time for our partners to become proficient with the technology, and set up 
additional training for a new member of Dr. van Horne’s team here at the 
University of Kentucky later that year. I spent one more week in Boston during 
the Spring of 2004, and we recorded signals from a small piece of freshly-
excised human brain provided by Dr. van Horne. 
 Our goal was simply to prove that we could record Glu from a surgically 
resected piece of human brain tissue. At the same time, we wanted to plan ways 
to refine our excised human tissue methods to conduct safe and efficient Glu 
recordings in the future. Several refinements are needed as we faced many 
challenges from the onset of this first effort. Our equipment was primarily limited 
to the basic FAST-16 recording setup and a brain slice recording chamber. We 
did not have timely access to oxygenation, perfusion, or heating systems for the 
chamber. The resected brain tissue had to be evaluated by the Pathology 
Department before it was released for further testing. Furthermore, the physical 
dimensions of the tissue also presented a problem for implantation-based Glu 
recordings. 
 To overcome these limitations, we had to adapt new ways to conduct the 
experiment and stimulate detectable Glu release. Microelectrode arrays 
configured for recording Glu on all sites were calibrated beforehand. We could 
not implant a microelectrode array due to the size and shape of the brain tissue. 
Instead the brain tissue was removed from ice storage and floated in a pool of 
0.05 M PBS in the central reservoir of the recording chamber at room 
temperature. The microelectrode array was lowered into the saline pool at a 
shallow angle, and recordings were begun. Using microforceps, the brain tissue 
was gently moved toward the microelectrode until it rested atop all four recording 
sites (see Figure A.1). To stimulate endogenous Glu release from the tissue, we 
applied small drops of a 120 mM potassium solution (120 mM 
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Figure A.1 Recording Setup for Our First Experience with Excised Human 
Brain Tissue 
Our basic setup included the FAST-16 recording system and a brain slice 
recording chamber. The inset photographs show the relationship of the 
microelectrode array and tissue before (left) and after (right) positioning the 
tissue onto the recording sites. The four platinum recording sites are clearly 
visible in the left inset picture. 
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 KCl, 29 mM NaCl, 2.5 mM CaCl2?2H2O, pH 7.4) directly onto the tissue using a 
pipettor. Because the microelectrode arrays were not configured for self-
referencing Glu recordings, we could not assess steady-state Glu levels. 
 These simple manipulations gave us the following results. Figures A.2 and 
A.3 demonstrate that when we moved the tissue onto the Glu recording sites 
(white arrows), we recorded signal increases on all four channels. Figure A.3 
also shows the recorded responses to high potassium applications (black 
arrows). The initial potassium application created prolonged signal increases on 
all four channels, while a second application had diminished or virtually no effect 
on the recorded signals. The final application floated the tissue off of the 
recording sites, and we observed universal signal decreases. 
 Unfortunately, at this point, we cannot definitively conclude that we 
achieved our goal of recording Glu from an excised piece of human brain tissue. 
This is primarily because we were not able to use microelectrode arrays 
configured to record Glu in a self-referencing mode for this experiment. Without 
evidence that our signal changes were not due to interfering neurochemicals, we 
simply cannot be sure that our results were wholely or partially due to 
endogenous Glu release. Whereas monitoring interferences is routinely 
beneficial, it is especially important when attempting to record from a piece of 
traumatized brain tissue that may be releasing chemicals that do not normally 
exist in the extracellular fluid at such high concentrations. Nonetheless, the 
behavior of the signals in response to our manipulations might be consistent with 
spontaneous (initial tissue contact) and evoked (potassium-driven depolarization) 
Glu releases, and we are hopeful that with appropriate modifications we will 
succeed in definitively recording Glu from human brain tissue. Ultimately, this 
experiment was an important opportunity to identify difficulties associated with 
excised human tissue recordings so that we can design better future studies. 
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Figure A.2 Initial Contact of the Excised Human Brain Tissue with the 
Microelectrode Array 
Immediately upon contact between the excised human brain tissue and the 
microelectrode array (white arrow), we observed dramatic signal increases on all 
four channels. The signals immediately began to approach steady levels, and 
remained higher than pre-contact levels after several minutes of recording. If 
these changes in signal are due to Glu detection, a 0.1 nA change in signal is 
approximately equal to 17.3 µM change in Glu concentration according to the 
calibration slopes for the microelectrode array used in these recordings. The 
traces have been offset from one another for clarity. 
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Figure A.3 Potassium-Evoked Signals from Excised Human Brain Tissue 
(Figure legend on the following page) 
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 Figure A.3 (continued) 
A) As we previously observed, all four channels displayed signal increases upon 
contact between the tissue and the recording sites (white arrow). Individual 
differences in response may be due to the fact that each recording site is 
contacting a different part of the brain tissue’s surface. The signals were allowed 
to equilibrate for a few minutes before applications of a 120 mM potassium 
solution were made directly onto the tissue (black arrows). The third application 
disrupted the seal between the array and the tissue, and all signals decreased 
uniformly. B) A closer look at the first and second potassium applications is 
shown. We observed signal increases on some of the channels in response to 
depolarizing stimuli, especially following the first application. If these signals are 
due to Glu release, a 0.02 nA change in current is roughly equal to a 3.5 µM 
change in Glu according to the calibration slopes for the microelectrode array 
used in the experiment. The traces have been offset from one another for clarity. 
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 Future Patient-Oriented Research 
 
 Our initial attempt to record Glu from a piece of excised human brain 
tissue represents the first of a series of steps that we may have to take to 
introduce our microelectrode-based Glu detection technology into the clinical 
setting. Our rationale unfolds in the following way. First, we would like to prove 
that we can record Glu from human brain tissue. Of course, the safest tissue to 
use is excised human brain tissue that has been removed by a neurosurgeon for 
a medically prescribed reason. Epileptogenic foci and brain tumors are often 
removed as surgical treatments of some forms of epilepsy and cancer. Once we 
have satisfactorily proven that we can record Glu from human brain tissue, the 
next step would be to target intact brain tissue. Once again, both epileptics and 
brain tumor patients scheduled for resections would be good candidates for our 
patient population. In fact, we would record the same type of brain tissue as 
previously described; however, we would conduct intraoperative recordings 
before the tissue was removed. During these studies, we would characterize Glu 
activity in abnormal brain tissue. Once we have demonstrated that 
microelectrode arrays can be used in a safe and efficient manner during 
neurosurgery, we would like to design similar intraoperative studies to 
characterize Glu regulation in normal brain tissue. The normal brain regions that 
we sample would not be removed following our recordings. Ultimately, we would 
have preliminary data to compare normal and abnormal Glu measures for each 
brain disorder so that we could use to propose larger studies. Furthermore, Glu 
measures might correlate with disease parameters so that our Glu detection 
technology could have an apparent therapeutical use. 
 
 Excised Abnormal Human Brain Tissue Recordings 
 In future attempts to record Glu from a piece of excised human brain 
tissue, we would benefit from gaining additional control over the tissue. Ideally, 
our methods would closely resemble those used for brain slice recordings. Our 
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 first goal would be accessing adequate volumes of brain tissue in a timely 
manner. The size of the excised tissue should be large enough that it can be 
sliced very thinly (300-400 µm thick) either immediately after resection in the 
surgical suite using a McIllwain tissue chopper or soon thereafter using brain 
sectioning equipment in the recording laboratory. The tissue sample should also 
be large enough so that the other physical dimensions provide substantial mass 
for the ceramic tip of our microelectrode array to be implanted through the slice 
without fracturing it. One cm3 blocks of resected brain tissue are standardly 
reported by groups who study human neocortical slices both in Europe and the 
United States (Burkhart et al., 1998, Gorji et al., 2002). Timing between removal 
of brain tissue and oxygenation is important to maintaining living cells within the 
slice. Research groups who study human neocortical slices often report 
preincubation procedures beginning within two to five minutes of resection. 
Depending on the nature of the excised tissue or the standard operating 
procedures of the medical center, the removed brain tissue may need to be 
evaluated by the Pathology department before it can be prepared for slice 
recordings. With proper approval by the Institutional Review Board and likely the 
informed consent of the patients, all or a portion of the resected brain tissue may 
bypass this step and immediately be entered into a research protocol. 
 The brain tissue slices would then be placed in oxygenated (95% O2, 5% 
CO2) artificial cerebrospinal fluid (aCSF, in mM: 124 NaCl, 5 KCl, 1.5 MgCl2. 2.5 
CaCl2, 1.4 NaH2PO4, 10 D-glucose, 26 NaHCO3, pH 7.3-7.4) and allowed to 
recover for 1-2 hours. Thereafter, a section would be placed in a recording 
chamber warmed to 32-34 °C and perfused with oxygenated aCSF. 
Microelectrode arrays configured for self-referencing Glu recordings would be 
prepared and calibrated beforehand. A prepared microelectrode array or 
microelectrode/micropipette assembly would be lowered by micromanipulator 
until the recording sites were positioned within the slice. Basal Glu levels could 
be monitored as previously described. Endogenous Glu release could be 
stimulated by local application (Picospritzer III via micropipette) or recording 
chamber perfusion (Minipuls 3 peristaltic pump, Gilson Inc., Middleton, WI) of an 
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 appropriate high potassium solution. Volumes of 5 mM Glu could also be ejected 
by micropipette to further study the Glu uptake system. At this level of control, we 
would not only maximize our chances of successfully and definitively recording 
Glu from excised human brain tissue, but also have an opportunity to begin 
characterizing the human neocortical Glu system. 
 
 Intact Human Brain Tissue Recordings 
 After we accomplish Glu recordings from excised human brain, the next 
step is to move the recordings from the laboratory to the neurosurgical suite 
where we can record Glu from an intact human brain. We would enroll patients 
with brain disorders, such as medically refractory epileptics, who are being 
surgically treated by having a section of their brains removed. Risks to the patient 
would be minimized primarily to increased surgical and anesthetic time, as we 
will only record Glu from abnormal tissue targeted for resection. In some ways, 
the methodology becomes much simpler for these recordings because we do not 
have to handle the tissue and artificially keep it alive, oxygenated, or warmed. 
Furthermore, concerns about alterations in the chemical composition of the 
extracellular fluid or changes in Glu regulation created by disrupting axonal 
connections, tissue trauma, and secondary injury are highly reduced. 
 Many of our primary goals to establish Glu recordings in the intact human 
brain are similar to those we set during the transition to Glu recordings in the 
brains of chronically-used nonhuman primates (see Chapter Five). Basically we 
need to modify our technology and methodology to safely and efficiently record 
Glu in the human neurosurgical operating room setting. We started to understand 
the challenges of this task first-hand as part of my experiences at the Brigham 
hospital. I was allowed to accompany Dr. van Horne to one of his cases and 
study the physical layout of a standard neurosurgical suite, learn about some of 
the equipment and technology that already exist in the OR, and observe the work 
dynamics among the scrub nurses, anesthesiologists, and surgeons. This 
experience provided an opportunity to envision conducting Glu recordings in this 
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 setting, specifically to imagine the logical progression of events before, during, 
and after the surgery and to identify the specific challenges of this endeavor. 
 The intraoperative recording session would be straightforward, and the 
major changes would be hardware modifications. Specifically, we need to create 
a more sophisticated version of the mobile FAST-16 (see Chapter Five) in which 
the computer and FAST-16 components would be efficiently housed and 
protected within a stable, mobile tower. All of the sensitive components including 
the cable connections would be behind a locked panel, and an outside user 
would only be able to access the computer power button, keyboard, mouse, 
monitor, and data ports, and the face of the FAST-16 potentiostat box. To protect 
the sterile field environment and avoid unnecessarily obstructing the walking 
workspace of the surgical suite staff, we would also need to lengthen our cable 
that connects the headstage (pre-amplifier) with the FAST-16 potentiostat from a 
few feet to 20-30 feet. Currently, a separate connector is used between the 
headstage and microelectrode array, but the new longer cable would likely have 
the headstage and microelectrode connector integrated at one end. Because we 
will be visualizing the brain area targeted for recordings, we will secure the 
connected microelectrode array onto the patient’s head frame and manually 
advance it using existing, approved electrode implantation equipment. Finally, we 
would not implant a Ag/AgCl reference electrode either in the brain or under a 
skin flap. Instead, we would use existing skin Ag/AgCl epoxy reference 
electrodes (e.g. BetterSkinTM Electrodes, World Precision Instruments, Inc., 
Sarasota, FL) that require double-sided adhesive disks and conductive recording 
gel to maintain good electrical contact with clean, shaven skin. Although this 
electrode would not be in ionic contact with the brain per se, the electrical 
environment of the gel on the skin simulates that of the brain extracellular fluid. 
We have tested this type of reference electrode on the shaven backs of Fischer 
344 rats with good experimental results (Figure A.4). The background current 
and amplitudes of similar volumes of 5 mM Glu in the same brain area increased 
slightly, but many of the characteristics of Glu signaling were maintained. 
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Figure A.4 Comparison of Ag/AgCl Reference Electrodes 
Initial testing was carried out in the rat frontal cortex to assess the feasibility of 
using skin-adhered Ag/AgCl reference electrodes (Ref) during electrochemical 
recordings of Glu. 5 mM Glu ejections (black arrows, ~62.5 nl each) were 
recorded at an applied voltage of +0.7 V versus a typical bare wire, brain-
implanted Ag/AgCl reference electrode (first three Glu responses). Then, the 
hardware’s reference electrode connection was switched to the Betterskin™ 
Ag/AgCl epoxy reference electrode adhered to the animal’s back, and the 5 mM 
Glu ejections were repeated (black arrows, ~62.5 nl, ~62.5 nl, 50 nl, last three 
Glu responses). 
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  We also need to develop methods to efficiently conduct microelectrode 
calibrations within the sterile field. The intraoperative calibration might progress 
as follows. A side table with a non-sterile stir plate is set up and sterilely draped. 
A sterile cup is placed on the drape over the stir plate and filled with sterile PBS 
along with a small sterile stir bar. A sterilized microelectrode array is removed 
from its packaging and connected it to the headstage/connector cable. The 
recording sites are placed in the PBS using a standard clamp system. A sterile 
glass-bodied Ag/AgCl reference electrode is then removed from its packaging, 
placed in the PBS, and connected. The opposite end of the headstage/connector 
cable is handed off and connected to the FAST-16 potentiostat. Note that at this 
point the cable will have a non-sterile portion and a sterile portion that will be 
clearly defined to the surgical staff, which is a routine scenario in the human OR. 
One-step calibrations of the interferent AA, the analyte Glu, and other test 
molecules are conducted using sterile pipetting techniques. These procedures 
require at least two people, a sterilely gowned and gloved person from the 
surgical team and the FAST-16 user who works outside of the sterile field. 
 To properly complete this protocol, the headstage/connector cable, 
prepared microelectrode arrays, and some of the calibration equipment need to 
be sterile. Fortunately, many of the materials are commercially available 
sterilized including the cup, PBS, pipette tips, and calibration chemical storage 
vials. The headstage/connector cable, magnetic stir bar, and glass-bodied 
Ag/AgCl reference electrode would be sterilized using standard gas or heating 
procedures. The calibration chemicals could be prepared and sterilely filtered into 
the storage vials in advance. The last and possibly most important challenge that 
we must overcome is the sterilization of the microelectrode arrays themselves 
without compromising electrode performance. We hypothesized that although the 
enzyme GluOx might withstand heat sterilization (see Chapter Two’s The 
Durability of L-Glutamate Oxidase subsection), the NafionTM and/or BSA might be 
damaged by the high temperatures. Initial testing of gas sterilization conducted in 
collaboration with Dr. van Horne’s team demonstrated that in vitro microelectrode 
performance suffered and the protein matrix layers were visably disrupted 
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 following treatment. Recently, we have partnered with AdTech Medical 
Instruments Corporation (Racine, WI) specifically to study the physical tolerances 
of the microelectrode materials. With their data, we hope to devise a sterilization 
strategy that maintains the integrity of the layers that make our microelectrodes 
selective for Glu. 
 Final concerns relate to simplifying the experiment so that it is streamlined 
and straightforward. An advantage of our use of microelectrodes as research 
tools has been our ability to acquire kinetics data using local applications of 
intracranial solutions. However, these Glu recordings require time, additional 
preparation and equipment, and extensively trained personnel, which can be 
disadvantages in the human OR setting. Instead, we would concentrate on 
conducting passive recordings of basal Glu levels in different parts of the 
targeted brain tissue. Furthermore, we currently have sophisticated software 
written for scientists familiar with designing and performing in vivo 
electrochemical recordings. We would like to simplify this software package and 
make it more user-friendly, easy-to-learn, and accessible. 
 In addition to the acquired Glu data, we are just as interested in the safety 
measures for our patient population. Surgeons commonly worry about increased 
OR time contributing to surgical complications, so in response, we are already 
planning to simplify and shorten our Glu recordings. There is also a valid concern 
about the increased risk of infection and bleeding that might result from 
intraoperative recordings. By initially focusing on brain tissue that will be excised, 
these concerns are minimized, but still exist. We never observed a brain infection 
or any other poor outcome in the nonhuan primates we recorded using non-
sterile implanted microelectrode arrays (Chapter Five) which supports the low 
risks of post-operative complications related to microelectrode use. Nonetheless, 
we must be extraordinarily cautious especially with respect to sterility before we 
implant our microelectrodes in a living human brain. We must also follow all of 
our patients and document any post-operative incidents to evaluate the safety of 
conducting intraoperative Glu recordings in the human brain. When we are 
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 convinced of the safety to the patient, we can shift our target from abnormal to 
normal human brain tissue and repeat both the Glu and safety measures. 
 
Future Clinical Applications 
 
 During the course of these initial investigations of the normal and disease-
altered human cortex, significant differences in Glu regulation might be revealed 
that expose opportunities to use our microelectrode array technology 
therapeutically. The choice of both epileptic and brain tumor patients as our first 
subjects for Glu recordings was not simply based on neurosurgical access to 
brain tissue but also because there is evidence supporting that Glu regulation is 
altered by these diseases. Chapter One describes in detail the support for Glu 
alterations in epilepsy. Perhaps most importantly, extracellular Glu levels have 
been shown to be increased immediately before and during a seizure, and basal 
Glu levels are increased in the epileptogenic foci of some patients in the time 
period between seizures (During and Spencer, 1993, Ronne-Engstrom et al., 
1992, Wilson et al., 1996, Thomas et al., 2003, Cavus et al., 2005). Furthermore, 
some brain tumors, specifically gliomas, have been shown to have altered, 
typically higher, basal Glu levels in the tumor and the adjacent brain tissue 
compared to normal cortex (Behrens et al., 2000, Roslin et al., 2003, Bianchi et 
al., 2004). In fact, Glu may connect these brain disorders because a seizure may 
be the first symptom of a low-grade glioma (Recht and Bernstein, 1995). 
 By focusing on the basal Glu levels in abnormal and normal intact human 
brain tissue, we are gathering information that might allow us to use Glu 
recording microelectrode arrays to determine the normalcy of brain tissue 
intraoperatively. In other words, we may be able to use our technology alone or 
in conjunction with other techniques to better define the borders of abnormal 
areas of the human brain. In epilepsy treatment, this might help the 
neurosurgeon determine the proper amount of brain to remove to reduce or 
eliminate seizure activity while preserving as much normal brain tissue and 
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 function as possible. On the other hand, surgeons who treat patients with 
gliomas are most interested in removing as many of the cancerous cells as they 
can even at the sacrifice of normal tissue. Gliomas often have necrotic foci but 
are not well-circumscribed tumors, so any technology that can help locate more 
abnormal brain cells might benefit the care of these patients. 
 Another long-term goal of our laboratory is the development of brain 
interface devices that would be chronically implanted to monitor and interact with 
the intracranial environment. Once again, epileptics may be among the first 
patients to experience this novel approach. Because extracellular Glu levels rise 
immediately before seizure onset, it may be possible to use a chronically 
implanted Glu recording microelectrode array to determine this critical period and 
relay the information in real time. Upon notification, the patient or medical staff 
could administer interventional treatment. A similar but more sophisticated 
approach would require the development and use of small implantable 
computers and drug delivery systems. In this case, the Glu recording would be 
monitored by a simple computer that would control the release of medications in 
response to fluctuations in Glu levels. These drugs could be delivered 
intravenously or perhaps intraparenchymally, directly into the brain at the site of 
abnormal activity. Obviously, these future clinical applications require appropriate 
laboratory testing and clinical trials prior to federal approval; however, we have 
made many of the first steps and are excited by the future potential benefits to 
patient care that we envision. 
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